Following The Patents: Covid-19 & Medical Tyranny

 


Over the past two decades, a company named M·CAM has been monitoring possible violations of the 1925 Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare (the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In their 2003-2004 Global Technology Assessment: Vector Weaponization, M·CAM highlighted China’s growing involvement in Polymerase Chain Reaction (PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a weekly basis, they have monitored the development of research and commercial efforts in this field, including, but not limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC), the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC), Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, and many other research institutions, and their commercial affiliations.

 

The National Institute of Health’s grant AI23946-08, issued to Dr. Ralph Baric at the University of North Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit. (Source: U.S. Provisional Application No. 60/206,537, filed May 21, 2000) In one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full-length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.

 

“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones.” (Source: https://www.pnas.org/content/100/22/12995)

 

On April 19, 2002, the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, “an infectious, replication defective, coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 before SARS was ever detected in humans!

 

Against this backdrop, they noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries.

 

In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852 patent (Claim 1), no research in the United States could be conducted without permission or infringement.

 

It was noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization’s International Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.

 

These entities also were affiliated with the WHO’s Global Preparedness Monitoring Board (GPMB) whose members were instrumental in the Open Philanthropy-funded global coronavirus pandemic “desk-top” exercise EVENT 201 in October 2019. This event, funded by the principal investor in Sherlock Biosciences and linking interlocking funding partner, the Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory disease global preparedness exercise to be completed by September 2020 alerted us to anticipate an “epidemic” scenario. We expected to see such a scenario emerge from Wuhan or Guangdong China, northern Italy, Seattle, New York or a combination thereof, as Dr. Zhengli Shi and Dr. Baric’s work on zoonotic transmission of coronavirus identified overlapping mutations in coronavirus in bat populations located in these areas.

35 U.S.C. § 101

 

Section 101 of the Patent Act:   "Whoever invents or discovers any new and useful ... composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title." 35 U.S.C. § 101.

 

We have "long held that this provision contains an important implicit exception[:] Laws of nature, natural phenomena, and abstract ideas are not patentable." Mayo, 566 U.S., at    , 132 S.Ct., at 1293 (internal quotation marks and brackets omitted). Rather, "`they are the basic tools of scientific and technological work'" that lie beyond the domain of patent protection. Id., at    , 132 S.Ct., at 1293. As the Court has explained, without this exception, there would be considerable danger that the grant of patents would "tie up" the use of such tools and thereby "inhibit future innovation premised upon them." Id., at     _, 132 S.Ct., at 1301. This would be at odds with the very point of patents, which exist to promote creation. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980) (Products of nature are not created, and "`manifestations... of nature [are] free to all men and reserved exclusively to none'").(Source: Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013))

 

In their majority opinion in 2013, the U.S. Supreme Court made it abundantly clear that the Court had “long held” that nature was not patentable. Merely isolating DNA does not constitute patentable subject matter. In their patent, the CDC made false and misleading claims to the United States Patent & Trademark Office by stating that, “A newly isolated human coronavirus has been identified as the causative agent of SARS, and is termed SARS-CoV.” (Source: U.S. Patent 7,220,852) No “causal” data was provided for this statement.

 

When they filed their patent application on April 25, 2003, their first claim (and the only one that survived to ultimate issuance over the objection of the patent examiner in 2006 and 2007) was the genome for SARS CoV.

 

While this patent is clearly illegal under 35 U.S.C. §101, not only did the CDC insist on its granting over non-final and final rejections, but they also continued to pay maintenance fees on the patent after the 2013 Supreme Court decision confirmed that it was illegal.

 

In addition, the CDC patented the detection of SARS CoV using a number of methods including reverse transcription polymerase chain reaction (RT-PCR). With this patent, they precluded anyone outside of their licensed or conspiring interest from legally engaging in independent verification of their claim that they had isolated a virus, that it was a causative agent for SARS, or that any therapy could be effective against the reported pathogen.

 

It is important to note that the CDC’s patent applications were also rejected in non-final and final rejections for ineligibility under 35 U.S.C. § 102 for being publicly disclosed prior to their own filing. In the first non-final rejection, the USPTO stated that the CDC’s genome was published in four Genbank accession entries on April 14, 18, and 21, 2003 with identity ranging from 96.8% to 99.9% identical sequences. (Source: USPTO Non-Final Rejection File #10822904, September 7, 2006, page 4.) Dr. Fauci knew, and failed to disclose evidence that the CDC patent was illegal, based on work he had funded in the years leading up to the SARS outbreak.

 

After seeking an illegal patent, petitioning to override the decision of an examiner to reject it, and ultimately prevailing with the patent’s grant, the CDC lied to the public by stating they were controlling the patent so that it would be “publicly available”. (Source: https://apnews.com/article/145b4e8d156cddc93e996ae52dc24ec0) Tragically, this public statement is falsified by the simple fact that their own publication in Genbank had, in fact, made it public domain and thereby unpatentable. This fact, confirmed by patent examiners, was overridden by CDC in a paid solicitation to override the law.

 

While not covered under 35 U.S.C. §101, Dr. Fauci’s abuse of the patent law is detailed below. Of note, however, is his willful and deceptive use of the term “vaccine” in patents and public pronouncements to pervert the meaning of the term for the manipulation of the public.

 

In the 1905 Jacobson v. Mass case, the court was clear that a PUBLIC BENEFIT was required for a vaccine to be mandated. Neither Pfizer nor Moderna have proved a disruption of transmission. In Jacobson v. Massachusetts, 197 U.S. 11 (1905), the court held that the context for their opinion rested on the following principle:

 

“This court has more than once recognized it as a fundamental principle that 'persons and property are subjected to all kinds of restraints and burdens in order to secure the general comfort, health, and prosperity of the state…”

 

The Moderna and Pfizer “alleged vaccine” trials have explicitly acknowledged that their gene therapy technology has no impact on viral infection or transmission whatsoever and merely conveys to the recipient the capacity to produce an S1 spike protein endogenously by the introduction of a synthetic mRNA sequence. Therefore, the basis for the Massachusetts statute and the Supreme Court’s determination is moot in this case.

Further, the USPTO, in its REJECTION of Anthony Fauci's HIV vaccine made the following statement supporting their rejection of his bogus "invention"




 

 

18 U.S.C. §2339 C et seq. – Funding and Conspiring to Commit Acts of Terror

Indirectly, unlawfully, and willfully provides or collects funds with the intention that such funds be used, or with the knowledge that such funds are to be used, in full or in part, in order to carry out—

    1. an act which constitutes an offense within the scope of a treaty specified in subsection (e)(7), as implemented by the United States, or
    2. any other act intended to cause death or serious bodily injury to a civilian, or to any other person not taking an active part in the hostilities in a situation of armed conflict, when the purpose of such act, by its nature or context, is to intimidate a population, or to compel a government or an international organization to do or to abstain from doing any act….

 

By no later than April 11, 2005, Dr. Anthony Fauci was publicly acknowledging the association of SARS with bioterror potential. Leveraging the fear of the anthrax bioterrorism of 2001, he publicly celebrated the economic boon that domestic terror had directed towards his budget. He specifically stated that NIAID was actively funding research on a “SARS Chip” DNA microarray to rapidly detect SARS (something that was not made available during the current “pandemic”) and two candidate vaccines focused on the SARS CoV spike protein. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/ ) Led by three Chinese researchers under his employment – Zhi-yong Yang, Wing-pui Kong, and Yue Huang – Fauci had at least one DNA vaccine in animal trials by 2004. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/ ) This team, part of the Vaccine Research Center at NIAID, was primarily focused on HIV vaccine development but was tasked to identify SARS vaccine candidates as well. Working in collaboration with Sanofi, Scripps Institute, Harvard, MIT and NIH, Dr. Fauci’s decision to unilaterally promote vaccines as a primary intervention for several designated “infectious diseases” precluded proven therapies from being applied to the sick and dying.(Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/)

 

The CDC and NIAID led by Anthony Fauci entered into trade among States (including, but not limited to working with EcoHealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights. This research was known to involve surface proteins in coronavirus that had the capacity to directly infect human respiratory systems. In flagrant violation of the NIH moratorium on gain of function research, NIAID and Ralph Baric persisted in working with chimeric coronavirus components specifically to amplify the pathogenicity of the biologic material.

 

By October 2013, the Wuhan Institute of Virology 1 coronavirus S1 spike protein was described in NIAID’s funded work in China. This work involved NIAID, USAID, and Peter Daszak, the head of EcoHealth Alliance. This work, funded under R01AI079231, was pivotal in isolating and manipulating viral fragments selected from sites across China which contained high risk for severe human response. (Source: Ge, XY., Li, JL., Yang, XL. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535–538 (2013).)

 

By March 2015, both the virulence of the S1 spike protein and the ACE II receptor was known to present a considerable risk to human health. NIAID, EcoHealth Alliance and numerous researchers lamented the fact that the public was not sufficiently concerned about coronavirus to adequately fund their desired research.(Source: Forum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington (DC): National Academies Press (US); 2016 Feb 12. 6, Developing MCMs for Coronaviruses. Available from: https://www.ncbi.nlm.nih.gov/books/NBK349040/)

 

Dr. Peter Daszak of EcoHealth Alliance offered the following assessment:

  

Daszak reiterated that, until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process, Daszak stated.”

 

Economics will follow the hype.

 

The CDC and NIAID entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016. These projects took place during a time when the work being performed was prohibited by the United States National Institutes of Health.

 

The public was clearly advised of the dangers being presented by NIAID-funded research by 2015 and 2016 when the Wuhan Institute of Virology material was being manipulated at UNC in Ralph Baric’s lab.

 

“The only impact of this work is the creation, in a lab, of a new, non-natural risk,” agrees Richard Ebright, a molecular biologist and biodefence expert at Rutgers University in Piscataway, New Jersey. Both Ebright and Wain-Hobson are long-standing critics of gain-of-function research.

 

In their paper, the study authors also concede that funders may think twice about allowing such experiments in the future. "Scientific review panels may deem similar studies building chimeric viruses based on circulating strains too risky to pursue," they write, adding that discussion is needed as to "whether these types of chimeric virus studies warrant further investigation versus the inherent risks involved”.

 

But Baric and others say the research did have benefits. The study findings “move this virus from a candidate emerging pathogen to a clear and present danger”, says Peter Daszak, who co-authored the 2013 paper. Daszak is president of the EcoHealth Alliance, an international network of scientists, headquartered in New York City, that samples viruses from animals and people in emerging-diseases hotspots across the globe.

 

Studies testing hybrid viruses in human cell culture and animal models are limited in what they can say about the threat posed by a wild virus, Daszak agrees. But he argues that they can help indicate which pathogens should be prioritized for further research attention.”(Source: https://www.nature.com/news/engineered-bat-virus-stirs-debate-over-risky-research-%201.18787 )

 

Knowing that the U.S. Department of Health and Human Services (through CDC, NIH, NIAID, and their funded laboratories and commercial partners) had patents on each proposed element of medical counter measures and their funding, Dr. Fauci, Dr. Gao (China CDC), and Dr. Elias (Bill and Melinda Gates Foundation) conspired to commit acts of terror on the global population – including the citizens of the United States – when, in September 2019, they published the following mandate:

 

“Countries, donors and multilateral institutions must be prepared for the worst. A rapidly spreading pandemic due to a lethal respiratory pathogen (whether naturally emergent or accidentally or deliberately released) poses additional preparedness requirements. Donors and multilateral institutions must ensure adequate investment in developing innovative vaccines and therapeutics, surge manufacturing capacity, broad-spectrum antivirals and appropriate non-pharmaceutical interventions. All countries must develop a system for immediately sharing genome sequences of any new pathogen for public health purposes along with the means to share limited medical countermeasures across countries.

 

Progress indicator(s) by September 2020

 

A.     Donors and countries commit and identify timelines for: financing and development of a universal influenza vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its Member States develop options for standard procedures and timelines for sharing of sequence data, specimens, and medical countermeasures for pathogens other than influenza.

 

B.      Donors, countries and multilateral institutions develop a multi-year plan and approach for strengthening R&D research capacity, in advance of and during an epidemic.

 

C.      WHO, the United Nations Children’s Fund, the International Federation of Red Cross and Red Crescent Societies, academic and other partners identify strategies for increasing capacity and integration of social science approaches and researchers across the entire preparedness/response continuum.”(Source: https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf (page 8) )

 

As if to confirm the utility of the September 2019 demand for “financing and development of” vaccine and the fortuitous SARS CoV-2 alleged outbreak in December of 2019, Dr. Fauci began gloating that his fortunes for additional funding were likely changing for the better. In a February 2020 interview in STAT, he was quoted as follows:

 

““The emergence of the new virus is going to change that figure, likely considerably, Fauci said. “I don’t know how much it’s going to be. But I think it’s going to generate more sustained interest in coronaviruses because it’s very clear that coronaviruses can do really interesting things.””(Source: https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interest-hurt-coronavirus-research/)

 

 

18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of American Citizens

Section 802 of the USA PATRIOT Act (Pub. L. No. 107-52) expanded the definition of terrorism to cover "domestic," as opposed to international, terrorism. A person engages in domestic terrorism if they do an act "dangerous to human life" that is a violation of the criminal laws of a state or the United States, if the act appears to be intended to: (i) intimidate or coerce a civilian population; (ii) influence the policy of a government by intimidation or coercion;

 

Dr. Anthony Fauci has intimidated and coerced a civilian population and sought to influence the policy of a government by intimidation and coercion.

 

With no corroboration, Dr. Anthony Fauci promoted (Source: https://www.cato.org/blog/did-mitigation-save-two-million-lives ) Professor Neil Ferguson’s computer simulation derived claims that,

 

“The world is facing the most serious public health crisis in generations. Here we provide concrete estimates of the scale of the threat countries now face.

 

“We use the latest estimates of severity to show that policy strategies which aim to mitigate the epidemic might halve deaths and reduce peak healthcare demand by two-thirds, but that this will not be enough to prevent health systems being overwhelmed. More intensive, and socially disruptive interventions will therefore be required to suppress transmission to low levels. It is likely such measures – most notably, large scale social distancing – will need to be in place for many months, perhaps until a vaccine becomes available.” (Source: https://www.imperial.ac.uk/news/196234/covid-19-imperial-researchers-model-likely-impact/)

 

Reporting to the President that as many as 2.2 million deaths may result from a pathogen that had not yet been isolated and could not be measured with any accuracy, Dr. Fauci intimidated and coerced the population and the government into reckless, untested, and harmful acts creating irreparable harm to lives and livelihoods. (Source: https://www.npr.org/2020/03/31/823916343/coronavirus-task-force-set-to-detail-the-data-that-led-to-extension-of-guideline) Neither the Imperial College nor the “independent” Institute for Health Metrics and Evaluation (principally funded by the Bill and Melinda Gates Foundation) (Source: https://www.gatesfoundation.org/Media-Center/Press-Releases/2017/01/IHME-Announcement) had any evidence of success in estimating previous burdens from coronavirus but, without consultation or peer-review, Dr. Fauci adopted their terrifying estimates as the basis for interventions that are explicitly against medical advice.

 

a.      The imposition of social distancing was based on computer simulation and environmental models with NO disease transmission evidence whatsoever.

 

b.      The imposition of face mask wearing was directly against controlled clinical trial evidence and against the written policy in the Journal of the American Medical Association.

 

Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people from becoming ill.”(Source: https://jamanetwork.com/journals/jama/fullarticle/2762694?fbclid=IwAR2RE-c4V-fhUodui0JQRbiHRcgEJuDKG_21N4oL5zAfciQfWCyHAsetJmo)

c.      In both the Imperial College and the IHME simulations, quarantines were modeled for the sick, not the healthy.

 

  

Insisting on vaccines while blockading the emergency use of proven pharmaceutical interventions may have contributed to the death of many patients and otherwise healthy individuals.(Source: https://www.reuters.com/investigates/special-report/health-coronavirus-usa-cost/)

Using the power of NIAID during the alleged pandemic, Dr. Anthony Fauci actively suppressed proven medical countermeasures used by, and validated in scientific proceedings, that offered alternatives to the products funded by his conspiring entities for which he had provided direct funding and for whom he would receive tangible and intangible benefit.

 

 

18 U.S.C. § 1001 – Lying to Congress


Except as otherwise provided in this section, whoever, in any matter within the jurisdiction of the executive, legislative, or judicial branch of the Government of the United States, knowingly and willfully—

      1. falsifies, conceals, or covers up by any trick, scheme, or device a material fact;
      2. makes any materially false, fictitious, or fraudulent statement or representation; or
      3. makes or uses any false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry;

shall be fined under this title, imprisoned not more than 5 years or, if the offense involves international or domestic terrorism (as defined in section 2331), imprisoned not more than 8 years, or both. If the matter relates to an offense under chapter 109A, 109B, 110, or 117, or section 1591, then the term of imprisonment imposed under this section shall be not more than 8 years.

 

On October 22, 2020, the United States Government Accountability Office (GAO) published a report entitled: BIOMEDICAL RESEARCH: NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property. In this document, the authors reported that the National Institutes of Health (NIH) received, “up to $2 billion in royalties from its contributions to 34 drugs sold from 1991-2019.”(Source: https://www.gao.gov/products/GAO-21-52)

 

A casual review of the NIH Office of Technology Transfer report of active licenses (Source: https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics) appears to conflict with the GAO report on several important facts. Conspicuously absent from the GAO report are over 30 patents associated with active compounds generating billions of dollars in revenue. Why would it be that the GAO and the NIH couldn’t agree on something as simple as drugs generating income for NIH?

 

Since the passage of the Bayh Dole Act (Pub. L. 96-517, December 12, 1980), federally funded research has been an economic bonanza for U.S. universities, federal agencies, and their selected patronage. For the first decade following Bayh Dole, NIH funding doubled from $3.4 billion to $7.1 billion. A decade later, it doubled again to $15.6 billion. In the wake of September 2001, the National Institute for Allergy and Infectious Diseases (NIAID) saw its direct budget increase over 300%, without accounting for DARPA, funds of as much as $1.7 billion annually from 2005 forward. In 2020, NIH’s budget was over $41 billion.

 

What has become of the $763 billion of taxpayer funds allocated to making America healthier since inventors have been commercially incentivized? Who has been enriched?

 

The answer, regrettably, is that no accountability exists to answer these questions. The NIH is the named owner of at least 138 patents since 1980.

The United States Department of Health and Human Services is the named owner of at least 2,600 patents.

 

NIAID grants or collaboration have resulted in 2,655 patents and patent applications of which only 95 include an assignment to the Department of Health and Human Services as an owner. Most of these patents are assigned to universities thereby making the ultimate commercial beneficiaries entirely opaque. One of the largest holders is SIGA Technologies (NASDAQ: SIGA) who, while publicly reporting close affiliation with NIAID, is not referenced in the NIH GAO report. SIGA’s CEO, Dr. Phillip L. Gomez spent 9 years at NIAID developing its vaccine program for HIV, SARS, Ebola, West Nile Virus, and Influenza before exiting to commercial ventures. While their technology is clearly derived from NIAID science, the company reports revenue from NIAID but no royalty or commercial payments to NIH or any of its programs.

  

NIAID’s Director, Dr. Anthony Fauci, is listed as an inventor on 8 granted U.S. patents. None of them are reported in NIAID, NIH, or GAO reports of active licensing despite the fact that Dr. Fauci reportedly was compelled to get paid for his interleukin-2 “invention” – payments he reportedly donated to an unnamed charity. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545012/)

 

Of the 21 patents listed in the U.S. Food and Drug Administration’s (FDA) Orange book, itemized in the GAO report, none of Dr. Anthony Fauci’s patents are listed. Furthermore, none of the NIAID patents are listed despite clear evidence that Gilead Sciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) have generated over $2 billion annually from sales that were the direct result of NIAID funded science. Missing from the GAO report are 2 patents for Velclade® which has been generating sales in excess of $2.18 billion annually for several years. None of the patents for Yescarta® are listed in the GAO report. None of the Lumoxiti® patents are listed in the GAO report. None of the Kepivance® patents are listed in the GAO report. In violation of 37 USC §410.10 and 35 USC §202(a), over 13 of the 21 patents in the GAO report fail to disclose government interest despite being the direct result of NIH funding.

 

Dr. Anthony Fauci’s Own Patent Track Record:

 

US Patent 6,190,656 and 6,548,055 - Immunologic enhancement with intermittent interleukin-2 therapy:

 

A method for activating a mammalian immune system entails a series of IL-2 administrations that are affected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T-cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is affected by delivering a genetically engineered retroviral vector directly to the patient.

 

This application is a continuation of U.S. patent application Ser. No. 08/487,075, filed Jun. 7, 1995, now abandoned, which is a continuation in part of U.S. patent application Ser. No. 08/063,315, filed May 19, 1993, now issued as U.S. Pat. No. 5,419,900, and U.S. patent application Ser. No. 08/452,440, filed May 26, 1995, now issued as U.S. Pat. No. 5,696,079, which is the National Stage filed under 35 USC 371 of PCT/US94/05397, filed May 19, 1994, the contents of which are incorporated herein by reference.

 

Filed May 19, 1993

 

Issued a Final Rejection January 20, 1998. Rejected after abandonment August 14, 1998 and April 12, 1999. Reduced and modified claims granted May 8, 2000.

 

This family of patents was the basis of Fauci’s lie to the British Medical Journal in which he falsely stated:

 

“Dr Anthony Fauci told the BMJ that as a government employee he was required by law to put his name on the patent for the development of interleukin 2 and was also required by law to receive part of the payment the government received for use of the patent. He said that he felt it was inappropriate to receive payment and donated the entire amount to charity.”

 

            US Patent 6,911,527 - HIV related peptides:

 

This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.

 

Filed May 6, 1999

 

Rejected as unpatentable January 22, 2003. Issued with a final rejection on July 15, 2004 after submitting reconsideration requests. Modified and restricted claims allowed September 29, 2004.

 

US Patent 7,368,114 - Fusion protein including of CD4:

 

Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.

 

Filed October 24, 2002

 

Rejected as unpatentable August 18, 2006. Paid appeal to overturn examiner’s findings February 15, 2007. Rejected again May 11, 2007. On October 10, 2007 applicants further narrowed the construction of what was clearly not a patent and the USPTO granted less than half the claims that had been sought in the original filing.

 

 

US Patent 9,896,509, 9,193,790 and 9,441,041 - Use of antagonists of the interaction between HIV GP120 and .alpha.4.beta.7 integrin:

 

Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist, thereby treating the HIV infection. In several examples, the .alpha.4 integrin antagonist is a monoclonal antibody that specifically binds to a .alpha.4, .beta.1 or .beta.7 integrin subunit, or a cyclic hexapeptide, with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

 

Rejected May 22, 2017 as Double Patenting. In their response, the applicants acknowledge the illegal act and seek only those components of their application that extend beyond the life of the issued patents. On October 11, 2017, the limited claims were issued.

 

A sample of the convoluted flow of funds that evades public disclosure.

 

U.S. Patent 8,999,351 was issued to Tekmira Pharmaceuticals Corporation in Burnaby, British Columbia. In their patent, they disclose that their research was supported by a grant from the National Institute of Allergy and Infectious Disease (Grant HHSN266200600012C). Ironically, this $23 million grant was awarded in 2006 to Alnylam Pharmaceuticals, Inc., not to Tekmira.(Source: Alnylam Awarded $23 Million U.S. Government Contract to Develop RNAi Therapeutics | Technology Networks)

 

 

In 2012, Alnylam agreed to pay Tekmira $65 million to settle legal disputes including a $1 billion damages claim for “relentless and egregious” misappropriation of Tekmira’s trade secrets. From the patent filing’s earliest priority of November 10, 2008, there is no public record stating Tekmira as the beneficiary of this NIAID grant. Notwithstanding, the lipid nanoparticle technology developed from this grant is the technology now used in the Moderna COVID-19 intervention. In their 10-Q filing, Alnylam reports to have a license to technology from Arbutus – formerly Tekmira – which has accused Acuitas of misappropriating trade secrets and licensing them to Moderna and Pfizer’s collaboration with BioNTech.

 

Additional references can be found at:

 

https://www.ott.nih.gov/nih-and-its-role-technology-transfer https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Orig1s000TAltr.pdf https://www.gao.gov/assets/720/710287.pdf https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22

 

 

15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity

 

Every contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce among the several States, or with foreign nations, is declared to be illegal. Every person who shall make any contract or engage in any combination or conspiracy hereby declared to be illegal shall be deemed guilty of a felony, and, on conviction thereof, shall be punished by fine not exceeding $100,000,000 if a corporation, or, if any

other person, $1,000,000, or by imprisonment not exceeding 10 years, or by both said punishments, in the discretion of the court.

 

The National Institute of Health’s grant AI23946-08 issued to Dr. Ralph Baric at the University of North Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.(Source: U.S. Provisional Application No. 60/206,537, filed May 21, 2000) In one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.

 

“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones.”(Source: https://www.pnas.org/content/100/22/12995)

 

On April 19, 2002, the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, “an infectious, replication defective, coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 before SARS was ever detected in humans.

 

Against this backdrop, we noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries.

 

In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852 patent (Claim 1), no research in the United States could be conducted without permission or infringement.

 

We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization’s International Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.

 

 

 

·        1986-1990    NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant Coronavirus” Filed 2002 and issued 2007 https://patents.google.com/patent/US7279327B2/ru

The paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf

 

·        1990    Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000 which was abandoned April 2010 making it public domain.

 

·        1990s    Work focused on CoV association with cardiomyopathy (see above)

Early reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf

 

·        2000    Ralph Baric AI23946 and GM63228 from the National Institutes of Health actively working recombinant CoV

 

·        2001    National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI

 

·        2002    Asia CoV SARS outbreak

 

·        2003    April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus.

Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges Scientific Advisory Board (served through 2010).

 

·        April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319

 

·        July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2

Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS CoV. This research is supported by several NIH grants including National Institutes of Health Grants A128785, A148436, and A1053822.

 

·        2004    January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators. https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706

At this conference, the term “The New Normal” was introduced by Merck

 

FAUCI AND BARIC start making money!!! National Institutes of Health, Allergy and Infectious Diseases. SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic mouse model for SARS-CoV infection.

 

National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million

 

·        November 22, 2004    University of Hong Kong patents SARS associated spike protein on CoV and pursues patent US 7,491,489

 

·        2005    DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker

 

Review timeline from https://www.youtube.com/watch?v=rO_EeYB0i0U and https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf

 

·        2008    Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104

 

·        2009    Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant from NIAID)

 

·        2010    Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID)

Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents.

 

·        August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 which attracted the investment of (and “inventorship” for) venture capitalists at Flagship Ventures. This patent grew out of the work of Dr. Jason P. Schrum of Harvard Medical School supported by National Science Foundation Grant #0434507. While the application claims priority to August 2010, the application didn’t get finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this original patent rejecting all claims.

https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding in https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf

 

 

·        2011    Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all of its SARS technology.

 

Biodefense Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill (non-competitive grant from NIAID)

 

·        2012    MERS isolated in Egypt

 

Biodefense Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive grant from NIAID)

 

·        2013    Biodefense Grant U54 AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant from NIAID)

 

·        2014    April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435

 

·        2015    Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the mRNA-1273 lead developer and inventor Guiseppe Ciaramella. https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html

 

·        2016    NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna’s technology. https://patents.google.com/patent/WO2018081318A1/en Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS

CoV-2 according to Moderna’s report here (“In January 2020, once it was discovered that the infection in Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic sequence for the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html

In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013 https://patents.google.com/patent/AU2014231357A1/en?inventor=Jason+MCLELLAN.

 

·        2017    August – Sanofi buys Protein Science Corp with considerable SARS patent holdings

·        2018    June – Sanofi buys Ablynx with considerable SARS patent holdings

·        2019    March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create- affordable-molecular-diagnostics/ funded by Open Philanthropy – the same organization that would be the financial sponsor of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan in October 2019.

 

 

 

 

15 U.S.C. §8 – Market Manipulation and Allocation

Every combination, conspiracy, trust, agreement, or contract is declared to be contrary to public policy, illegal, and void when the same is made by or between two or more persons or corporations, either of whom, as agent or principal, is engaged in importing any article from any foreign country into the United States, and when such combination, conspiracy, trust, agreement, or contract is intended to operate in restraint of lawful trade, or free competition in lawful trade or commerce, or to increase the market price in any part of the United States of any article or articles imported or intended to be imported into the United States, or of any manufacture into which such imported article enters or is intended to enter. Every person who shall be engaged in the importation of goods or any commodity from any foreign country in violation of this section, or who shall combine or conspire with another to violate the same, is guilty of a misdemeanor, and on conviction thereof in any court of the

United States such person shall be fined in a sum not less than $100 and not exceeding $5,000, and shall be further punished by imprisonment, in the discretion of the court, for a term not less than three months nor exceeding twelve months.

 

Through non-competitive grant awards to UNC Chapel Hill’s Ralph Baric, to selection of the Bio-Safety Level 4 laboratory locations, to the setting of prices for Remdesivir and mRNA therapies from Moderna and Pfizer, NIAID, CDC, and the U.S. Department of Health and Human Services have been involved in allocating Federal funds to conspiring parties without independent review.

 

Around March 12, 2020, in an effort to enrich their own economic interests by way of securing additional funding from both Federal and Foundation actors, the CDC and NIAID’s Dr Fauci elected to suspend testing and classify COVID-19 by capricious symptom presentation alone. Forcing the public to rely on The COVID Tracking Project – funded by the Bloomberg, Zuckerberg and Gates Foundation and presented by a media outlet (The Atlantic) not a public health agency Dr. Fauci used fraudulent testing technology (RT-PCR) to conflate “COVID cases” with positive PCR tests in the living while insisting that COVID deaths be counted by symptoms alone. This perpetuated a market demand for his desired vaccine agenda which was recited by him and his conspiring parties around the world until the present. Not surprisingly, this was necessitated by the apparent fall in cases that constituted Dr. Fauci’s and others’ criteria for depriving citizens of their 1st Amendment rights.

 

 

15 U.S.C. § 19 – Interlocking Directorates


No person shall, at the same time, serve as a director or officer in any two corporations (other than banks, banking associations, and trust companies) that are—

      1. engaged in whole or in part in commerce; and
      2. by virtue of their business and location of operation, competitors, so that the elimination of competition by agreement between them would constitute a violation of any of the antitrust laws; if each of the corporations has capital, surplus, and undivided profits aggregating more than $10,000,000 as adjusted pursuant to paragraph (5) of this subsection.

 

 

Dr. Fauci is on the Leadership Council of the Bill and Malinda Gates Global Vaccine Action Plan

 

Dr. Fauci while controlling the economic dispensation of Federal research funding, Dr. Fauci has been, and continues to be, on the World Health Organization’s Global Preparedness Monitoring Board. He is joined on this board by the conflicted donor from the Bill and Melinda Gates Foundation’s Dr. Chris Elias and the State Council of China’s Dr. George

F. Gao of the Chinese CDC. This GPMB stipulated that all member states must take part in a global simulation of the release of a respiratory pathogen.

 

Dr. Baric is one of the primary beneficiaries of U.S. Federal funds, runs a BSL-4 facility and sits on the International Committee on Taxonomy of Virus Coronaviridae Working Group tasked to confirm the presence of absence of the pathogen for which he is directly compensated.

 

As referenced in the section covering violations of 18 U.S.C. § 1001 above, numerous undisclosed commercial relationships exist between funded researchers, their funding agencies, and commercial interests in which disclosed and undisclosed commercial terms exist. A complete list of all potential implicated parties is listed in the section below entitled “The Commercial Actors”.

 

It appears that during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material were illegal, the CDC and National Institute of Allergy and Infectious Diseases led by Anthony Fauci (hereinafter “NIAID” and "Dr Fauci", respectively) entered into trade among States (including, but not limited to working with Ecohealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights.

 

It further appears that during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material was illegal, the CDC and National Institute of Allergy and Infectious Diseases (hereinafter “NIAID”) entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016.

 

It further appears that during the period of patent enforcement and after the Supreme Court ruling confirming that patents on generic material was illegal, the CDC and NIAID entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations to conduct chimeric construction of novel coronavirus material with specific virulence properties prior to, during, and following the determination made by the National Institutes for Health in October 17, 2014 that this work was not sufficiently understood for its biosecurity and safety standards.

 

In this inquiry, it is presumed that the CDC and its associates were: a) fully aware of the work being performed using their patented technology; b) entered into explicit or implicit agreements including licensing, or other consideration; and, c) willfully engaged one or more foreign interests to carry forward the exploitation of their proprietary technology when the U.S. Supreme Court confirmed that such patents were illegal and when the National Institutes of Health issued a moratorium on such research.

 

Reportedly, in January 2018, the U.S. Embassy in China sent investigators to Wuhan Institute of Virology and found that, “During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory.” The Washington Post reported that this information was contained in a cable dated 19 January 2018. Over a year later, in June 2019, the CDC conducted an inspection of Fort Detrick’s U.S. Army Medical Research Institute of Infectious Diseases (hereinafter “USAMRIID”) and ordered it closed after alleging that their inspection found biosafety hazards. A report in the journal Nature in 2003 (423(6936): 103) reported cooperation between CDC and USAMRIID on coronavirus research followed by considerable subsequent collaboration. The CDC, for what appear to be the same type of concern identified in Wuhan, elected to continue work with the Chinese government while closing the U.S. Army facility.

 

The CDC reported the first case of SARS-CoV like illness in the United States in January 2020 with the CDC’s Epidemic Intelligence Service reporting 650 clinical cases and 210 tests. Given that the suspected pathogen was first implicated in official reports on December 31, 2019, one can only conclude that CDC: a) had the mechanism and wherewithal to conduct tests to confirm the existence of a “novel coronavirus”; or, b) did not have said mechanism and falsely reported the information in January. It tests credulity to suggest that the WHO or the CDC could manufacture and distribute tests for a “novel” pathogen when their own subsequent record on development and deployment of tests has been shown to be without reliability.

 

35 U.S.C. §200 - 206 – Disclosure of Government Interest

35 U.S.C. §202 (c)(6)

 

An obligation on the part of the contractor, in the event a United States patent application is filed by or on its behalf or by any assignee of the contractor, to include within the specification of such application and any patent issuing thereon, a statement specifying that the invention was made with Government support and that the Government has certain rights in the invention.

 

Over 5000 patents and patent applications have included reference to SARS Coronavirus dating back to priority dates of 1998. They are summarized below.

 

 


On July 23, 2020, the Patent Trial and Appeal Board of the United States Patent and Trademark Office rejected Moderna’s efforts to invalidate U.S. Patent 8,058,069. This patent, owned by Arbutus Biopharma Corp (principally owned by Roivant Science Ltd), covers the lipid nanoparticle (LNP) required to deliver an mRNA vaccine. Some of the core technology was based on work originally done at the University of British Columbia and was first licensed in 1998.

 

mRNA-1273 – the experimental vaccine developed by Moderna for COVID-19 – uses the LNP technology that Moderna thought it had licensed from Acuitas Therapeutics Inc., a firm developed by a former principal of Arbutus’ prior company Tekmira. That license did not authorize Moderna to use the technology for the COVID-19 vaccine.

 

M·CAM and Knowledge Ecology International have independently confirmed that Moderna has violated U.S. law in failing to disclose the U.S. government’s funding interest in their patents and patent applications. While this negligence impacts all of Moderna’s over 130 granted U.S. patents, it is particularly problematic for U.S. Patent 10,702,600 (‘600) which is the patent relating to, “a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle.” The specific claims addressing the pivot to the SARS Coronavirus were patented on March 28, 2019 – 9 months before the SARS CoV-2 outbreak! Both the patent and the DARPA funding for the technology were disclosed in scientific publication (New England Journal of Medicine) but the government funds were not acknowledged in the patent.

 

In 2013, the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program awarded grant funding to Moderna Therapeutics for the development of a new type of vaccine based on messenger RNA. The initial DARPA grant was W911NF-13-1-0417. The company used that technology to develop its COVID-19 vaccine, currently undergoing clinical trials in conjunction with NIH.(Source: https://crsreports.congress.gov/product/pdf/IN/IN11446)

 

Under the Federal Acquisition Regulation (FAR) rules, contractor to the Federal Government must provide information regarding intellectual property infringement issues as part of their contract. Under FAR §27.201-1(c) and (d), the Government both requires a notice of infringement or potential infringement as well as retention of economic liability for patent infringements. Specifically, in FAR §52.227.3 (a), the “Contractor shall indemnify the Government and its officers, agents, and employees against liability, including costs for infringement of any United States Patent…”. In addition to the patents cited by the USPTO in their examination of ‘600, M·CAM has identified fourteen other issued patents preceding the ‘600 patent which were used by patent examiners to limit patents arising from the same funded research including patents sought by CureVac.

 

In short, while Moderna enjoys hundreds of millions of dollars of funding, allegiance, and advocacy from Anthony Fauci and his NIAID, since its inception, it has been engaged in illegal patent activity and demonstrated contempt for U.S. Patent law. To make matters worse, the U.S. Government has given it financial backing in the face of undisclosed infringement risks potentially contributing to the very infringement for which they are indemnified.

 

 

21 C.F.R. § 50.24 et seq., Illegal Clinical Trial

 

It is unlawful to conduct medical research (even in the case of emergency) without a series of steps taken to:

    1. Establish the research with a duly authorized and independent institutional review board;
    2. Secure informed consent of all participants including a statement of risks and benefits; and,
    3. Engage in consultation with the community in which the study is to be conducted.

 

Dr. Anthony Fauci has forced upon the healthy population of the United States an unlawful clinical trial in which the U.S. Department of Health and Human Services are extrapolating epidemiologic data. No informed consent has been sought or secured for any of the “medical countermeasures” forced upon the population and no independent review board – as defined by the statute – has been empaneled.

 

Through April 2020, the official recommendation by the Journal of the American Medical Association was unambiguous.

 

“Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people from becoming ill.”(Source: Medical Masks | Infectious Diseases | JAMA | JAMA Network)

 

Part of that lack of evidence in fact showed that cloth facemasks actually increased influenza-linked illness. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420971/)

 

In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a “belief” that face masks limit the spread of SARS CoV-2. To date, not a single study has confirmed that a mask prevented the transmission of, or the infection by SARS CoV-2.

 

All parties mandating the use of facemasks are not only willfully ignoring established science but are engaging in what amounts to a whole population clinical trial. This conclusion is reached by the fact that facemask use and COVID-19 incidence are being reported in scientific opinion pieces promoted by the United States Centers for Disease Control and Prevention and others.(Source: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html)

 

Social distancing of up to 6 feet has been promoted as a means of preventing person-to-person transmission of influenza-like viruses. While one study hypothesized that infection could happen in a 6 foot range, the study explicitly states that person-to-person transfer was not tested and viability of the virus at 6 feet was not even a subject of the investigation.(Source: Werner E. Bischoff, Katrina Swett, Iris Leng, Timothy R. Peters, Exposure to Influenza Virus Aerosols During Routine Patient Care, The Journal of Infectious Diseases, Volume 207, Issue 7, 1 April 2013, Pages 1037–1046, https://doi.org/10.1093/infdis/jis773) That did not stop the misrepresentation of the study to be used as the basis for an unverified medical counter measure of social distancing. To date, no study has established the efficacy of social distancing to modify the transmission of SARS CoV-2. Public health officials have referenced:

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907354/#CR43

 

In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a “belief” that social distancing of a healthy population limits the spread of SARS CoV-2. To date, not a single study has confirmed that social distancing of any population prevented the transmission of, or the infection by SARS CoV-2.

 

 

It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product or service can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well- controlled human clinical studies, substantiating that the claims are true at the time they are made. As a result, every party promoting the use of face masks is violating the FTC Act.

 

 

 

The Commercial Actors

SARS coronavirus is a new topic for many individuals. Since 1999, the ability to manipulate and exploit coronavirus for a variety of purposes has attracted the attention of individuals, institutions and commercial organizations in public, private, and not-for-profit sectors.

The following is a list of over 4,000 patents and patent applications filed for the express purpose of controlling some aspect of the SARS coronavirus.

PATENT

Title

Owner

Priority

File Date

Issue Date

 

US9995706

 

Amperometric gas sensor

 

Steris Corporation

25-

Jun- 12

30-

Sep

-14

12-

Jun- 18

 

 

US9995705

 

Amperometric gas sensor

 

Steris Corporation

25-

Jun- 12

30-

Sep

-14

12-

Jun- 18

 

US9994558

 

Multicyclic compounds and methods of using same

 

Karyopharm Therapeutics Inc.

20-

Sep- 13

19-

Sep

-14

12-

Jun- 18

 

US9994550

Heterocyclic modulators of lipid synthesis for use against cancer and viral infections

 

3-V Biosciences, Inc.

7-

Jan- 14

7-

Jan

-15

12-

Jun- 18

 

US9993543

Immunogenic compositions comprising silicified virus and methods of use

 

Portland State University

31-

Jan- 13

31-

Jan

-14

12-

Jun- 18

 

US9982257

 

Chiral control

 

WAVE LIFE SCIENCES LTD.

13-

Jul-12

12-

Jul- 13

29-

May

-18

 

US9982241

 

Recombinant HCMV and RHCMV vectors and uses thereof

 

Oregon Health & Science University

14-

May- 10

1-

Oct

-15

29-

May

-18

 

US9982025

 

Monomeric griffithsin tandemers

The United States of America, as represented by the Secretary, Department of Health and Human Services

5-

Jun- 13

5-

Jun

-14

29-

May

-18

 

US9981036

 

Compositions, comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same

 

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

12-

Dec- 11

26-

Feb

-16

29-

May

-18

 

US9975885

 

Broad-spectrum non-covalent coronavirus protease inhibitors

 

PURDUE RESEARCH FOUNDATION

28-

Apr- 16

28-

Apr

-17

22-

May

-18

 

US9974850

 

Immunogenic compositions and uses thereof

 

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

25-

Mar- 15

25-

Mar

-16

22-

May

-18

 

US9974848

 

Tetanus toxoid and CCL3 improve DC vaccines

 

Duke University

14-

Nov- 13

14-

Nov

-14

22-

May

-18

 

US9974845

 

Combination of vaccination and inhibition of the PD-1 pathway

 

CureVac AG

22-

Feb- 13

21-

Feb

-14

22-

May

-18

 

US9970061

 

Bioagent detection oligonucleotides

 

IBIS BIOSCIENCES, INC.

27-

Dec- 11

27-

Dec

-12

15-

May

-18

 

US9969793

 

Compositions and methods for the treatment of immunodeficiency

 

ADMA Biologics, Inc.

28-

Oct- 14

13-

Nov

-17

15-

May

-18

 

US9963718

LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus- producing cells for the therapy of tumors

 

VIRATHERAPEUTICS GMBH

8-

Oct- 08

7-

Apr

-17

8-

May

-18

 

US9963611

Composition for use in decreasing the transmission of human pathogens

 

Innonix Technologies, Incorporated

29-

May- 09

21-

May

-10

8-

May

-18

 

US9963427

 

Dithiol mucolytic agents

 

PARION SCIENCES, INC.

23-

Aug- 13

11-

Mar

-16

8-

May

-18

 

US9962439

 

Injectable vaccine composition

 

NITTO DENKO CORPORATION

3-

Oct- 13

2-

Oct

-14

8-

May

-18

 

US9957302

 

Treating cancer with viral nucleic acid

 

Mayo Foundation for Medical Education and Research

20-

Feb- 07

6-

Jul- 15

1-

May

-18

 

US9957300

Virus-like particles, methods of preparation, and immunogenic compositions

 

Emory University

17-

May- 02

4-

May

-15

1-

May

-18

 

US9957238

Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

 

Parion Sciences, Inc.

13-

Dec- 13

1-

Mar

-17

1-

May

-18

 

US9951317

 

Highly efficient influenza matrix (M1) proteins

 

NOVAVAX, INC.

11-

Jul-03

6-

Oct

-16

24-

Apr- 18

 

US9951124

 

Antibody producing non-human mammals

 

MERUS N.V.

27-

Jun- 08

25-

Jan

-13

24-

Apr- 18

 

US9951122

 

Antibodies against influenza virus and methods of use thereof

 

BURNHAM INSTITUTE FOR MEDICAL RESEARCH

6-

Dec- 07

12-

Aug

-13

24-

Apr- 18

 

US9950062

 

Compounds and compositions as TLR activity modulators

 

GLAXOSMITHKLINE BIOLOGICALS SA

2-

Sep- 09

1-

Sep

-10

24-

Apr- 18

 

US9945856

Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics

 

AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V.

18-

Aug- 03

13-

Aug

-14

17-

Apr- 18

 

US9945780

Use of a fluorescent material to detect failure or deteriorated performance of a fluorometer

 

GEN-PROBE INCORPORATED

14-

Jun- 12

7-

Jun

-13

17-

Apr- 18

 

US9944928

Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions

 

York Yuan Yuan Zhu

23-

Jul-07

2-

Jul- 15

17-

Apr- 18

 

US9944695

 

Antibody producing non-human mammals

 

Merus N.V.

27-

Jun- 08

30-

Apr

-14

17-

Apr- 18

 

US9944686

 

Treatment of tumors with recombinant interferon alpha

 

SUPERLAB FAR EAST LIMITED

28-

Feb- 01

5-

Sep

-13

17-

Apr- 18

 

US9944649

 

Compounds and compositions as toll-like receptor 7 agonists

 

Novartis Ag

1-

May- 14

29-

Apr

-15

17-

Apr- 18

 

US9943614

Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods

 

BRIGHAM YOUNG UNIVERSITY

17-

Jun- 08

16-

Jun

-09

17-

Apr- 18

 

US9938300

 

Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors

 

Forma Therapeutics, Inc.

5-

Feb- 15

4-

Feb

-16

10-

Apr- 18

 

US9938275

Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines

 

3M Innovative Properties Company

18-

Jun- 04

23-

Jan

-17

10-

Apr- 18

 

US9938258

 

Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof

 

Karyopharm Therapeutics Inc.

29-

Nov- 12

27-

Nov

-13

10-

Apr- 18

 

US9932351

 

Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors

 

Forma Therapeutics, Inc.

5-

Feb- 15

4-

Feb

-16

3-

Apr- 18

 

US9932323

Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones

 

Rutgers, The State University of New Jersey

11-

Sep- 12

13-

Jan

-17

3-

Apr- 18

 

US9931316

Antiviral activity from medicinal mushrooms and their active constituents

 

Not Available

31-

Mar- 15

14-

Sep

-15

3-

Apr- 18

 

US9926340

NAD analogs and methods of using said NAD analogs in determining ribosylation of proteins with PARP mutants

Biolog Life Science Institute Forshungslabor und Biochemica-Vertrieb GmbH

8-

Apr- 15

1-

Apr

-16

27-

Mar

-18

 

 

 

 

US9925215

 

 

Anionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as medicine, particularly for propylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hMPV), human rhinoviruses (HRV), and infection by influenza virus type A (IAV) and pharmaceutical composition comprising the anionically modified polyallylamine derivative

 

 

 

 

UNIWERSYTET JAGIELLONSKI

 

 

 

 

29-

Jul-14

 

 

 

25-

Oct

-17

 

 

 

27-

Mar

-18

 

US9920314

 

Compositions for and methods of identifying antigens

 

President and Fellows of Harvard College

21-

Feb- 06

6-

May

-15

20-

Mar

-18

 

US9920128

 

Synthetic antiserum for rapid-turnaround therapies

 

The Johns Hopkins University

28-

Jan- 15

20-

Jan

-16

20-

Mar

-18

 

US9919034

Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V

 

TAMIR BIOTECHNOLOGY, INC.

28-

Mar- 14

10-

Jun

-15

20-

Mar

-18

 

US9915613

Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector

 

GEN-PROBE INCORPORATED

24-

Feb- 11

21-

Mar

-14

13-

Mar

-18

 

US9914976

 

Methods and compositions for prostate cancer metastasis

FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FA

25-

Mar- 11

27-

May

-16

13-

Mar

-18

 

US9913801

Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione

 

YOUR ENERGY SYSTEMS, LLC

15-

Feb- 13

15-

Mar

-13

13-

Mar

-18

 

US9909176

Efficient deep sequencing and rapid genomic speciation of RNA viruses (vRNAseq)

 

The Johns Hopkins University

8-

Sep- 14

1-

Sep

-15

6-

Mar

-18

 

US9908946

 

Generation of binding molecules

 

Merus N.V.

26-

Sep- 11

16-

Sep

-15

6-

Mar

-18

 

US9908675

 

Powdered pouch and method of making same

 

MONOSOL, LLC

16-

Apr- 12

19-

Jul- 16

6-

Mar

-18


 

US9907796

 

Methods of treating tumoral diseases, or bacterial or viral infections

 

INHIBIKASE THERAPEUTICS, INC.

4-

Oct- 12

15-

Sep

-16

6-

Mar

-18

 

US9895692

 

Sample-to-answer microfluidic cartridge

 

Micronics, Inc.

29-

Jan- 10

5-

Aug

-15

20-

Feb

-18

 

US9895411

 

Analogs of C5a and methods of using same

 

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

29-

Jun- 10

29-

Jun

-11

20-

Feb

-18

 

US9895341

 

Inflammation and immunity treatments

 

Ocean Spray Cranberries, Inc.

1-

Apr- 11

30-

Mar

-12

20-

Feb

-18

 

US9894888

 

Transgenic immunodeficient mouse expressing human SIRP-alpha

 

INSTITUT PASTEUR

26-

Mar- 12

26-

Mar

-13

20-

Feb

-18

 

US9890419

 

Nanoreporters and methods of manufacturing and use thereof

 

NanoString Technologies, Inc.

23-

Dec- 05

20-

May

-16

13-

Feb

-18

 

US9890408

 

Multiple displacement amplification

 

IBIS BIOSCIENCES, INC.

15-

Oct- 09

15-

Oct

-10

13-

Feb

-18

 

US9890362

 

Compositions, methods and uses for inducing viral growth

 

Takeda Vaccines, Inc.

5-

Dec- 08

19-

Sep

-14

13-

Feb

-18

 

US9890361

Methods for increasing the infectivity of viruses utilizing alkyne- modified fatty acids

 

LIFE TECHNOLOGIES CORPORATION

26-

Jan- 12

25-

Jan

-13

13-

Feb

-18

 

US9890206

 

H1N1 flu virus neutralizing antibodies

 

Medigen Biotechnology Corporation

20-

Aug- 15

20-

Aug

-15

13-

Feb

-18

 

US9890169

 

Triazolinone compounds as HNE inhibitors

 

CHIESI FARMACEUTICI S.P.A.

14-

Dec- 15

12-

Dec

-16

13-

Feb

-18

 

US9890124

 

Benzazepine sulfonamide compounds

 

Hoffmann-La Roche Inc.

15-

Dec- 15

14-

Jun

-17

13-

Feb

-18

 

US9889194

 

Immunogenic composition for MERS coronavirus infection

 

New York Blood Center, Inc.

1-

Mar- 13

28-

Feb

-14

13-

Feb

-18

 

US9885092

 

Materials and methods for detection of HPV nucleic acids

 

QIAGEN GAITHERSBURG INC.

24-

Feb- 11

23-

Feb

-12

6-

Feb

-18

 

US9885082

 

Embodiments of a probe and method for targeting nucleic acids

 

University of Idaho

19-

Jul-11

19-

Jul- 12

6-

Feb

-18

 

US9885037

 

Chiral control

 

WAVE LIFE SCIENCES LTD.

13-

Jul-12

12-

Jul- 13

6-

Feb

-18

 

US9884895

 

Methods and compositions for chimeric coronavirus spike proteins

 

The University of North Carolina at Chapel Hill

20-

Mar- 14

20-

Mar

-15

6-

Feb

-18

 

US9884876

Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

 

Kineta, Inc.

9-

May- 14

8-

May

-15

6-

Feb

-18

 

US9884129

 

Release of agents from cells

 

The Brigham and Women's Hospital, Inc.

15-

Oct- 09

5-

Jan

-15

6-

Feb

-18

 

US9884032

Esters of short chains fatty acids for use in the treatment of immunogenic disorders

 

PROPONENT BIOTECH GMBH

3-

Oct- 12

3-

Mar

-16

6-

Feb

-18

 

US9884026

 

Modular particles for immunotherapy

 

YALE UNIVERSITY

1-

Nov- 13

31-

Oct

-14

6-

Feb

-18

 

US9880151

Method of determining, identifying or isolating cell-penetrating peptides

 

Phylogica Limited

23-

May- 11

23-

May

-12

30-

Jan- 18

 

US9879026

 

Substituted spirocycles

 

Boehringer Ingelheim International GmbH

12-

Sep- 14

29-

Nov

-16

30-

Jan- 18

 

US9879003

 

Host targeted inhibitors of dengue virus and other viruses

 

Dana-Farber Cancer Institute, Inc.

11-

Apr- 12

15-

Mar

-13

30-

Jan- 18

 

US9878988

 

Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases

 

PARION SCIENCES, INC.

29-

May- 12

5-

Jan

-16

30-

Jan- 18

 

US9873678

 

Chemical compounds

 

AstraZeneca AB

18-

Mar- 14

17-

Mar

-15

23-

Jan- 18

 

US9873674

 

C-Rel inhibitors and uses thereof

 

CORNELL UNIVERSITY

21-

Sep- 12

19-

Sep

-13

23-

Jan- 18

 

US9872900

 

Nucleic acid vaccines

 

ModernaTX, Inc.

23-

Apr- 14

5-

Apr

-16

23-

Jan- 18

 

US9872898

Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome

 

Ohio State Innovation Founation

24-

Apr- 12

3-

Oct

-16

23-

Jan- 18

 

US9872895

TLR5 ligands, therapeutic methods, and compositions related thereto

 

Emory University

24-

Sep- 10

20-

Sep

-11

23-

Jan- 18

 

US9868952

Compositions and methods for “resistance-proof†SiRNA therapeutics for influenza

 

Sirnaomics, Inc.

8-Jul- 12

7-

Jul- 13

16-

Jan- 18

 

US9868740

 

Pyrimidinone compounds which are HNE inhibitors

 

CHIESI FARMACEUTICI S.p.A.

12-

Jun- 14

12-

Jun

-14

16-

Jan- 18

 

US9868736

 

Deubiquitinase inhibitors and methods for use of the same

 

THE REGENTS OF THE UNIVERSITY OF MICHIGAN

10-

Oct- 13

10-

Oct

-14

16-

Jan- 18

 

US9867882

 

Carbohydrate conjugates as delivery agents for oligonucleotides

 

Alnylam Pharmaceuticals, Inc.

4-

Dec- 07

25-

Aug

-15

16-

Jan- 18

 

US9867877

 

Methods for preparing squalene

 

NOVARTIS AG

12-

May- 10

22-

Nov

-16

16-

Jan- 18

 

US9862706

 

Compounds

 

CHIESI FARMACEUTICI S.p.A.

31-

May- 16

26-

May

-17

9-

Jan- 18

 

US9861614

 

Nuclear transport modulators and uses thereof

 

Karyopharm Therapeutics Inc.

9-

May- 12

23-

Jun

-15

9-

Jan- 18

 

US9856254

 

Alkoxy substituted imidazoquinolines

 

3M Innovative Properties Company

3-

Oct- 03

13-

Jun

-16

2-

Jan- 18

 

US9856241

Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

 

Karyopharm Therapeutics Inc.

3-Jul- 13

3-

Jul- 14

2-

Jan- 18

 

US9856228

 

Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors

 

PROZYMEX A/S

9-

Sep- 13

8-

Sep

-14

2-

Jan- 18

 

US9856224

 

Stable sodium channel blockers

 

PARION SCIENCES, INC.

30-

Jun- 14

30-

Jan

-17

2-

Jan- 18

 

US9855287

 

Anti-viral azide containing compounds

 

LIFE TECHNOLOGIES CORPORATION

28-

Jul-10

20-

Aug

-15

2-

Jan- 18

 

US9855284

 

Pharmaceutical compositions and methods

 

Pop Test Oncology LLC

3-

Aug- 15

6-

Dec

-16

2-

Jan- 18

 

US9849143

 

Broad spectrum antiviral and methods of use

 

The Burlington HC Research Group, Inc.

17-

Apr- 06

16-

Feb

-17

26-

Dec

-17

 

US9845342

Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria

 

Spogen Biotech Inc.

17-

Sep- 14

17-

Sep

-15

19-

Dec

-17

 

US9840731

 

Preservation of biological materials in non-aqueous fluid media

 

Gentegra, LLC

14-

Mar- 13

14-

Mar

-14

12-

Dec

-17

 

US9840719

Variant AAV and compositions, methods and uses for gene transfer to cells, organs and tissues

 

The Children's Hospital of Philadelphia

22-

Jul-13

22-

Jul- 14

12-

Dec

-17

 

US9840491

Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

 

FORMA Therapeutics, Inc.

5-

Feb- 15

4-

Feb

-16

12-

Dec

-17

 

US9839687

Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule

 

SUZHOU M-CONJ BIOTECH CO., LTD.

15-

Jul-15

15-

Jul- 15

12-

Dec

-17

 

US9834812

 

Probe kit for detecting a single strand target nucleotide sequence

 

Fondazione Istituto Italiano Di Tecnologia

27-

Dec- 12

27-

Dec

-13

5-

Dec

-17

 

US9834791

 

CRISPR-related methods and compositions with governing gRNAS

 

Editas Medicine, Inc.

7-

Nov- 13

7-

Nov

-14

5-

Dec

-17

 

US9834757

Hand, foot, and mouth vaccines and methods of manufacture and use thereof

 

Takeda Vaccines, Inc.

7-

Nov- 14

6-

Nov

-15

5-

Dec

-17

 

US9834595

Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

 

Ablynx N.V.

5-

Jun- 08

29-

Oct

-15

5-

Dec

-17

 

US9833504

 

Virus-like particles and process for preparing same

 

Folia Biotech Inc.

13-

May- 11

1-

May

-12

5-

Dec

-17

 

US9833492

 

Combinations of a caspase inhibitor and an antiviral agent

 

Centre National de la Recherche Scientifique

2-

Nov- 07

15-

May

-15

5-

Dec

-17

 

US9832998

 

Antiviral compositions

 

Long Island University

30-

May- 07

19-

Mar

-15

5-

Dec

-17

 

US9828382

 

Pyrimidinone compounds as human neutrophil elastase inhibitors

 

Chiesi Farmaceutici S.p.A.

18-

Dec- 12

10-

May

-16

28-

Nov

-17

 

US9828379

Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof

 

ABIDE THERAPEUTICS, INC.

3-Jul- 13

1-

Jul- 14

28-

Nov

-17

 

US9828370

 

Compositions and methods for inhibiting kinases

 

INHIBIKASE THERAPEUTICS, INC.

23-

Apr- 15

22-

Apr

-16

28-

Nov

-17

 

US9828346

 

N-myristoyl transferase inhibitors

 

University of Dundee

2-

Sep- 08

31-

Aug

-15

28-

Nov

-17

 

US9828342

Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof

 

CITY OF HOPE

24-

Feb- 12

25-

Feb

-13

28-

Nov

-17

 

US9827190

Intradermal delivery of immunological compositions comprising toll- like receptor 7 agonists

 

GLAXOSMITHKLINE BIOLOGICALS SA

1-

Feb- 13

30-

Jan

-14

28-

Nov

-17

 

US9822339

Means and methods for influencing the stability of antibody producing cells

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

9-

Dec- 05

26-

Aug

-15

21-

Nov

-17

 

US9822173

 

Heterodimeric immunoglobulins

 

AMGEN INC.

21-

Nov- 12

21-

Nov

-13

21-

Nov

-17

 

US9822165

Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region

 

DANA-FARBER CANCER INSTITUTE, INC.

18-

Jun- 09

18-

Jun

-10

21-

Nov

-17

 

US9822155

Method of preventively treating a subject at the risk of developing infections of a respiratory virus

 

Xiangxue Group (Hong Kong) Company Limited

9-

May- 13

23-

Aug

-16

21-

Nov

-17

 

US9822127

 

GAK modulators as antivirals

The Board of Trustees of the Leland Stanford Junior University

23-

Jul-14

23-

Jul- 15

21-

Nov

-17

 

US9822065

 

Benzazepine dicarboxamide compounds

 

Hoffmann-La Roche Inc.

6-

Mar- 15

14-

Feb

-17

21-

Nov

-17

 

US9821052

 

Reverse genetics systems

 

Seqirus UK Limited

31-

Jul-09

30-

Jul- 10

21-

Nov

-17

 

US9821051

 

Reducing hospitalization in elderly influenza vaccine recipients

 

Seqirus UK Limited

28-

Oct- 10

21-

Oct

-11

21-

Nov

-17

 

US9816078

Compositions for increasing polypeptide stability and activity, and related methods

 

SOLIS BIODYNE OÜ

19-

Nov- 09

11-

Mar

-16

14-

Nov

-17

 

US9815886

 

Compositions and methods for the treatment of immunodeficiency

 

ADMA BIOLOGICS, INC.

28-

Oct- 14

8-

Jan

-15

14-

Nov

-17

 

US9815805

 

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as dipeptidyl peptidase 1 inhibitors

 

ASTRAZENECA AB

24-

Jan- 14

8-

Nov

-16

14-

Nov

-17

 

US9814777

 

Targeting lipids

 

Arbutus Biopharma Corporation

4-

Dec- 07

22-

Oct

-13

14-

Nov

-17

 

US9810683

Use of live cell inteferometry with reflective floor of observation chamber to determine changes in mass of mammalian cells

 

The Regents of the University of California

6-

May- 09

25-

Nov

-13

7-

Nov

-17

 

US9809845

 

Methods and reagents for amplifying nucleic acids

The United States of America, as represented by the Secretary, Department of Health and Human Services

6-

Aug- 12

6-

Aug

-12

7-

Nov

-17

 

US9809796

 

Animal protein-free media for cultivation of cells

 

Baxalta GmbH

29-

Oct- 04

18-

May

-17

7-

Nov

-17

 

US9809632

 

Universal protein tag for double stranded nucleic acid delivery

University of Washington Through its Center for Commercialization

23-

Oct- 13

22-

Oct

-14

7-

Nov

-17

 

US9809591

 

Heterocyclic modulators of lipid synthesis

 

3-V Biosciences, Inc.

8-

Mar- 11

5-

Oct

-15

7-

Nov

-17

 

US9808490

 

Induced hepatocytes and uses thereof

 

ACCELERATED BIOSCIENCES CORP.

26-

Nov- 14

25-

Nov

-15

7-

Nov

-17

 

US9803236

Microarray-based assay integrated with particles for analyzing molecular interactions

 

CapitalBio Corporation

6-

Aug- 10

6-

Aug

-10

31-

Oct- 17

 

US9803197

 

Particle-nucleic acid conjugates and therapeutic uses related thereto

 

Emory University

25-

Jun- 12

27-

Feb

-13

31-

Oct- 17

 

US9802937

 

Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors

 

ORIGENIS GMBH

21-

Apr- 11

23-

Apr

-12

31-

Oct- 17

 

US9802919

 

Compounds

 

CHIESI FARMACEUTICI S.p.A.

31-

May- 16

26-

May

-17

31-

Oct- 17

 

US9801948

 

Antimicrobial compositions and methods of use thereof

 

Yale University

21-

Sep- 11

21-

Sep

-12

31-

Oct- 17

 

US9801947

 

Methods and compositions for enhancing immune response

 

3M INNOVATIVE PROPERTIES COMPANY

10-

Apr- 03

6-

Oct

-14

31-

Oct- 17

 

US9801935

 

Soluble needle arrays for delivery of influenza vaccines

 

SEQIRUS UK LIMITED

20-

Aug- 10

11-

Oct

-16

31-

Oct- 17

 

US9801897

 

Delivery of RNA to trigger multiple immune pathways

 

GLAXOSMITHKLINE BIOLOGICALS SA

6-Jul- 10

6-

Jul- 11

31-

Oct- 17

 

US9797000

Non-target amplification method for detection of RNA splice-forms in a sample

 

QIAGEN GAITHERSBURG INC.

1-

May- 09

30-

Apr

-10

24-

Oct- 17

 

US9796979

 

Oligonucleotide modulators of the toll-like receptor pathway

 

Quark Pharmaceuticals Inc.

3-

Mar- 11

28-

Jul- 16

24-

Oct- 17

 

US9796735

 

Boron-containing small molecules

 

Anacor Pharmaceuticals, Inc.

20-

Jun- 07

7-

Nov

-14

24-

Oct- 17

 

US9795669

Lipidated immune response modifier compound compositions, formulations, and methods

 

3M INNOVATIVE PROPERTIES COMPANY

17-

Aug- 10

15-

Dec

-15

24-

Oct- 17

 

US9795668

Delivery of self-replicating RNA using biodegradable polymer particles

 

GlaxoSmithKline Biologicals S.A.

6-Jul- 10

23-

Nov

-15

24-

Oct- 17

 

US9795666

High-yield transgenic mammalian expression system for generating virus-like particles

 

Academia Sinica

5-

Sep- 06

11-

Feb

-15

24-

Oct- 17

 

US9791437

 

Multianalyte assay

 

Nexus Dx, Inc.

30-

Apr- 07

15-

Jun

-15

17-

Oct- 17

 

US9789180

D-amino acid derivative-modified peptidoglycan and methods of use thereof

 

The Regents of the University of California

30-

Nov- 12

31-

Mar

-16

17-

Oct- 17

 

US9786050

 

Stain-free histopathology by chemical imaging

 

The Board of Trustees of the University of Illinois

15-

Mar- 13

14-

Mar

-14

10-

Oct- 17

 

US9783595

 

Neutralizing GP41 antibodies and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services

7-

Nov- 11

2-

Aug

-16

10-

Oct- 17

 

US9782470

 

Method of obtaining thermostable dried vaccine formulations

 

Merck Sharp & Dohme Corp.

16-

Oct- 13

13-

Oct

-14

10-

Oct- 17

 

US9782434

Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution

 

Sonoma Pharmaceuticals, Inc.

20-

Jan- 06

7-

Jul- 15

10-

Oct- 17

 

US9770504

 

Generating peptoid vaccines

 

The Board of Regents of the University of Texas System

3-

May- 13

2-

May

-14

26-

Sep

-17

 

US9770463

 

Delivery of RNA to different cell types

 

GLAXOSMITHKLINE BIOLOGICALS SA

6-Jul- 10

7-

Jun

-11

26-

Sep

-17

 

US9765395

System and method for DNA sequencing and blood chemistry analysis

 

Nanomedical Diagnostics, Inc.

28-

Apr- 14

10-

Apr

-15

19-

Sep

-17

 

US9765133

 

Antibody producing non-human mammals

 

Merus N.V.

27-

Jun- 08

29-

Apr

-14

19-

Sep

-17

 

US9765071

 

Substituted imidazo ring systems and methods

 

3M INNOVATIVE PROPERTIES COMPANY

25-

Nov- 03

14-

Mar

-16

19-

Sep

-17

 

US9764027

 

Outer membrane vesicles

 

GLAXOSMITHKLINE BIOLOGICALS SA

18-

Sep- 12

18-

Sep

-13

19-

Sep

-17

 

US9759723

 

B-cell antigen presenting cell assay

University of Pittsburgh—Of the Commonwealth System of Higher Education

8-

Apr- 10

21-

Mar

-16

12-

Sep

-17

 

US9758840

 

Parasite detection via endosymbiont detection

 

IBIS BIOSCIENCES, INC.

14-

Mar- 10

11-

Mar

-11

12-

Sep

-17

 

US9758820

 

Organism identification panel

 

BioFire Diagnostics, LLC

2-

Apr- 07

1-

Apr

-08

12-

Sep

-17

 

US9758775

 

TAL effector-mediated DNA modification

 

Iowa State University Research Foundation, Inc.

10-

Dec- 09

14-

Apr

-14

12-

Sep

-17

 

US9758568

 

Oligopeptide-free cell culture media

 

Baxalta GmbH

4-

Jan- 06

16-

Nov

-15

12-

Sep

-17

 

US9758553

Yeast strain for the production of proteins with terminal alpha-1,3- linked galactose

 

MERCK SHARP & DOHME CORP.

30-

May- 08

2-

Jul- 14

12-

Sep

-17

 

US9757478

 

Mutant protease biosensors with enhanced detection characteristics

 

Promega Corporation

11-

May- 10

7-

Jan

-16

12-

Sep

-17

 

US9757470

 

Peptides for assisting delivery across the blood brain barrier

 

Children's Medical Center Corporation

22-

May- 06

30-

Apr

-14

12-

Sep

-17

 

US9757446

 

Influenza virus vectors and uses therefor

 

FLUGEN, INC.

17-

Mar- 14

13-

Mar

-15

12-

Sep

-17

 

US9757407

Treatment of viral infections by modulation of host cell metabolic pathways

 

The Trustees of Princeton University

1-

Jun- 07

21-

Dec

-15

12-

Sep

-17

 

US9751945

 

Sortase-modified VHH domains and uses thereof

 

Whitehead Institute for Biomedical Research

13-

Apr- 12

15-

Apr

-13

5-

Sep

-17

 

US9750798

Bunyaviruses with segmented glycoprotein precursor genes and methods for generating these viruses

 

STICHTING WAGENINGEN RESEARCH

21-

May- 13

21-

May

-14

5-

Sep

-17

 

US9750797

 

Sustained release vaccine composition

 

VIRBAC CORPORATION

16-

Jun- 04

16-

Jun

-05

5-

Sep

-17

 

US9750690

Circulation of components during microfluidization and/or homogenization of emulsions

 

NOVARTIS AG

3-

Dec- 09

5-

Sep

-14

5-

Sep

-17

 

US9746985

System and method for detecting, collecting, analyzing, and communicating event-related information

 

Georgetown University

25-

Feb- 08

20-

Apr

-11

29-

Aug

-17

 

US9746459

 

Antigen presenting cell assay

University of Pittsburgh—Of the Commonwealth System of Higher Education

8-

Apr- 10

11-

Oct

-13

29-

Aug

-17

 

 

US9745306

2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4- D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin- 4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors

 

 

Respivert Limited

 

15-

Mar- 13

 

14-

Mar

-14

 

29-

Aug

-17

 

US9744231

Quality control methods for oil-in-water emulsions containing squalene

 

NOVARTIS AG

8-

Nov- 06

27-

Aug

-13

29-

Aug

-17

 

US9744229

Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same

 

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

4-

Apr- 08

28-

Apr

-14

29-

Aug

-17

 

US9744183

 

Nucleic acid prodrugs and methods of use thereof

 

WAVE LIFE SCIENCES LTD.

6-Jul- 09

6-

Jul- 10

29-

Aug

-17

 

US9738894

 

Short interfering RNA (siRNA) analogues

 

Roche Innovation Center Copenhagen A/S

21-

Mar- 03

28-

Mar

-16

22-

Aug

-17

 

US9738624

 

Nuclear transport modulators and uses thereof

 

Karyopharm Therapeutics Inc.

21-

Jun- 13

20-

Jun

-14

22-

Aug

-17

 

US9737618

Adeno-associated virus (AAV) glades, sequences, vectors containing same, and uses therefor

 

The Trustees of the University of Pennsylvania

30-

Sep- 03

20-

Jul- 15

22-

Aug

-17

 

US9737593

 

Carbon nanotube compositions and methods of use thereof

 

Yale University

19-

Mar- 08

15-

Mar

-13

22-

Aug

-17

 

US9730997

 

Alphavirus vectors for respiratory pathogen vaccines

 

Novartis Vaccines and Diagnostics, Inc.

21-

May- 04

20-

Aug

-14

15-

Aug

-17

 

US9730912

 

Pharmaceutical compounds

 

ASTEX THERAPEUTICS LIMITED

12-

Oct- 06

12-

Oct

-07

15-

Aug

-17

 

US9727810

 

Spatially addressable molecular barcoding

 

Cellular Research, Inc.

27-

Feb- 15

26-

Feb

-16

8-

Aug

-17

 

US9726607

 

Systems and methods for detecting multiple optical signals

 

GEN-PROBE INCORPORATED

10-

Mar- 05

3-

Mar

-14

8-

Aug

-17

 

US9725770

Methods and compositions for identification of source of microbial contamination in a sample

 

The Regents of the University of California

6-

Mar- 12

6-

Mar

-13

8-

Aug

-17

 

US9725487

 

Compositions and methods for measles virus inhibition

 

Autoimmune Technologies, LLC

4-

Nov- 03

13-

May

-15

8-

Aug

-17

 

US9719106

Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof

 

The Trustees of the University of Pennsylvania

29-

Apr- 13

29-

Apr

-14

1-

Aug

-17

 

US9719083

 

Bioagent detection methods

 

IBIS BIOSCIENCES, INC.

8-

Mar- 09

8-

Mar

-10

1-

Aug

-17

 

US9718774

 

Indole carboxamide derivatives as P2X7 receptor antagonist

 

IDORSIA PHARMACEUTICALS LTD

12-

Dec- 12

11-

Dec

-13

1-

Aug

-17

 

US9717755

 

Method of treating inflammation

 

Cytosorbents Corporation

1-

Apr- 10

1-

Apr

-11

1-

Aug

-17

 

US9717749

 

Production of stable non-polyadenylated RNAs

 

Massachusetts Institute of Technology

16-

Oct- 12

16-

Oct

-13

1-

Aug

-17

 

US9717732

 

Drug combination

 

VERONA PHARMA PLC

15-

Mar- 13

17-

Mar

-14

1-

Aug

-17

 

US9714411

 

Animal protein-free media for cultivation of cells

 

Baxalta GmbH

29-

Oct- 04

30-

Nov

-15

25-

Jul- 17

 

US9714283

 

Compositions and methods for the treatment of immunodeficiency

 

ADMA BIOLOGICS, INC.

28-

Oct- 14

2-

Jul- 15

25-

Jul- 17

 

US9714226

 

Hydrazide containing nuclear transport modulators and uses thereof

 

Karyopharm Therapeutics Inc.

29-

Jul-11

13-

Nov

-15

25-

Jul- 17

 

US9713641

 

Anti-TIGIT antigen-binding proteins and methods of use thereof

 

Potenza Therapeutics, Inc.

13-

Feb- 17

13-

Feb

-17

25-

Jul- 17

 

 

US9713606

 

Methods for treating pulmonary emphysema using substituted 2- Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides inhibitors of cathepsin C

 

 

Boehringer Ingelheim International GmbH

 

14-

Mar- 13

 

1-

Dec

-15

 

25-

Jul- 17

 

US9708375

 

Inhibitory polypeptides specific to WNT inhibitors

 

Amgen Inc.

15-

Mar- 13

14-

Mar

-14

18-

Jul- 17

 

US9707278

Methods of modulating immune responses by modifying Akt3 bioactivity

 

Augusta University Research Institute, Inc.

17-

Apr- 14

17-

Apr

-15

18-

Jul- 17

 

US9701736

Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection

 

New York Blood Center, Inc.

20-

Oct- 10

9-

Oct

-14

11-

Jul- 17

 

US9701638

 

Therapeutic hydroxyquinolones

 

Rutgers, The State University of New Jersey

9-

Nov- 12

8-

Nov

-13

11-

Jul- 17

 

US9700616

Arranging interaction and back pressure chambers for microfluidization

 

NOVARTIS AG

3-

Dec- 09

22-

Mar

-16

11-

Jul- 17

 

US9700614

 

Intranasal vaccination dosage regimen

 

Eurocine Vaccines AB

17-

Dec- 12

17-

Dec

-13

11-

Jul- 17

 

US9700558

Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist

 

VERONA PHARMA PLC

15-

Mar- 13

17-

Mar

-14

11-

Jul- 17

 

US9696247

 

Sample fixation and stabilisation

 

RNASSIST LTD.

1-

Mar- 13

28-

Feb

-14

4-

Jul- 17

 

US9695445

Method for production of reprogrammed cell using chromosomally unintegrated virus vector

 

ID Pharma Co., Ltd.

16-

Jul-08

29-

Jul- 15

4-

Jul- 17

 

US9695135

 

Therapeutic catechols

 

Rutgers, The State University of New Jersey

12-

May- 14

11-

May

-15

4-

Jul- 17

 

US9695134

3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine- 2-carboxamide compounds

 

Parion Sciences, Inc.

17-

Dec- 12

8-

Jan

-15

4-

Jul- 17

 

US9689018

Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses

 

Diagnostic Hybrids, Inc.

24-

Apr- 98

4-

Aug

-14

27-

Jun- 17

 

US9688982

Methods and compositions for the treatment of cancer or other diseases

 

CITY OF HOPE

26-

Jan- 07

11-

Oct

-13

27-

Jun- 17

 

US9687536

 

Methods and compositions for intranasal delivery

 

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

15-

Apr- 10

15-

Apr

-11

27-

Jun- 17

 

US9683256

 

Biological specimen collection and transport system

 

Longhorn Vaccines and Diagnostics, LLC

1-

Oct- 07

15-

Dec

-15

20-

Jun- 17

 

US9683017

 

Inhibitory peptides of viral infection

 

UNIVERSITY TENNESSEE RESEARCH FOUNDATION

17-

Jul-14

16-

Jul- 15

20-

Jun- 17

 

US9682133

 

Disrupted adenovirus-based vaccine against drugs of abuse

 

CORNELL UNIVERSITY

17-

Mar- 10

17-

Mar

-11

20-

Jun- 17

 

US9677089

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

 

The Trustees of the University of Pennsylvania

17-

Dec- 01

30-

Mar

-16

13-

Jun- 17

 

US9676867

Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody

 

Dana-Farber Cancer Institute Inc.

2-

Dec- 05

8-

May

-13

13-

Jun- 17

 

US9676857

 

Soluble engineered monomeric Fc

The United States of America, as represented by the Secretary, Department of Health and Human Services

16-

Mar- 12

14-

Mar

-13

13-

Jun- 17

 

US9676727

 

Myxovirus therapeutics, compounds, and uses related thereto

 

Children's Healthcare of Atlanta, Inc.

24-

Oct- 11

7-

Jul- 16

13-

Jun- 17

 

US9675550

Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine

 

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

26-

Jul-10

25-

Jan

-13

13-

Jun- 17

 

US9670507

 

Directed evolution and in vivo panning of virus vectors

 

The University of North Carolina at Chapel Hill

30-

Apr- 08

28-

Jun

-16

6-

Jun- 17

 

US9670166

Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

 

Boehringer Ingelheim International GmbH

6-

Feb- 13

5-

Aug

-16

6-

Jun- 17

 

US9669092

 

Antagonism of the VIP signaling pathway

 

Emory University

2-

Feb- 11

31-

Jan

-12

6-

Jun- 17

 

 

US9669089

 

Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

 

 

CureVac AG

 

15-

Feb- 12

 

15-

Feb

-13

 

6-

Jun- 17

 

US9669088

 

Vaccination with multiple clades of H5 influenza A virus

 

Seqirus UK Limited

26-

Nov- 07

25-

Nov

-08

6-

Jun- 17

 

US9661856

 

Synergy of plant antimicrobials with silver

The Arizona Board of Regents on Behalf of The University of Arizona

24-

Aug- 12

26-

Aug

-13

30-

May

-17

 

US9657278

 

Methods to produce bunyavirus replicon particles

 

Stichting Dienst Landbouwkundig Onderzoek

20-

Sep- 10

10-

Jul- 15

23-

May

-17

 

US9657076

GM-CSF and IL-4 conjugates, compositions, and methods related thereto

 

Children's Healthcare of Atlanta, Inc.

23-

Oct- 12

23-

Oct

-13

23-

May

-17

 

US9657048

 

Enantiomers of the 1′,6′-isomer of neplanocin A

 

Auburn University

4-

Aug- 14

4-

Aug

-15

23-

May

-17

 

US9657015

Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

 

Boehringer Ingelheim International GmbH

31-

Jul-14

27-

Jul- 15

23-

May

-17

 

US9655896

Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity

 

PARION SCIENCES, INC.

27-

Jun- 11

12-

Jan

-15

23-

May

-17

 

US9655845

 

Oil-in-water emulsions that contain nucleic acids

 

GlaxoSmithKline Biologicals, S.A.

6-Jul- 11

6-

Jul- 12

23-

May

-17

 

US9655367

 

Disinfecting composition and wipes with reduced contact time

 

LONZA, INC.

6-

Nov- 13

4-

Nov

-14

23-

May

-17

 

US9651543

 

Malaria antigen screening method

The United States of America as Represented by the Secretary of the Navy

31-

Aug- 05

19-

Apr

-13

16-

May

-17

 

US9650685

 

Selective detection of human rhinovirus

The United States of America, as represented by the Secretary, Department of Health and Human Services

5-

Dec- 08

15-

Dec

-14

16-

May

-17

 

US9650649

LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus- producing cells for the therapy of tumors

 

VIRATHERAPEUTICS GMBH

8-

Oct- 08

8-

Oct

-09

16-

May

-17

 

US9649324

 

Use of tylvalosin as antiviral agent

 

CAMBRIDGE UNIVERSITY TECHNICAL SERVICES

13-

Jul-06

8-

Jun

-15

16-

May

-17

 

US9649309

Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity

 

The University of North Carolina at Chapel Hill

11-

Apr- 14

3-

Apr

-15

16-

May

-17

 

US9644180

 

Synthetic membrane-receiver complexes

 

RUBIUS THERAPEUTICS, INC.

18-

Nov- 13

12-

Jun

-15

9-

May

-17

 

US9642876

Method of preventing or treating sinusitis with oxidative reductive potential water solution

 

SONOMA PHARMACEUTICALS, INC.

30-

Dec- 03

27-

Oct

-15

9-

May

-17

 

US9642873

Combinations of TGFβ and COX-2 inhibitors and methods for their therapeutic application

 

Sirnaomics, Inc.

4-

May- 10

4-

May

-11

9-

May

-17

 

US9637524

Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector

 

The Regents of the University of California

27-

Feb- 09

5-

Nov

-14

2-

May

-17

 

US9637491

 

Pyrazolo[4,3-D]pyrimidines as kinase inhibitors

 

ORIGENIS GMBH

19-

Oct- 12

18-

Oct

-13

2-

May

-17

 

US9636410

 

Cationic oil-in-water emulsions

 

GLAXOSMITHKLINE BIOLOGICALS SA

6-Jul- 11

6-

Jul- 12

2-

May

-17

 

US9636397

 

Adjuvant compositions and related methods

 

Vaxliant, LLC

24-

Mar- 15

24-

Mar

-16

2-

May

-17

 

US9636370

 

AAV vectors targeted to oligodendrocytes

 

The University of North Carolina at Chapel Hill

28-

Sep- 12

27-

Sep

-13

2-

May

-17

 

US9629907

Compositions for and methods of inducing mucosal immune responses

 

The Trustees of the University of Pennsylvania

19-

Nov- 04

28-

Oct

-11

25-

Apr- 17

 

US9624173

 

Heterocyclic modulators of lipid synthesis

 

3-V Biosciences, Inc.

8-

Mar- 11

19-

Mar

-15

18-

Apr- 17

 

US9623040

Immunomodulation by controlling expression levels of microRNAs in dendritic cells

The Board of Trustees of the Leland Stanford Junior University

14-

Jul-14

10-

Jul- 15

18-

Apr- 17

 

US9618508

 

Flow cytometry analysis of materials adsorbed to metal salts

 

GlaxoSmithKline Biologicals SA

14-

Dec- 10

14-

Dec

-11

11-

Apr- 17

 

US9618476

 

System and method for electronic biological sample analysis

 

NANOMEDICAL DIAGNOSTICS, INC.

28-

Apr- 14

28-

Apr

-14

11-

Apr- 17

 

US9618429

 

Polymer stabilization of chromogen solutions

 

Ventana Medical Systems, Inc.

23-

Jan- 12

18-

Jan

-13

11-

Apr- 17

 

US9611481

Chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof

 

UNIVERSITE DE MONTPELLIER

24-

Sep- 09

23-

Sep

-10

4-

Apr- 17

 

US9611474

Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof

 

QUARK PHARMACEUTICALS, INC.

12-

Sep- 12

12-

Sep

-13

4-

Apr- 17

 

US9605276

 

Replication defective adenovirus vector in vaccination

 

Etubics Corporation

24-

Aug- 12

15-

Mar

-13

28-

Mar

-17

 

US9603864

 

Substituted nucleosides, nucleotides and analogs thereof

 

Alios BioPharma, Inc.

24-

Jun- 14

22-

Jun

-15

28-

Mar

-17

 

US9603850

 

MerTK-specific pyrazolopyrimidine compounds

 

The University of North Carolina at Chapel Hill

11-

Apr- 14

3-

Apr

-15

28-

Mar

-17

 

US9599606

 

ADP-ribose detection reagents

 

The Board of Regents of the University of Texas System

10-

Jun- 14

9-

Jun

-15

21-

Mar

-17

 

US9598459

 

Pharmaceutical compositions and methods

 

Pop Test Oncology LLC

3-

Aug- 15

28-

Jul- 16

21-

Mar

-17

 

US9597333

 

Benzazepine dicarboxamide compounds

 

Hoffmann-La Roche Inc.

6-

Mar- 15

28-

Sep

-16

21-

Mar

-17

 

US9593334

Use of the chromosome 19 microRNA cluster (C19MC) for treating viral disease and promoting authophagy

University of Pittsburgh—Of the Commonwealth System of Higher Education

7-

Mar- 12

6-

Mar

-13

14-

Mar

-17

 

US9593331

 

Double-stranded nucleic acid molecule for gene expression control

 

Osaka City University

2-

Nov- 11

1-

Nov

-12

14-

Mar

-17

 

US9593084

Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity

 

Parion Sciences, Inc.

17-

Dec- 12

13-

Dec

-13

14-

Mar

-17

 

US9592284

Immunization regimen with E4-deleted adenovirus prime and E1- deleted adenovirus boost

 

The Trustees of the University of Pennsylvania

28-

Apr- 04

27-

Apr

-05

14-

Mar

-17

 

US9592277

 

Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

 

Avirid, Inc.

14-

Apr- 04

14-

Apr

-05

14-

Mar

-17

 

US9588069

 

Methods for performing thermal melt analysis

 

GEN-PROBE INCORPORATED

31-

Jul-12

31-

Jul- 13

7-

Mar

-17

 

US9587250

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

 

Trustees of the University of Pennsylvania

17-

Dec- 01

16-

Jan

-15

7-

Mar

-17

 

US9586998

 

Methods of propagating monkey adenoviral vectors

 

GenVec, Inc.

9-

Nov- 09

4-

Aug

-15

7-

Mar

-17

 

US9586911

Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compounds

 

Parion Sciences, Inc.

13-

Dec- 13

19-

Dec

-14

7-

Mar

-17

 

 

US9586910

 

3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6- pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra zine-2-carboxamide

 

 

Parion Sciences, Inc.

 

27-

Jun- 11

 

18-

Dec

-13

 

7-

Mar

-17

 

US9585968

Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom

 

3M Innovative Properties Company

3-

Jun- 11

14-

Aug

-15

7-

Mar

-17

 

US9585953

Immunogenic compositions in particulate form and methods for producing the same

 

MUCOSIS B.V.

22-

Mar- 11

22-

Mar

-12

7-

Mar

-17

 

US9585874

 

Nuclear transport modulators and uses thereof

 

Karyopharm Therapeutics Inc.

9-

May- 12

6-

Jan

-16

7-

Mar

-17

 

US9585849

 

Broad spectrum antiviral and methods of use

 

The Burlington HC Research Group, Inc.

17-

Apr- 06

17-

Apr

-07

7-

Mar

-17

 

US9580474

 

Polyionic papilloma virus-like particle (VLP) vaccines

 

THE JOHNS HOPKINS UNIVERSITY

8-

Sep- 10

8-

Sep

-11

28-

Feb

-17

 

US9580468

Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells

CENTRE DE INVESTIGACION BIOMEDICA EN RED

BIOINGENIERA BIOMATERIALS Y NANOMEDICINA (CIBER BBN)

13-

Jan- 11

13-

Jan

-12

28-

Feb

-17

 

US9580429

 

Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy

 

AstraZeneca AB

6-

Dec- 04

15-

Sep

-14

28-

Feb

-17

 

US9574189

 

Enzymatic encoding methods for efficient synthesis of large libraries

 

Nuevolution A/S

1-

Dec- 05

1-

Dec

-06

21-

Feb

-17

 

US9574181

 

Influenza virus reassortment method

 

Seqirus UK Limited

21-

May- 10

24-

Oct

-14

21-

Feb

-17

 

US9573955

 

Compounds

 

Chiese Farmaceutici S.p.A.

16-

Dec- 13

16-

Dec

-14

21-

Feb

-17

 

US9573938

Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones

 

Rutgers, The State University of New Jersey

11-

Sep- 12

11-

Sep

-13

21-

Feb

-17

 

US9572899

 

Compositions for enhancing transport of molecules into cells

 

AVI BIOPHARMA, INC.

29-

Apr- 03

5-

Nov

-08

21-

Feb

-17

 

US9572864

 

Compositions and uses of lectins

 

Emory University

12-

Feb- 10

11-

Dec

-15

21-

Feb

-17

 

US9572823

 

Boron-containing small molecules

 

Anacor Pharmaceuticals, Inc.

16-

Feb- 05

5-

Apr

-16

21-

Feb

-17

 

US9567336

 

Conjugated TLR7 and/or TLR8 and TLR2 agonists

 

INVIVOGEN

19-

Nov- 12

15-

Mar

-13

14-

Feb

-17

 

US9566326

 

Adjuvanted influenza vaccines for pediatric use

 

Seqirus UK Limited

22-

Feb- 08

21-

Jun

-13

14-

Feb

-17

 

US9566291

 

Nutritional composition comprising indigestible oligosaccharides

 

N.V. Nutricia

24-

Aug- 04

24-

Aug

-05

14-

Feb

-17

 

US9566290

 

Boron-containing small molecules

 

Anacor Pharmaceuticals, Inc.

16-

Feb- 05

20-

Apr

-16

14-

Feb

-17

 

US9566289

 

Boron-containing small molecules

 

Anacor Pharmaceuticals, Inc.

16-

Feb- 05

17-

Feb

-16

14-

Feb

-17

 

US9565857

 

Antimicrobial solutions

 

Board of Regents, The University of Texas System

10-

Sep- 10

9-

Sep

-11

14-

Feb

-17

 

US9562110

 

Bispecific antibody

 

Wuhan YZY Biopharma Co., Ltd.

21-

Nov- 12

21-

Nov

-12

7-

Feb

-17

 

US9561263

 

Treatment of inflammatory illnesses with ACE2

 

Apeiron Biologics AG

18-

Dec- 07

18-

Dec

-08

7-

Feb

-17

 

US9556237

 

Antiviral rift valley fever virus peptides and methods of use

The United States of America, as represented by the Secretary of the Army, on behalf of the U.S. Army Medical

Research Institute of Infectious Diseases

6-

Dec- 12

4-

Jun

-15

31-

Jan- 17

 

US9556229

 

Modification of peptides using a bis(thioether)arylbridge approach

 

The Regents of the University of California

18-

May- 12

17-

May

-13

31-

Jan- 17

 

US9556184

 

Phosphoinositide 3-kinase inhibitors

 

Respivert, Ltd.

15-

Mar- 13

4-

Dec

-15

31-

Jan- 17

 

US9556117

 

Indole carboxamide derivatives as P2X7 receptor antagonists

 

ACTELION PHARMACEUTICALS LTD.

18-

Dec- 12

17-

Dec

-13

31-

Jan- 17

 

US9555031

Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity

 

The University of North Carolina at Chapel Hill

11-

Apr- 14

3-

Apr

-15

31-

Jan- 17

 

US9555030

Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity

 

The University of North Carolina at Chapel Hill

11-

Apr- 14

3-

Apr

-15

31-

Jan- 17

 

US9550773

Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines

 

3M Innovative Properties Company

18-

Jun- 04

13-

Apr

-15

24-

Jan- 17

 

US9550757

 

Nuclear transport modulators and uses thereof

 

Karyopharm Therapeutics Inc.

5-

Mar- 10

28-

Jun

-13

24-

Jan- 17

 

US9549949

 

Antiviral agent

 

NBC MESHTEC, INC.

3-

Sep- 08

31-

Aug

-09

24-

Jan- 17

 

US9549938

 

Boron-containing small molecules

 

Anacor Pharmaceuticals, Inc.

16-

Feb- 05

11-

Mar

-16

24-

Jan- 17

 

 

US9546371

 

Chimeric polynucleotides and polypeptides enabling secretion of a polypeptide of interest in association with exosomes and use thereof for the production of immunogenic compositions

 

 

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

 

18-

Mar- 08

 

18-

Mar

-09

 

17-

Jan- 17

 

US9546184

 

Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines

 

3M INNOVATIVE PROPERTIES COMPANY

13-

Aug- 08

8-

Jun

-15

17-

Jan- 17

 

US9546150

Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7

 

HYBRIGENICS SA

2-

Sep- 11

29-

Aug

-12

17-

Jan- 17

 

US9545440

 

Methods for preparing squalene

 

NOVARTIS AG

12-

May- 10

23-

Oct

-15

17-

Jan- 17

 

US9540373

 

Substituted spirocycles

 

Boehringer Ingelheim International GmbH

12-

Sep- 14

10-

Sep

-15

10-

Jan- 17

 

US9539321

 

HMGB1-derived peptides enhance immune response to antigens

 

The Regents of the University of California

27-

Jul-10

9-

Mar

-15

10-

Jan- 17

 

US9539217

 

Nanoparticle compositions

 

Allertein Therapeutics, LLC

3-

Apr- 13

3-

Apr

-14

10-

Jan- 17

 

US9533978

Pyrimidine derivatives and their use in the treatment of cancer and further diseases

 

Sumitomo Dainippon Pharma Co., Ltd

21-

May- 09

26-

Aug

-14

3-

Jan- 17

 

US9533037

Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes

 

Declion Holdings LLC

16-

Oct- 07

16-

Oct

-08

3-

Jan- 17

 

US9529974

System and method for detecting, collecting, analyzing, and communicating event-related information

 

Georgetown University

25-

Feb- 08

27-

Jul- 11

27-

Dec

-16

 

US9527903

 

Engineered antibody constant domain molecules

The United States of America, as represent by the Secretary, Department of Health and Human Services

31-

Jan- 08

1-

Oct

-13

27-

Dec

-16

 

US9526803

 

Diagnostic chewing gum for pathogens

 

Julius-Maximilians-Universitaet Wuerzburg

8-

Mar- 12

8-

Mar

-13

27-

Dec

-16

 

US9526700

 

Composition for inactivating an enveloped virus

 

VIROBLOCK SA

19-

May- 06

17-

Nov

-14

27-

Dec

-16

 

US9522962

Peptides, conjugates and method for increasing immunogenicity of a vaccine

 

Academisch Ziekenhuis Leiden h.o.d.n. LUMC

15-

Mar- 10

15-

Mar

-11

20-

Dec

-16

 

US9522894

 

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as dipeptidyl peptidase 1 inhibitors

 

AstraZeneca AB

24-

Jan- 14

21-

Jan

-15

20-

Dec

-16

 

US9522171

EV576 for use in the treatment of viral infections of the respiratory tract

 

Volution Immuno Pharmaceuticals SA

8-

Jan- 10

2-

Jan

-15

20-

Dec

-16

 

US9518093

 

Topical formulation of arginine-rich cyclic antimicrobial peptides

 

NOVABIOTICS LIMITED

24-

Feb- 06

9-

Nov

-15

13-

Dec

-16

 

US9518083

 

Gadd45beta targeting agents

 

Imperial Innovations Limited

22-

Oct- 09

10-

Feb

-15

13-

Dec

-16

 

US9517263

 

Benzonaphthyridine-containing vaccines

 

GlaxoSmithKline Biologicals SA

10-

Jun- 09

10-

Jun

-10

13-

Dec

-16

 

US9517205

 

Soluble needle arrays for delivery of influenza vaccines

 

Seqirus UK Limited

20-

Aug- 10

19-

Aug

-11

13-

Dec

-16

 

US9512471

 

Methods and kits for detecting human papillomavirus

 

DIACARTA Inc

30-

Jun- 10

30-

Jun

-10

6-

Dec

-16

 

US9512443

 

Recombinant expression of multiprotein complexes using polygenes

 

ETH ZURICH

8-

Nov- 05

6-

Nov

-06

6-

Dec

-16

 

US9512181

Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor

 

Tetragenetics, Inc.

27-

May- 11

29-

May

-12

6-

Dec

-16

 

US9511070

 

Heterocyclyl carboxamides for treating viral diseases

 

NovaDrug, LLC

31-

Aug- 12

30-

Aug

-13

6-

Dec

-16

 

US9506063

SiRNA compositions and methods for treatment of HPV and other infections

 

Sirnaomics, Inc.

29-

Jul-10

29-

Jan

-13

29-

Nov

-16

 

US9504747

 

Lipids and lipid compositions for the delivery of active agents

 

Novartis AG

8-

Mar- 13

7-

Mar

-14

29-

Nov

-16

 

US9504673

Agent for the prophylaxis and treatment of highly pathogenic infectious diseases

 

LTD “Valenta-Intellektâ€

21-

May- 09

10-

May

-10

29-

Nov

-16

 

US9504255

 

Physical antimicrobial method

 

NMS TECHNOLOGIES CO., LTD.

1-

Aug- 12

16-

Jul- 13

29-

Nov

-16

 

US9499799

Cells and methodology to generate non-segmented negative-strand RNA viruses

 

Centre National De La Recherche Scientifique

22-

Dec- 06

15-

Oct

-13

22-

Nov

-16

 

US9499535

 

Kinase inhibitors

 

ORIGENIS GMBH

21-

Apr- 11

23-

Apr

-12

22-

Nov

-16

 

US9499489

 

Myxovirus therapeutics, compounds, and uses related thereto

 

Children's Healthcare of Atlanta, Inc.

24-

Oct- 11

24-

Oct

-12

22-

Nov

-16

 

US9498548

Method of using oxidative reductive potential water solution in dental applications

 

Oculus Innovative Sciences, Inc.

2-

May- 05

2-

May

-06

22-

Nov

-16

 

US9498544

Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents

 

Tissue Regeneration Therapeutics Inc.

21-

Apr- 08

13-

Mar

-15

22-

Nov

-16

 

US9498527

 

Vaccine composition

 

NITTO DENKO CORPORATION

4-

Apr- 12

3-

Apr

-13

22-

Nov

-16

 

US9494571

 

Methods of testing for intracellular pathogens

 

Novartis AG

8-

Mar- 10

7-

Mar

-11

15-

Nov

-16

 

US9493788

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

 

The Trustees of the University of Pennsylvania

17-

Dec- 01

16-

Jan

-15

15-

Nov

-16

 

US9493572

GITR antibodies and methods of inducing or enhancing an immune response

 

GITR, Inc.

25-

Mar- 05

23-

Mar

-15

15-

Nov

-16

 

US9493518

Compositions and methods for treating clostridium difficile- associated diseases

 

National Health Research Institutes

14-

Mar- 13

13-

Mar

-14

15-

Nov

-16

 

US9492528

 

Influenza virus-like particles (VLPS) comprising hemagglutinin

 

MEDICAGO INC.

13-

Jul-07

2-

Jul- 09

15-

Nov

-16

 

US9492413

Use of salt of an acetylsalicylic acid for the treatment of viral infections

 

Ventaleon GMBH

14-

Jan- 08

14-

Jan

-09

15-

Nov

-16

 

US9489495

System and method for detecting, collecting, analyzing, and communicating event-related information

 

GEORGETOWN UNIVERSITY

25-

Feb- 08

28-

Aug

-08

8-

Nov

-16

 

US9487838

 

Oligonucleotide probe for the detection of adenovirus

 

QIAGEN HAMBURG GMBH

28-

Dec- 10

28-

Dec

-10

8-

Nov

-16

 

US9487837

Exosome-mediated diagnosis of hepatitis virus infections and diseases

 

MOREHOUSE SCHOOL OF MEDICINE

6-

Oct- 08

21-

Jan

-14

8-

Nov

-16

 

US9487778

 

Oligonucleotide modulators of the toll-like receptor pathway

 

QUARK PHARMACEUTICALS, INC.

3-

Mar- 11

1-

Mar

-12

8-

Nov

-16

 

US9487749

 

Use of methylsulfonylmethane (MSM) to modulate microbial activity

 

Biogenic Innovations, LLC

30-

Oct- 09

12-

Aug

-14

8-

Nov

-16

 

US9487528

 

Compounds

 

Chiesi Farmaceutici S.p.A.

9-

Jun- 14

5-

Jun

-15

8-

Nov

-16

 

US9486479

Antimicrobial solutions containing dichloride monoxide and methods of making and using the same

 

Oculus Innovative Sciences, Inc.

13-

Mar- 07

21-

Jul- 14

8-

Nov

-16

 

US9481912

Compositions and methods for detecting and identifying nucleic acid sequences in biological samples

 

Longhorn Vaccines and Diagnostics, LLC

12-

Sep- 06

8-

Oct

-13

1-

Nov

-16

 

US9481724

 

hDC-sign binding peptides

 

Sloan-Kettering Institute for Cancer Research

19-

Dec- 11

10-

Dec

-12

1-

Nov

-16

 

US9481630

Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same

 

KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

19-

Oct- 11

28-

Sep

-12

1-

Nov

-16

 

US9476090

 

Signal propagation biomolecules, devices and methods

 

STC.UNM

21-

May- 13

21-

May

-14

25-

Oct- 16

 

US9476032

 

Attenuated viruses useful for vaccines

The Research Foundation for The State University of New York

30-

Mar- 07

31-

Mar

-08

25-

Oct- 16

 

US9475872

Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F

 

ImmunoQure AG

28-

Dec- 11

2-

Jan

-13

25-

Oct- 16

 

US9475862

 

Neutralizing GP41 antibodies and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services

7-

Nov- 11

7-

Nov

-12

25-

Oct- 16

 

US9475832

 

Phosphonates with reduced toxicity for treatment of viral infections

 

The Regents of the University of California

14-

Apr- 10

29-

Sep

-14

25-

Oct- 16

 

US9475804

Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom

 

3M Innovative Properties Company

3-

Jun- 11

1-

Jun

-12

25-

Oct- 16

 

US9475779

Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

 

Boehringer Ingelheim International GmbH

31-

Jul-14

27-

Jul- 15

25-

Oct- 16

 

US9475775

 

Benzazepine dicarboxamide compounds

 

Hoffmann-La Roche Inc.

6-

Mar- 15

4-

Mar

-16

25-

Oct- 16

 

US9474844

Methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto

 

Hemalux LLC

22-

Oct- 14

29-

Dec

-15

25-

Oct- 16

 

US9474759

Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses

 

Kansas State University Research Foundation

27-

Sep- 11

27-

Sep

-12

25-

Oct- 16

 

US9469876

 

Circulating biomarkers for metastatic prostate cancer

 

Caris Life Sciences Switzerland Holdings GmbH

6-

Apr- 10

6-

Apr

-11

18-

Oct- 16

 

US9464276

 

Highly efficient influenza matrix (M1) proteins

 

Novavax, Inc.

11-

Jul-03

23-

Feb

-15

11-

Oct- 16

 

US9464123

Peptides having activity of inhibiting infections of respiratory viruses and use of the same

 

XIANGXUE GROUP (HONG KONG) COMPANY LIMITED

9-

May- 13

21-

Feb

-14

11-

Oct- 16

 

US9463240

Arranging interaction and back pressure chambers for microfluidization

 

NOVARTIS AG

3-

Dec- 09

11-

Jul- 14

11-

Oct- 16

 

US9459247

Quantitative measurement of nano/micro particle endocytosis with cell mass spectrometry

 

Academia Sinica

29-

Mar- 10

29-

Mar

-11

4-

Oct- 16

 

US9459233

 

Amperometric gas sensor

 

Steris Corporation

25-

Jun- 12

26-

Feb

-13

4-

Oct- 16

 

US9458492

 

Methods and cells for identifying RIG-I pathway regulators

 

Kineta, Inc.

25-

Feb- 11

23-

Feb

-12

4-

Oct- 16

 

US9458470

Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin

 

MEDICAGO INC.

21-

Jan- 08

23-

Jan

-13

4-

Oct- 16

 

US9458184

 

Compositions of TLR7 and/or TLR8 agonists conjugated to lipids

 

INVIVOGEN

15-

Jun- 12

15-

Mar

-13

4-

Oct- 16

 

US9458113

Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

 

Boehringer Ingelheim International GmbH

31-

Jul-14

27-

Jul- 15

4-

Oct- 16

 

US9457074

Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome

 

Ohio State Innovation Foundation

24-

Apr- 12

23-

Feb

-15

4-

Oct- 16

 

US9453043

 

Nucleic acid chemical modifications

 

ALNYLAM PHARMACEUTICALS, INC.

2-

Mar- 09

22-

Jan

-15

27-

Sep

-16

 

US9452973

 

Modulators of the relaxin receptor 1

THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES

4-

May- 12

15-

Mar

-13

27-

Sep

-16

 

US9452210

Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant

 

MEDICAGO INC.

13-

Jul-07

4-

Jan

-13

27-

Sep

-16

 

US9447462

Methods for concurrent identification and quantification of an unknown bioagent

 

IBIS BIOSCIENCES, INC.

18-

Feb- 04

27-

Jan

-14

20-

Sep

-16

 

US9447132

 

Highly active nucleoside derivative for the treatment of HCV

 

Achillion Pharmaceuticals, Inc.

12-

Apr- 13

14-

Apr

-14

20-

Sep

-16

 

US9447097

 

4-amino-imidazoquinoline compounds

 

Hoffmann-La Roche Inc.

22-

Apr- 14

7-

Apr

-16

20-

Sep

-16

 

US9446062

 

Methods of treating ischemia-reperfusion injury with siRNAs

 

Quark Pharmaceuticals, Inc.

25-

Oct- 06

8-

Jan

-15

20-

Sep

-16

 

US9442107

Antibody-nanoparticle conjugates and methods for making and using such conjugates

 

Ventana Medical Systems, Inc.

27-

Apr- 10

21-

Apr

-15

13-

Sep

-16

 

US9441247

 

TC-83-derived alphavirus vectors, particles and methods

 

ALPHAVAX, INC.

18-

May- 04

6-

Jul- 15

13-

Sep

-16

 

US9440960

 

Substituted oxetanes and their use as inhibitors of cathepsin C

 

Boehringer Ingelheim International GmbH

1-

Aug- 14

31-

Jul- 15

13-

Sep

-16

 

US9440930

Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

 

Boehringer Ingelheim International GmbH

31-

Jul-14

27-

Jul- 15

13-

Sep

-16

 

US9435795

 

Enhanced deposition of chromogens utilizing pyrimidine analogs

 

Ventana Medical Systems, Inc.

30-

Dec- 10

6-

Oct

-14

6-

Sep

-16

 

US9435000

 

Primate T-lymphotropic viruses

 

Johns Hopkins University

21-

Feb- 05

20-

Sep

-13

6-

Sep

-16

 

US9434997

Methods, compounds and systems for detecting a microorganism in a sample

 

Lawrence Livermore National Security, LLC

24-

Aug- 07

21-

Aug

-08

6-

Sep

-16

 

US9434769

Peptide compositions and methods for inhibiting herpesvirus infection

 

The Administrators of the Tulane Educational Fund

30-

Oct- 09

9-

Jul- 14

6-

Sep

-16

 

US9433672

Compositions and methods for activating innate and allergic immunity

 

ID Biomedical Corporation of Quebec

26-

Apr- 12

28-

Apr

-14

6-

Sep

-16

 

US9430610

 

Re-sequencing pathogen microarray

The United States of America, as represented by the Secretary of the Navy

2-Jul- 04

10-

Apr

-08

30-

Aug

-16

 

US9428739

 

Norovirus and Sapovirus antigens

 

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

24-

Mar- 01

27-

Nov

-12

30-

Aug

-16

 

US9428574

Polypeptides and uses thereof for treatment of autoimmune disorders and infection

 

COMPUGEN LTD.

30-

Jun- 11

1-

Jul- 12

30-

Aug

-16

 

US9428571

 

Antibodies and processes for preparing the same

 

TAIGA BIOTECHNOLOGIES, INC.

16-

May- 08

18-

Mar

-15

30-

Aug

-16

 

US9428490

 

Nuclear transport modulators and uses thereof

 

Karyopharm Therapeutics Inc.

29-

Jul-11

26-

Jul- 12

30-

Aug

-16

 

US9428439

 

Hydrobenzamide derivatives as inhibitors of Hsp90

 

ASTEX THERAPEUTICS LTD.

12-

Oct- 06

7-

Jan

-14

30-

Aug

-16

 

US9426989

 

Organic peroxide compounds for microorganism inactivation

 

NOVARTIS AG

6-

May- 10

6-

May

-11

30-

Aug

-16

 

US9422367

 

Antigenic GM-CSF peptides and antibodies to GM-CSF

 

Morphotek, Inc.

7-

Feb- 06

26-

Nov

-13

23-

Aug

-16

 

US9421254

Immunostimulatory combinations of TLR ligands and methods of use

The United States of America, as represented by the Secretary, Department of Health and Human Services

24-

Sep- 07

24-

Sep

-08

23-

Aug

-16

 

US9416416

 

Biological specimen collection/transport compositions and methods

 

Longhorn Vaccines and Diagnostics, LLC

1-

Oct- 07

16-

Dec

-11

16-

Aug

-16

 

US9416409

Capture primers and capture sequence linked solid supports for molecular diagnostic tests

 

IBIS BIOSCIENCES, INC.

31-

Jul-09

30-

Jul- 10

16-

Aug

-16

 

US9416396

Covalently linked thermostable kinase for decontamination process validation

 

The Secretary of State for Health

20-

Feb- 08

18-

Feb

-09

16-

Aug

-16

 

US9415392

 

Slip chip device and methods

 

The University of Chicago

24-

Mar- 09

23-

Mar

-10

16-

Aug

-16

 

US9415087

 

Compositions and methods for treating coronavirus infection

 

Ludwig-Maximilians-Universitaet Muenchen

11-

Mar- 14

8-

May

-15

16-

Aug

-16

 

US9415033

Esters of short chains fatty acids for use in the treatment of immunogenic disorders

 

PROPONENT BIOTECH GMBH

3-

Oct- 12

3-

Oct

-13

16-

Aug

-16

 

US9409987

Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer

 

COMPUGEN LTD

15-

Apr- 11

16-

Apr

-12

9-

Aug

-16

 

US9409917

 

Heterocyclic amide derivatives as P2X7 receptor antagonists

 

ACTELION PHARMACEUTICALS LTD.

20-

Jan- 12

18-

Jan

-13

9-

Aug

-16

 

US9409870

 

Compounds

 

CHIESI FARMACEUTICI S.p.A.

15-

Dec- 14

27-

Nov

-15

9-

Aug

-16

 

US9408908

 

Combination adjuvant formulation

 

Not Available

16-

Oct- 08

15-

Feb

-13

9-

Aug

-16

 

US9408907

Homogenous suspension of immunopotentiating compounds and uses thereof

 

GlaxoSmithKline Biologicals SA

15-

Dec- 09

15-

Dec

-10

9-

Aug

-16

 

US9404160

 

Methods for the detection of microorganisms

 

Becton, Dickinson and Company

22-

Dec- 09

21-

Dec

-10

2-

Aug

-16

 

US9403868

 

Crystalline tripeptide epoxy ketone protease inhibitors

 

Onyx Therapeutics, Inc.

20-

Mar- 09

5-

Mar

-15

2-

Aug

-16

 

US9402921

 

Directed evolution and in vitro panning of virus vectors

 

The University of North Carolina at Chapel Hill

30-

Apr- 08

22-

Oct

-14

2-

Aug

-16

 

US9402878

 

Depsipeptide and uses thereof

 

NovoBiotic Pharmaceuticals, LLC

3-

Dec- 12

1-

Jul- 15

2-

Aug

-16

 

US9402812

 

Methods for the preparation of liposomes

 

Indu Javeri

23-

Sep- 09

23-

Sep

-10

2-

Aug

-16

 

US9394092

 

Powdered pouch and method of making same

 

MONOSOL, LLC

16-

Apr- 12

14-

Mar

-13

19-

Jul- 16

 

US9393564

 

Bioagent detection systems, devices, and methods

 

IBIS BIOSCIENCES, INC.

30-

Mar- 09

30-

Mar

-10

19-

Jul- 16

 

US9393295

 

Nanoparticles for use in pharmaceutical compositions

 

Novartis AG

28-

Apr- 08

28-

Apr

-09

19-

Jul- 16

 

US9393215

 

Nanoparticles for use in immunogenic compositions

 

Novartis AG

2-

Dec- 05

1-

Dec

-06

19-

Jul- 16

 

US9388429

Method for propagating adenoviral vectors encoding inhibitory gene products

 

GenVec, Inc.

10-

Nov- 05

28-

May

-14

12-

Jul- 16

 

US9388234

Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds

 

Not Available

6-

Jun- 03

19-

Jun

-13

12-

Jul- 16

 

US9388198

 

Heterocyclic amide derivatives as P2X7 receptor antagonists

 

ACTELION PHARMACEUTICALS LTD.

21-

Jan- 14

21-

Jan

-14

12-

Jul- 16

 

US9388197

 

Heterocyclic amide derivatives as P2X7 receptor antagonists

 

ACTELION PHARMACEUTICALS LTD.

22-

Jan- 13

21-

Jan

-14

12-

Jul- 16

 

US9387242

Chimeric viruses presenting non-native surface proteins and uses thereof

 

Icahn School of Medicine at Mount Sinai

2-

Dec- 05

1-

Dec

-06

12-

Jul- 16

 

US9382590

 

Methods and compositions for prostate cancer metastasis

FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU)

25-

Mar- 11

20-

May

-15

5-

Jul- 16

 

US9382545

CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

 

COLEY PHARMACEUTICAL GMBH

27-

Sep- 06

4-

Oct

-13

5-

Jul- 16

 

US9382288

Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral action

 

Justus-Liebig-Universitat Giessen

6-

Oct- 10

6-

Oct

-11

5-

Jul- 16

 

US9381244

 

VISTA modulators for diagnosis and treatment of cancer

 

KING'S COLLEGE LONDON

7-

Sep- 12

9-

Sep

-13

5-

Jul- 16

 

US9381239

VLPS derived from cells that do not express a viral matrix or core protein

 

Novavax, Inc.

25-

May- 07

14-

Apr

-14

5-

Jul- 16

 

US9381226

 

Methods and compositions related to inhibition of viral entry

 

UNIVERSITY OF UTAH RESEARCH FOUNDATION

8-

Feb- 07

8-

Feb

-08

5-

Jul- 16

 

US9381220

 

Sceletium extract and uses thereof

 

H. L. Hall & Sons Limited

20-

Mar- 09

15-

Jul- 14

5-

Jul- 16

 

US9380785

 

Antiviral resin member

 

NBC MESHTEC, INC.

6-Jul- 11

6-

Jul- 12

5-

Jul- 16

 

US9376486

Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof

 

DSO National Laboratories

14-

Dec- 10

14-

Dec

-11

28-

Jun- 16

 

US9376398

 

Carboxylic acid compounds

 

Astrazeneca Aktiebolag

18-

May- 12

17-

May

-13

28-

Jun- 16

 

US9375465

Conjugates of GM-CSF and IL-7, compositions and methods related thereto

 

Children's Healthcare of Atlanta, Inc.

14-

Nov- 11

13-

Nov

-12

28-

Jun- 16

 

US9372156

System for processing contents of a receptacle to detect an optical signal emitted by the contents

 

GEN-PROBE INCORPORATED

10-

Mar- 05

22-

Feb

-11

21-

Jun- 16

 

US9371563

 

Nanoreporters and methods of manufacturing and use thereof

 

NanoString Technologies, Inc.

23-

Dec- 05

11-

Mar

-13

21-

Jun- 16

 

US9370582

 

Carbohydrate conjugates as delivery agents for oligonucleotides

 

ALNYLAM PHARMACEUTICALS, INC.

4-

Dec- 07

11-

Jul- 14

21-

Jun- 16

 

US9370581

 

Carbohydrate conjugates as delivery agents for oligonucleotides

 

ALNYLAM PHARMACEUTICALS, INC.

4-

Dec- 07

11-

Jul- 14

21-

Jun- 16

 

US9370570

 

Polychlorinated biphenyls and squalene-containing adjuvants

 

Novartis AG

28-

Dec- 07

10-

Dec

-13

21-

Jun- 16

 

US9370531

Method of providing patient specific immune response in amyloidoses and protein aggregation disorders

 

New York University

31-

Aug- 07

1-

Sep

-08

21-

Jun- 16

 

US9365577

 

Pyrimidinone compounds as human neutrophil elastase inhibitors

 

Chiesi Farmaceutici S.p.A.

18-

Dec- 12

17-

Dec

-13

14-

Jun- 16

 

US9365567

 

Alkoxy substituted imidazoquinolines

 

3M Innovative Properties Company

3-

Oct- 03

30-

Sep

-14

14-

Jun- 16

 

US9365523

 

Imidazolyl amide compounds and uses related thereto

 

Children's Healthcare of Atlanta, Inc.

31-

Mar- 11

28-

Mar

-12

14-

Jun- 16

 

US9365506

 

Compounds and compositions as TLR2 agonists

 

NOVARTIS AG

23-

Mar- 10

9-

Jul- 14

14-

Jun- 16

 

US9364511

 

Antiviral preparations obtained from a natural cinnamon extract

 

RAMOT AT TEL-AVIV UNIVERSITY LTD.

24-

Dec- 03

22-

Jun

-06

14-

Jun- 16

 

US9359360

 

TLR agonists

 

The Regents of The University of California

22-

Aug- 05

20-

Nov

-12

7-

Jun- 16

 

US9358280

Decreasing potential iatrogenic risks associated with influenza vaccines

 

Novartis AG

9-

Sep- 04

11-

Jan

-13

7-

Jun- 16

 

US9353133

 

Boron-containing small molecules

 

Anacor Pharmaceuticals, Inc.

16-

Feb- 05

7-

Mar

-14

31-

May

-16

 

US9352048

 

Carbohydrate conjugates as delivery agents for oligonucleotides

 

ALNYLAM PHARMACEUTICALS, INC.

4-

Dec- 07

22-

Jul- 14

31-

May

-16

 

US9347055

Method and kit for preparation of sample for use in nucleic acid amplification

 

EIKEN KAGAKU KABUSHIKI KAISHA

5-

Nov- 07

5-

Nov

-08

24-

May

-16

 

US9346866

 

Inhibition of tace activity with cyclic peptides

 

The Regents of the University of California

2-

Jun- 11

19-

Sep

-14

24-

May

-16

 

US9346794

Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity

 

Boehringer Ingelheim International GmbH

23-

Aug- 12

29-

Dec

-15

24-

May

-16

 

US9346769

 

Tetrazolones as inhibitors of fatty acid synthase

 

Infinity Pharmaceuticals, Inc.

5-

May- 10

23-

Aug

-13

24-

May

-16

 

US9346753

 

Dithiol mucolytic agents

 

PARION SCIENCES, INC.

23-

Aug- 13

13-

Aug

-14

24-

May

-16

 

US9345760

IPNV-ISAV bivalent vaccine using a virus-like particle-based platform and methods of using the same

 

Advanced Bionutrition Corporation

9-

Sep- 11

7-

Sep

-12

24-

May

-16

 

US9340507

Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity

 

Boehringer Ingelheim International GmbH

23-

Aug- 12

2-

Sep

-15

17-

May

-16

 

US9339561

 

Mutant protease biosensors with enhanced detection characteristics

 

PROMEGA CORPORATION

11-

May- 10

5-

May

-14

17-

May

-16

 

US9339525

 

Inhibition of biofilm organisms

 

Novabiotics Limited

31-

Mar- 09

31-

Mar

-10

17-

May

-16

 

US9334268

 

4-amino-imidazoquinoline compounds

 

HOFFMAN-LA ROCHE INC.

22-

Apr- 14

22-

Apr

-15

10-

May

-16

 

US9328110

 

Substituted imidazo ring systems and methods

 

3M INNOVATIVE PROPERTIES COMPANY

25-

Nov- 03

11-

Mar

-14

3-

May

-16

 

US9328093

Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications

 

HYBRIGENICS SA

15-

Jan- 10

17-

Sep

-14

3-

May

-16

 

 

US9326972

 

Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression

 

 

Ohio University

 

16-

Mar- 04

 

9-

Feb

-12

 

3-

May

-16

 

US9322827

 

B-cell antigen presenting cell assay

University of Pittsburgh - Of the Commonwealth System of Higher Education

8-

Apr- 10

8-

Apr

-11

26-

Apr- 16

 

US9321999

Compositions for increasing polypeptide stability and activity, and related methods

 

SOLIS BIODYNE OÜ

19-

Nov- 09

19-

Nov

-10

26-

Apr- 16

 

US9321847

Activatable toxin complexes comprising a cleavable inhibitory peptide

 

RAMOT at Tel Aviv University Ltd.

20-

Sep- 10

22-

Aug

-11

26-

Apr- 16

 

US9321831

 

RSV-specific binding molecules and means for producing them

 

MedImmune Limited

1-

Jun- 07

13-

Sep

-13

26-

Apr- 16

 

US9320784

Peptides shared among lethal cancers and therapeutic compositions comprising said peptides

 

Not Available

7-

Aug- 09

19-

Jul- 12

26-

Apr- 16

 

US9320748

 

Immunologically useful arginine salts

 

Novartis AG

7-

Mar- 12

7-

Mar

-13

26-

Apr- 16

 

US9315530

 

Adsorption of immunopotentiators to insoluble metal salts

 

Novartis AG

1-

Sep- 10

1-

Sep

-11

19-

Apr- 16

 

US9310375

Luminophore-labeled molecules coupled with particles for microarray-based assays

 

CapitalBio Corporation

27-

Oct- 10

27-

Oct

-10

12-

Apr- 16

 

 

US9310088

 

Device and method for reducing spread of microorganisms and airborne health hazardous matter and/or for protection from microorganisms and airborne health hazardous matter

 

 

Technical University of Denmark

 

17-

Jul-09

 

14-

Jul- 10

 

12-

Apr- 16

 

US9309325

 

Antibodies and methods of use thereof

 

The Regents of the University of California

7-

May- 09

4-

May

-10

12-

Apr- 16

 

US9303068

D-amino acid derivative-modified peptidoglycan and methods of use thereof

 

The Regents of the University of California

30-

Nov- 12

27-

Nov

-13

5-

Apr- 16

 

US9303000

 

Olefin containing nuclear transport modulators and uses thereof

 

KARYOPHARM THERAPEUTICS INC.

17-

Jan- 11

16-

Jan

-12

5-

Apr- 16

 

US9297010

 

Short interfering RNA (siRNA) analogues

 

Roche Innovation Center Copenhagen A/S

21-

Mar- 03

11-

Feb

-14

29-

Mar

-16

 

US9295732

 

Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists

 

INVIVOGEN

22-

Feb- 13

22-

Feb

-13

29-

Mar

-16

 

US9295708

 

Modified release formulations for oprozomib

 

Onyx Therapeutics, Inc.

24-

Oct- 12

24-

Oct

-13

29-

Mar

-16

 

US9295646

 

Cationic oil-in-water emulsions

 

Novartis AG

6-Jul- 10

18-

Sep

-11

29-

Mar

-16

 

US9291628

 

Direct clone analysis and selection technology

 

Dublin City University

13-

Jul-10

13-

Jul- 11

22-

Mar

-16

 

US9291597

 

Detecting targets using mass tags and mass spectrometry

 

VENTANA MEDICAL SYSTEMS, INC.

2-Jul- 10

1-

Jul- 11

22-

Mar

-16

 

US9290794

 

Mutant protease biosensors with enhanced detection characteristics

 

PROMEGA CORPORATION

11-

May- 10

12-

Nov

-12

22-

Mar

-16

 

US9290786

 

Monoclonal antibody production by EBV transformation of B cells

 

Institute for Research in Biomedicine

26-

Feb- 03

25-

Apr

-13

22-

Mar

-16

 

US9290760

 

Modified iRNA agents

 

ALNYLAM PHARMACEUTICALS, INC.

15-

Sep- 10

14-

Sep

-11

22-

Mar

-16

 

US9290745

 

Luciferase biosensor

 

PROMEGA CORPORATION

10-

Oct- 03

14-

Feb

-14

22-

Mar

-16

 

US9290545

 

Compositions and methods for the treatment of viral infections

 

Dana-Farber Cancer Institute, Inc.

23-

Jan- 08

23-

Jul- 10

22-

Mar

-16

 

US9290459

Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

 

Boehringer Ingelheim International GmbH

6-

Feb- 13

9-

Nov

-15

22-

Mar

-16

 

US9290457

Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

 

Boehringer Ingelheim International GmbH

31-

Jul-14

27-

Jul- 15

22-

Mar

-16

 

US9289487

 

II-key/antigenic epitope hybrid peptide vaccines

 

Antigen Express, Inc.

14-

Sep- 99

11-

Jan

-05

22-

Mar

-16

 

US9284560

Application of highly conserved domain sequences from viral genome as template to design therapeutic sliRNAs

 

Biocross Institute of Molecular Medicine (Nantong) Co., Ltd.

19-

Sep- 11

19-

Sep

-11

15-

Mar

-16

 

US9278128

Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same

 

The Trustees of the University of Pennsylvania

14-

Sep- 09

6-

Jan

-14

8-

Mar

-16

 

US9278126

 

Influenza vaccines with reduced amounts of squalene

 

Seqirus UK Limited

10-

Feb- 09

10-

Feb

-10

8-

Mar

-16

 

US9272024

 

Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same

 

The Trustees of the University of Pennsylvania

12-

Dec- 11

11-

Dec

-12

1-

Mar

-16

 

US9271494

Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid antimicrobial compositions

 

Ecolab USA, Inc.

30-

Aug- 07

30-

Aug

-07

1-

Mar

-16

 

US9266844

 

Suppression of SARS replication by SARS helicase inhibitors

 

The Curators of the University of Missouri

15-

Jun- 12

17-

Jun

-13

23-

Feb

-16

 

US9266843

 

Nuclear transport modulators and uses thereof

 

Karyopharm Therapeutics Inc.

9-

May- 12

9-

May

-13

23-

Feb

-16

 

US9265876

Systems and methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto

 

Hemalux Technologies LLC

22-

Oct- 14

22-

Oct

-14

23-

Feb

-16

 

US9260398

 

Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases

 

PARION SCIENCES, INC.

29-

May- 12

9-

Dec

-14

16-

Feb

-16

 

US9255144

 

Anti-IL-18 antibodies and their uses

 

MedImmune Limited

20-

Dec- 10

20-

Dec

-11

9-

Feb

-16

 

US9255140

Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus

 

NEW YORK BLOOD CENTER, INC.

15-

Jun- 04

23-

Mar

-09

9-

Feb

-16

 

US9254315

Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds

 

Not Available

28-

Apr- 04

3-

Feb

-10

9-

Feb

-16

 

US9254265

 

Small liposomes for delivery of immunogen encoding RNA

 

NOVARTIS AG

31-

Aug- 10

31-

Aug

-11

9-

Feb

-16

 

US9249427

 

Recombinant HCMV and RHCMV vectors and uses thereof

 

Oregon Health & Science University

14-

May- 10

14-

Nov

-12

2-

Feb

-16

 

US9249195

 

Reovirus vaccines and methods of use therefor

 

Vanderbilt University

7-

Apr- 10

4-

Apr

-11

2-

Feb

-16

 

US9248201

 

Mutant protease biosensors with enhanced detection characteristics

 

PROMEGA CORPORATION

11-

May- 10

5-

May

-14

2-

Feb

-16

 

US9248178

Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens

 

Not Available

8-

Jun- 09

8-

Jun

-10

2-

Feb

-16

 

US9242980

Lipidated immune response modifier compound compositions, formulations, and methods

 

3M Innovative Properties Company

17-

Aug- 10

16-

Aug

-11

26-

Jan- 16

 

US9238809

Compositions, methods, and kits for isolating and analyzing nucleic acids using an anion exchange material

 

QIAGEN GAITHERSBURG, INC.

24-

Sep- 09

5-

Aug

-10

19-

Jan- 16

 

US9234175

 

Creating bioengineered lymph nodes

 

H. Lee Moffitt Cancer Center and Research Institute, Inc.

17-

Nov- 09

16-

Nov

-10

12-

Jan- 16

 

US9233148

 

Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza

 

Not Available

9-

Jan- 09

16-

Oct

-09

12-

Jan- 16

 

US9227977

 

Phosphoinositide 3-kinase inhibitors

 

Respivert Ltd.

15-

Mar- 13

14-

Mar

-14

5-

Jan- 16

 

US9222075

 

Animal protein-free media for cultivation of cells

 

Baxalta GmbH

29-

Oct- 04

2-

May

-14

29-

Dec

-15

 

US9221832

 

Heterocyclic amide derivatives as P2X7 receptor antagonists

 

ACTELION PHARMACEUTICALS LTD.

22-

Jul-11

20-

Jul- 12

29-

Dec

-15

 

US9221807

Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity

 

Boehringer Ingelheim International GmbH

21-

Feb- 14

12-

Feb

-15

29-

Dec

-15

 

US9220768

Decreasing potential iatrogenic risks associated with influenza vaccines

 

Novartis AG

9-

Sep- 04

14-

Oct

-11

29-

Dec

-15

 

US9217745

Arrayed detector system for measurement of influenza immune response

 

University of Rochester

2-

May- 08

11-

Jul- 13

22-

Dec

-15

 

US9217157

 

Recombinant influenza viruses and uses thereof

 

Icahn School of Medicine at Mount Sinai

27-

Jul-09

27-

Jul- 10

22-

Dec

-15

 

US9216192

 

Toll-like receptor agonist formulations and their use

 

VentiRx Pharmaceuticals, Inc.

1-

Aug- 08

16-

Jul- 12

22-

Dec

-15

 

US9213027

Lipoparticles comprising proteins, methods of making, and using the same

 

Integral Molecular, Inc.

30-

Jul-03

1-

Nov

-13

15-

Dec

-15

 

US9212399

Biological specimen collection and transport system and method of use

 

Longhorn Vaccines and Diagnostics, LLC

1-

Oct- 07

7-

Jan

-14

15-

Dec

-15

 

US9212205

 

Nucleic acid binding compounds and methods of use

 

University of Rochester

26-

Jul-07

28-

Jul- 08

15-

Dec

-15

 

US9206396

 

Methods and devices for quantitative viral assays

 

Wisconsin Alumni Research Foundation

16-

Nov- 05

16-

Nov

-06

8-

Dec

-15

 

US9206158

 

Hydrazide containing nuclear transport modulators and uses thereof

 

Karyopharm Therapeutics Inc.

29-

Jul-11

10-

Jun

-15

8-

Dec

-15

 

US9200329

 

Rapid epidemiologic typing of bacteria

 

BioFire Diagnostics, LLC

19-

May- 08

18-

May

-09

1-

Dec

-15

 

US9200287

Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity

 

AdiuTide Pharmaceuticals GmbH

18-

May- 07

15-

May

-08

1-

Dec

-15

 

US9200280

Methods and compositions for the treatment of cancer or other diseases

 

CITY OF HOPE

26-

Jan- 07

9-

Jun

-14

1-

Dec

-15

 

US9200279

Methods and compositions for the treatment of cancer or other diseases

 

CITY OF HOPE

26-

Jan- 07

14-

Jan

-14

1-

Dec

-15

 

US9200074

 

Antibodies to IL-1 R1 and methods of making them

 

MEDIMMUNE LIMITED

7-

Nov- 08

16-

Apr

-14

1-

Dec

-15

 

US9199981

 

Compounds and compositions as C-kit kinase inhibitors

 

NOVARTIS AG

1-

Sep- 11

27-

Aug

-12

1-

Dec

-15

 

US9199897

 

Methods for preparing squalene

 

NOVARTIS AG

12-

May- 10

12-

May

-11

1-

Dec

-15

 

US9198927

Targeting opposite strand replication intermediates of single- stranded viruses by RNAI

 

ALNYLAM PHARMACEUTICALS, INC.

24-

Sep- 04

1-

Mar

-10

1-

Dec

-15

 

US9193780

Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

 

Ablynx N.V.

5-

Jun- 08

5-

Jun

-09

24-

Nov

-15

 

US9192661

Delivery of self-replicating RNA using biodegradable polymer particles

 

Novartis AG

6-Jul- 10

7-

Jun

-11

24-

Nov

-15

 

US9187748

 

Compositions and methods for silencing ebola virus gene expression

 

Not Available

20-

Jul-09

28-

Mar

-14

17-

Nov

-15

 

US9187426

 

Organic compounds

 

Novartis AG

27-

Jun- 08

25-

Jun

-09

17-

Nov

-15

 

US9186419

 

Directed evolution and in vitro panning of virus vectors

 

The University of North Carolina at Chapel Hill

30-

Apr- 08

17-

Jan

-14

17-

Nov

-15

 

US9186399

Immune stimulatory oligonucleotide analogs containing modified sugar moieties

 

AdiutTide Pharmaceuticals GmbH

9-

Oct- 07

29-

Sep

-08

17-

Nov

-15

 

US9181303

 

Treatment of bacterial infections with cyclic antimicrobial peptides

 

NovaBiotics Limited

22-

Dec- 05

20-

Jun

-14

10-

Nov

-15

 

US9181290

Inhibition of biofilm formation by 1,2,3,4,6-penta-O-galloyl-D- glucopyranose

 

CHANG GUNG UNIVERSITY

17-

Jun- 11

19-

Sep

-11

10-

Nov

-15

 

US9175047

 

Peptidomimetic macrocycles

 

Aileron Therapeutics, Inc.

14-

Jan- 09

14-

Jan

-10

3-

Nov

-15

 

US9174925

 

Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same

 

KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

26-

Oct- 11

28-

Sep

-12

3-

Nov

-15

 

US9169318

 

Neutralizing molecules to viral antigens

 

Sea Lane Biotechnologies, Inc.

28-

Mar- 08

18-

Jul- 11

27-

Oct- 15

 

US9168318

Oxidative reductive potential water solution and methods of using the same

 

Oculus Innovative Sciences, Inc.

30-

Dec- 03

11-

Aug

-04

27-

Oct- 15

 

US9168299

Methods for treating juvenile arthritis with ant-bile salt-stimulated lipase (BSSL) antibodies

 

LIPUM AB

8-

Apr- 09

30-

Oct

-13

27-

Oct- 15

 

US9168269

Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals

 

THE TRUSTEES OF PRINCETON UNIVERSITY

18-

Feb- 10

18-

Feb

-11

27-

Oct- 15

 

US9163222

 

Mutations in OAS1 genes

 

Kineta Two, LLC

4-

May- 05

14-

Nov

-12

20-

Oct- 15

 

US9163065

 

Depsipeptide and uses thereof

 

NovoBiotic Pharmaceuticals, LLC

3-

Dec- 12

3-

Dec

-13

20-

Oct- 15

 

US9161976

 

Immunotherapy comprising TLR9 ligand and CD40 ligand

 

Trustees of Dartmouth College

30-

Dec- 02

22-

Oct

-12

20-

Oct- 15

 

US9156811

 

N-myristoyl transferase inhibitors

 

Univeristy of Dundee

2-

Sep- 08

29-

Aug

-09

13-

Oct- 15

 

US9155309

 

Virus inactivating sheet

 

NBC MESHTEC, INC.

2-

Oct- 09

4-

Oct

-10

13-

Oct- 15

 

US9149473

Targeted whole genome amplification method for identification of pathogens

 

IBIS BIOSCIENCES, INC.

14-

Sep- 06

14-

Sep

-07

6-

Oct- 15

 

US9149445

Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections

 

THE TRUSTEES OF PRINCETON UNIVERSITY

27-

Jul-09

27-

Jul- 10

6-

Oct- 15

 

US9145588

 

Generation of binding molecules

 

MERUS BIOPHARMACEUTICALS B.V.

26-

Sep- 11

26-

Sep

-12

29-

Sep

-15

 

US9145585

 

Method for using permuted nucleic acid probes

 

Ventana Medical Systems, Inc.

1-

Sep- 06

5-

Aug

-14

29-

Sep

-15

 

US9145410

 

Pyrazolopyridines and analogs thereof

 

3M Innovative Properties Company

3-

Oct- 03

26-

Jan

-12

29-

Sep

-15

 

US9144575

 

Anti-viral azide containing compounds

 

LIFE TECHNOLOGIES CORPORATION

28-

Jul-10

28-

Jul- 11

29-

Sep

-15

 

US9139833

 

Modified small interfering RNA molecules and methods of use

 

Arrowhead Research Corporation

26-

Jul-02

12-

Mar

-13

22-

Sep

-15

 

US9139647

 

Diagnosis and treatment of cancer using anti-TM4SF20 antibody

 

FORERUNNER PHARMA RESEARCH CO., LTD.

25-

Dec- 08

25-

Dec

-09

22-

Sep

-15

 

US9139620

 

Feline morbillivirus and uses thereof

THE GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF

CHINA

20-

Jan- 12

22-

Jan

-13

22-

Sep

-15

 

US9138472

 

CD40L vaccines, compositions, and methods related thereto

 

EMORY UNIVERSITY

28-

Sep- 10

28-

Sep

-11

22-

Sep

-15

 

US9134247

Method and apparatus for two-step surface-enhanced raman spectroscopy

 

REAL-TIME ANALYZERS, INC.

16-

Dec- 11

16-

Dec

-11

15-

Sep

-15

 

US9133248

 

Methods of propagating monkey adenoviral vectors

 

GenVec, Inc.

9-

Nov- 09

9-

Nov

-10

15-

Sep

-15

 

US9132423

 

Sample-to-answer microfluidic cartridge

 

Micronics, Inc.

29-

Jan- 10

28-

Jan

-11

15-

Sep

-15

 

US9132175

 

Bacillus based delivery system and methods of use

 

The Curators of the University of Missouri

18-

Apr- 11

18-

Apr

-11

15-

Sep

-15

 

US9128101

 

Biomarkers for theranostics

 

Caris Life Sciences Switzerland Holdings GmbH

1-

Mar- 10

1-

Mar

-11

8-

Sep

-15

 

US9127256

Method for production of reprogrammed cell using chromosomally unintegrated virus vector

 

DNAVEC CORPORATION

16-

Jul-08

16-

Jul- 09

8-

Sep

-15

 

US9127251

Means and methods for influencing the stability of antibody producing cells

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

9-

Dec- 05

8-

Dec

-06

8-

Sep

-15

 

US9127028

Substrates for chromogenic detection and methods of use in detection assays and kits

 

Ventana Medical Systems, Inc.

16-

Aug- 10

12-

Aug

-11

8-

Sep

-15

 

US9125952

Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes

Industry Academic Cooperation Foundation, Hallym University

17-

Jul-09

13-

Aug

-14

8-

Sep

-15

 

US9115093

Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

 

Boehringer Ingelheim International GmbH

4-

Mar- 13

20-

Feb

-14

25-

Aug

-15

 

 

US9115065

 

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses

 

 

Kineta, Inc.

 

6-

Dec- 04

 

26-

Feb

-13

 

25-

Aug

-15

 

US9109199

 

Methods to produce bunyavirus replicon particles

 

STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK

20-

Sep- 10

20-

Sep

-11

18-

Aug

-15

 

US9107970

 

Method and a filter for capturing airborne agents

 

Not Available

15-

Jul-08

13-

Jul- 09

18-

Aug

-15

 

US9107958

Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom

 

3M Innovative Properties Company

3-

Jun- 11

1-

Jun

-12

18-

Aug

-15

 

US9107906

 

Compositions and methods for the treatment of immunodeficiency

 

ADMA BIOLOGICS, INC.

28-

Oct- 14

8-

Jan

-15

18-

Aug

-15

 

US9107904

 

Immunostimulatory compositions and methods of use thereof

 

Massachusetts Institute of Technology

5-

Apr- 12

15-

Mar

-13

18-

Aug

-15

 

US9102938

 

2′ and 5′ modified monomers and oligonucleotides

 

ALNYLAM PHARMACEUTICALS, INC.

31-

Mar- 11

31-

Mar

-11

11-

Aug

-15

 

US9102911

 

High density self-contained biological analysis

 

BioFire Diagnostics, LLC

15-

May- 09

28-

Jan

-13

11-

Aug

-15

 

US9102741

 

GAS57 mutant antigens and GAS57 antibodies

 

Novartis AG

12-

Sep- 07

13-

Oct

-14

11-

Aug

-15

 

US9102740

 

Cna-B domain antigens in vaccines against gram positive bacteria

 

NOVARTIS AG

12-

Jan- 09

7-

Jun

-13

11-

Aug

-15

 

US9102633

Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

 

Parion Sciences, Inc.

13-

Dec- 13

13-

Dec

-13

11-

Aug

-15

 

US9102624

Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity

 

Boehringer Ingelheim International GmbH

23-

Aug- 12

20-

Aug

-13

11-

Aug

-15

 

US9101597

 

Immunoprotective primary mesenchymal stem cells and methods

 

Autoimmune Technologies, LLC

14-

Mar- 13

14-

Mar

-13

11-

Aug

-15

 

US9101582

Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen

The United States of America as represented by the Secretary of the Department of Health and Human

Services, Centers for Disease Control and Prevention

31-

Jul-08

27-

Mar

-13

11-

Aug

-15

 

US9096585

 

Antiviral compounds and uses thereof

 

Icahn School of Medicine at Mount Sinai

28-

May- 10

31-

May

-11

4-

Aug

-15

 

US9096543

 

Nuclear transport modulators and uses thereof

 

Karyopharm Therapeutics Inc.

9-

May- 12

9-

May

-13

4-

Aug

-15

 

US9090897

 

Production of IFN-lambda by conventional dendritic cells

 

Bavarian Nordic A/S

18-

Dec- 09

17-

Dec

-10

28-

Jul- 15

 

US9085641

 

Peptides regulating the surface expression of the T cell receptor

 

Max-Delbruck-Centrum Fur Molekulare Medizin

23-

Jun- 06

23-

Jun

-07

21-

Jul- 15

 

US9084808

 

Modified small interfering RNA molecules and methods of use

 

Arrowhead Research Corporation

1-

Oct- 04

9-

May

-14

21-

Jul- 15

 

US9084758

Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereof

The Catholic University of Korea Industry-Academic Cooperation Foundation

24-

Jul-12

25-

Aug

-14

21-

Jul- 15

 

US9080209

 

Non-mass determined base compositions for nucleic acid detection

 

IBIS BIOSCIENCES, INC.

6-

Aug- 09

6-

Aug

-10

14-

Jul- 15

 

US9080204

Compositions and methods for rapid, real-time detection of influenza a virus (H1N1) Swine 2009

 

Longhorn Vaccines and Diagnostics, LLC

12-

Sep- 06

30-

Dec

-11

14-

Jul- 15

 

US9079965

 

Bispecific antibody

 

Wuhan YZY Biopharma Co., LTD.

21-

Nov- 12

13-

Mar

-14

14-

Jul- 15

 

US9079943

 

TC-83-derived alphavirus vectors, particles and methods

 

ALPHAVAX, INC.

18-

May- 04

28-

Mar

-14

14-

Jul- 15

 

US9079865

 

Hydrazide containing nuclear transport modulators and uses thereof

 

Karyopharm Therapeutics Inc.

29-

Jul-11

29-

Jul- 12

14-

Jul- 15

 

US9078885

 

Respiratory disease treatment

 

Pulmagen Therapeutics (Inflammation) Limited

7-

Aug- 08

7-

Apr

-14

14-

Jul- 15

 

US9078868

Therapeutic agent for accelerating recovery of animal under medical treatment

 

DAIICHI SANKYO COMPANY, LIMITED

15-

Jan- 10

14-

Jan

-11

14-

Jul- 15

 

US9073869

 

Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C

 

Boehringer Ingelheim International GmbH

14-

Mar- 13

11-

Sep

-14

7-

Jul- 15

 

US9072738

Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity

 

PARION SCIENCES, INC.

27-

Jun- 11

27-

Jun

-12

7-

Jul- 15

 

US9072726

Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution

 

Oculus Innovative Sciences, Inc.

20-

Jan- 06

21-

Dec

-09

7-

Jul- 15

 

US9072702

 

Reverse genetics using non-endogenous pol I promoters

 

Novartis AG

21-

May- 09

21-

May

-10

7-

Jul- 15

 

 

US9067873

 

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses

 

 

Kineta Four, LLC

 

6-

Dec- 04

 

19-

Dec

-13

 

30-

Jun- 15

 

US9066964

 

Use of tylvalosin as antiviral agent

 

Cambridge University Technical Services

13-

Jul-06

13-

Jul- 07

30-

Jun- 15

 

US9063150

Method for detection of antigen-specific antibodies in biological samples

The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control Prevention

2-

Sep- 08

25-

Aug

-09

23-

Jun- 15

 

US9061001

 

Combination adjuvant formulation

 

Dalhousie University

16-

Oct- 08

15-

Oct

-09

23-

Jun- 15

 

US9056900

 

Compositions and methods for coronavirus inhibition

 

Autoimmune Technologies, LLC.

4-

Nov- 03

8-

Aug

-13

16-

Jun- 15

 

US9056898

 

Attenuated RNA virus and applications thereof

 

Washington University

20-

Sep- 07

22-

Sep

-08

16-

Jun- 15

 

US9056071

 

Compounds and methods for preventing or treating a viral infection

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)

2-

Nov- 07

19-

Jun

-13

16-

Jun- 15

 

US9051619

 

Methods and compositions for prostate cancer metastasis

FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU)

25-

Mar- 11

23-

Mar

-12

9-

Jun- 15

 

US9051564

 

Compositions for and methods of identifying antigens

 

President and Fellows of Harvard College

21-

Feb- 06

21-

Feb

-07

9-

Jun- 15

 

US9051353

 

Crystalline tripeptide epoxy ketone protease inhibitors

 

Onyx Therapeutics, Inc.

20-

Mar- 09

24-

Sep

-13

9-

Jun- 15

 

US9050376

 

Conjugates of synthetic TLR agonists and uses therefor

 

The Regents of the University of California

7-

Feb- 07

19-

Jun

-14

9-

Jun- 15

 

US9046523

 

Rapid bioluminescence detection system

 

THE SECRETARY OF STATE FOR HEALTH

7-

Jan- 09

2-

Aug

-13

2-

Jun- 15

 

US9045855

 

Anti-viral member

 

NBC Meshtec, Inc.

26-

Dec- 08

28-

Dec

-09

2-

Jun- 15

 

US9045727

Virus-like particles, methods of preparation, and immunogenic compositions

 

EMORY UNIVERSITY

17-

May- 02

4-

Apr

-06

2-

Jun- 15

 

US9045472

 

Imidazoquinoline compounds

 

ASTRAZENECA AB

16-

Dec- 10

16-

Dec

-11

2-

Jun- 15

 

US9045470

 

Compounds and compositions as TLR activity modulators

 

IRM LLC

2-

Sep- 09

1-

Sep

-10

2-

Jun- 15

 

US9044420

Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses

 

IMMUNE DESIGN CORP.

8-

Apr- 11

6-

Apr

-12

2-

Jun- 15

 

US9040310

Antibody-nanoparticle conjugates and methods for making and using such conjugates

 

Ventana Medical Systems, Inc.

27-

Apr- 10

27-

Apr

-11

26-

May

-15

 

US9034646

Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof

 

ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD.

25-

May- 10

26-

Nov

-12

19-

May

-15

 

US9034313

Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same

 

Inovio Pharmaceuticals, Inc.

8-

Feb- 10

8-

Feb

-11

19-

May

-15

 

US9029413

Treatment of viral infections by modulation of host cell metabolic pathways

 

The Trustees of Princeton University

1-

Jun- 07

3-

Apr

-12

12-

May

-15

 

US9029382

3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds

 

Parion Sciences, Inc.

17-

Dec- 12

13-

Dec

-13

12-

May

-15

 

US9029315

 

Soluble PD-1 variants, fusion constructs, and uses thereof

 

The University of Hong Kong

11-

Nov- 10

11-

Nov

-11

12-

May

-15

 

US9028841

Synergistic bacterial compositions and methods of production and use thereof

 

Seres Health, Inc.

23-

Nov- 12

20-

Mar

-14

12-

May

-15

 

US9028837

 

Methods and compositions for poxvirus A35R protein

 

East Carolina University

7-

Jun- 12

20-

Dec

-12

12-

May

-15

 

US9028823

 

Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies

 

GITR, Inc.

25-

Mar- 05

1-

Mar

-13

12-

May

-15

 

US9024001

 

Alphavirus replicon packaging constructs

 

Novartis Vaccines and Diagnostics, Inc.

25-

May- 04

20-

May

-05

5-

May

-15

 

US9023855

 

Compounds

 

Chiesi Farmaceutici S.p.A.

14-

Sep- 11

11-

Feb

-14

5-

May

-15

 

US9023839

 

Compounds and compositions as c-kit kinase inhibitors

 

IRM LLC

1-

Sep- 11

22-

Apr

-14

5-

May

-15

 

US9017699

Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus

 

New York Blood Center, Inc.

15-

Jun- 04

18-

Feb

-10

28-

Apr- 15

 

US9017696

 

Adenovirus vectors

 

Isis Innovation Limited

10-

Apr- 07

10-

Apr

-08

28-

Apr- 15

 

US9012622

Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer

 

Not Available

31-

Dec- 08

31-

Dec

-09

21-

Apr- 15

 

US9011767

Transportable vacuum assisted decontamination unit and decontamination process

 

STERIS Inc.

1-

Apr- 13

31-

Mar

-14

21-

Apr- 15

 

US9006264

Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines

 

3M Innovative Properties Company

18-

Jun- 04

9-

Sep

-13

14-

Apr- 15

 

US9006194

Compositions and methods for diminishing viral infection and inflammation associated with viral infection

 

Drexel University

19-

Dec- 08

17-

Dec

-09

14-

Apr- 15

 

US9005974

 

Means and methods for influencing the stability of cells

Academish Medisch Centrum Bij de Universiteit van Amsterdam

9-

Dec- 05

9-

Dec

-05

14-

Apr- 15

 

US9005665

Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome

 

Ohio State Innovation Foundation

24-

Apr- 12

24-

Apr

-13

14-

Apr- 15

 

US9005599

Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents

 

Tissue Regeneration Therapeutics Inc.

21-

Apr- 08

20-

Apr

-09

14-

Apr- 15

 

US8999996

 

Hydrazide containing nuclear transport modulators and uses thereof

 

Karyopharm Therapeutics Inc.

29-

Jul-11

19-

Mar

-14

7-

Apr- 15

 

US8999975

Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C

 

Boehringer Ingelheim International GmbH

19-

Sep- 11

14-

Sep

-12

7-

Apr- 15

 

US8999678

 

Method of increasing the function of an AAV vector

 

The Trustees of the University of Pennsylvania

7-

Apr- 05

7-

Apr

-06

7-

Apr- 15

 

US8999349

 

HMGB1-derived peptides enhance immune response to antigens

 

The Regents of the University of California

27-

Jul-10

27-

Jul- 11

7-

Apr- 15

 

US8999316

 

Antiviral compounds

 

Long Island University

30-

May- 07

30-

May

-08

7-

Apr- 15

 

US8993717

 

Gadd45beta targeting agents

 

Imperial Innovations Limited

22-

Oct- 09

22-

Oct

-10

31-

Mar

-15

 

US8993581

 

Methods for treating viral disorders

 

Trustees of Boston University

24-

Sep- 09

11-

Jun

-13

31-

Mar

-15

 

US8993295

Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting

 

The General Hospital Corporation

20-

Jul-06

20-

Jul- 07

31-

Mar

-15

 

US8992939

 

Highly efficient influenza matrix (M1) proteins

 

Novavax, Inc.

11-

Jul-03

24-

Oct

-11

31-

Mar

-15

 

US8987249

Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl- cyano-methyl)-amides inhibitors of Cathepsin C

 

Boehringer Ingelheim International GmbH

14-

Mar- 13

12-

Mar

-14

24-

Mar

-15

 

US8987191

 

Bioactive peptides and methods of using same

 

Compugen Ltd.

12-

Jul-07

21-

Jun

-13

24-

Mar

-15

 

US8986933

 

Selective detection of human rhinovirus

The United States of America as represented by the Secretary of the Department of Health and Human

Services, Centers for Disease Control

5-

Dec- 08

5-

Dec

-08

24-

Mar

-15

 

US8986926

Compositions comprising oriented, immobilized macromolecules and methods for their preparation

 

NanoString Technologies, Inc.

23-

Dec- 05

22-

Dec

-06

24-

Mar

-15

 

US8986702

 

Antibodies and processes for preparing the same

 

Taiga Biotechnologies, Inc.

16-

May- 08

18-

May

-09

24-

Mar

-15

 

US8980898

 

Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases

 

Parion Sciences, Inc.

29-

May- 12

29-

May

-13

17-

Mar

-15

 

US8980338

 

Sceletium extract and uses thereof

 

H.L. Hall & Sons Limited

20-

Mar- 09

16-

Mar

-10

17-

Mar

-15

 

US8980281

High-yield transgenic mammalian expression system for generating virus-like particles

 

Academia Sinica

5-

Sep- 06

12-

Feb

-10

17-

Mar

-15

 

US8975389

 

Nucleic acid chemical modifications

 

Alnylam Pharmaceuticals, Inc.

2-

Mar- 09

2-

Mar

-10

10-

Mar

-15

 

US8969362

 

9-substituted 8-oxoadenine compound

 

AstraZeneca Aktiebolag

26-

Mar- 04

21-

Oct

-13

3-

Mar

-15

 

US8969350

Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient

 

Astrazeneca AB

18-

Dec- 08

17-

Dec

-09

3-

Mar

-15

 

US8962580

Chemical modifications of monomers and oligonucleotides with cycloaddition

 

Alnylam Pharmaceuticals, Inc.

23-

Sep- 08

23-

Sep

-09

24-

Feb

-15

 

US8962332

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

 

The Trustees of the University of Pennsylvania

17-

Dec- 01

13-

Sep

-13

24-

Feb

-15

 

US8962330

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

 

The Trustees of the University of Pennsylvania

17-

Dec- 01

31-

Oct

-07

24-

Feb

-15

 

US8961983

 

Mucosal vaccine using cationic nanogel

National University Corporation Tokyo Medical and Dental University

31-

Oct- 08

5-

Sep

-14

24-

Feb

-15

 

US8961477

 

Delivery of immune response modifier compounds

 

3M Innovative Properties Company

25-

Aug- 03

25-

Aug

-04

24-

Feb

-15

 

US8956863

 

Agents from cells

 

The Brigham and Women's Hospital, Inc.

15-

Oct- 09

15-

Oct

-10

17-

Feb

-15

 

US8956616

Constructs binding to phosphatidylserine and their use in disease treatment

 

Board of Regents, The University of Texas System

24-

Jan- 05

24-

Jan

-06

17-

Feb

-15

 

US8951768

 

Mutations in OAS1 genes

 

Kineta Two, LLC

4-

May- 05

11-

Jul- 11

10-

Feb

-15

 

US8951528

 

Immune response modifier conjugates

 

3M Innovative Properties Company

22-

Feb- 06

21-

Feb

-07

10-

Feb

-15

 

US8945943

Personal glucose meters for detection and quantification of a broad range of analytes

 

The Board of Trustees of the University of Illinois

26-

May- 10

26-

May

-11

3-

Feb

-15

 

US8945904

 

Influenza virus reassortment

 

Novartis AG

21-

May- 10

20-

May

-11

3-

Feb

-15

 

US8945610

Condensation products based on bicyclic or polycyclic aromatics or heteroaromatics

 

BASF SE

14-

Nov- 07

11-

Nov

-08

3-

Feb

-15

 

US8940864

 

Stabilized therapeutic small helical antiviral peptides

 

New York Blood Center, Inc.

5-

Oct- 06

2-

Oct

-07

27-

Jan- 15

 

US8940501

 

Methods for ligation and uses thereof

 

Whitehead Institute for Biomedical Research

30-

Jan- 09

1-

Feb

-10

27-

Jan- 15

 

US8937154

 

Stabilized therapeutic small helical antiviral peptides

 

New York Blood Center, Inc.

5-

Oct- 06

2-

Feb

-12

20-

Jan- 15

 

US8933210

 

Label-free functional nucleic acid sensors for detecting target agents

 

The Board of Trustees of the University of Illinois

6-

Oct- 10

6-

Oct

-11

13-

Jan- 15

 

US8933019

 

Antiviral cell-penetrating peptides

 

New York Blood Center, Inc.

6-

May- 08

31-

Oct

-12

13-

Jan- 15

 

US8916552

 

Pharmaceutical combinations

 

Astex Therapeutics Limited

12-

Oct- 06

12-

Oct

-07

23-

Dec

-14

 

US8916340

Method for identifying and validating dominant T helper cell epitopes using an HLA-DM-assisted class II binding assay

 

The John Hopkins University

6-

Jan- 06

8-

Jan

-07

23-

Dec

-14

 

US8906872

Antisense antiviral compound and method for treating ssRNA viral infection

 

Sarepta Therapeutics, Inc.

16-

Sep- 04

22-

Dec

-11

9-

Dec

-14

 

US8906863

Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector

 

The Regents of the University of California

27-

Feb- 09

1-

Sep

-11

9-

Dec

-14

 

US8906862

 

Multiple antigen delivery system using hepatitis E virus-like particle

 

National Institute of Infectious Disease

27-

Feb- 09

29-

Aug

-11

9-

Dec

-14

 

US8901071

 

Compounds and their use

 

Novabiotics Limited

31-

Mar- 10

30-

Mar

-11

2-

Dec

-14

 

US8900585

Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection

 

New York Blood Center, Inc.

20-

Oct- 10

20-

Oct

-11

2-

Dec

-14

 

US8895629

 

Circulation of components during homogenization of emulsions

 

Novartis AG

3-

Dec- 09

3-

Dec

-10

25-

Nov

-14

 

US8895577

 

Compounds and compositions as TLR activity modulators

 

Not Available

3-

Mar- 08

22-

Apr

-13

25-

Nov

-14

 

US8895570

 

Purine derivatives

 

AstraZeneca AB

17-

Dec- 10

14-

Dec

-11

25-

Nov

-14

 

US8895534

 

Boron containing small molecules

 

Anacor Pharmaceuticals, Inc.

20-

Jun- 07

30-

Jul- 10

25-

Nov

-14

 

US8895295

 

High density self-contained biological analysis

 

Biofire Diagnostics, LLC

15-

Nov- 06

14-

Nov

-07

25-

Nov

-14

 

US8889708

Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C

 

Boehringer Ingelheim International GmbH

14-

Mar- 13

12-

Mar

-14

18-

Nov

-14

 

US8889692

Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses

 

AstraZeneca AB

27-

Jun- 07

14-

Sep

-12

18-

Nov

-14

 

US8889656

 

Boron-containing small molecules

 

Anacor Pharmaceuticals, Inc.

16-

Feb- 05

30-

Apr

-13

18-

Nov

-14

 

US8889398

 

Composition for inactivating an enveloped virus

 

Viroblock SA

19-

May- 06

18-

May

-07

18-

Nov

-14

 

US8889181

Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes

Industry Academic Cooperation Foundation, Hallym University

17-

Jul-09

16-

Jun

-10

18-

Nov

-14

 

US8889118

Anticancer agent containing dendritic cell having RNA virus transferred thereinto

 

DNA VEC Research Inc.

24-

Jun- 04

28-

Apr

-05

18-

Nov

-14

 

US8889117

 

Modular nanoparticles for adaptable vaccines

 

Yale University

15-

Feb- 07

15-

Feb

-08

18-

Nov

-14

 

US8884020

 

Indole compounds

 

Ironwood Pharmaceuticals, Inc.

7-

Aug- 06

7-

Aug

-07

11-

Nov

-14

 

US8883790

 

Pharmaceutical combinations

 

Astex Therapeutics Limited

12-

Oct- 06

12-

Oct

-07

11-

Nov

-14

 

US8883500

Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy

 

Northeastern University

5-

Dec- 08

7-

Dec

-09

11-

Nov

-14

 

US8883481

 

Reverse genetics methods for virus rescue

 

Novartis AG

20-

Oct- 09

20-

Oct

-10

11-

Nov

-14

 

US8883477

 

Oligoadenylate synthetase (OAS)

 

Kineta Two, LLC

23-

Nov- 05

14-

Jun

-13

11-

Nov

-14

 

US8882484

Methods and compositions for production of recombinant protein in HBX-expressing mammalian cells

 

Bayer HealthCare LLC

28-

May- 08

27-

May

-09

11-

Nov

-14

 

US8881040

System and method for detecting, collecting, analyzing, and communicating event-related information

 

Georgetown University

28-

Aug- 08

2-

Dec

-09

4-

Nov

-14

 

US8877775

Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl- cyano-methyl)-amides inhibitors of cathepsin C

 

Boehringer Ingelheim International GmbH

14-

Mar- 13

12-

Mar

-14

4-

Nov

-14

 

US8877187

Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases

 

Avianax, LLC

25-

Jul-05

23-

Nov

-10

4-

Nov

-14

 

US8877060

 

Methods for removing pathogens from a platelet preparation

 

Biovec Transfusion, LLC

23-

Nov- 10

31-

Oct

-11

4-

Nov

-14

 

US8871816

 

Methods for producing vaccine adjuvants

 

Novartis AG

3-

Dec- 09

3-

Dec

-10

28-

Oct- 14

 

US8871790

 

Heterocyclic modulators of lipid synthesis

 

3-V Biosciences, Inc.

8-

Mar- 11

8-

Mar

-12

28-

Oct- 14

 

US8871783

Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano- methyl)-amides inhibitors of cathepsin C

 

Boehringer Ingelheim International GmBh

14-

Mar- 13

12-

Mar

-14

28-

Oct- 14

 

US8871782

 

Alkoxy substituted imidazoquinolines

 

3M Innovative Properties Company

3-

Oct- 03

1-

Oct

-04

28-

Oct- 14

 

US8871503

 

Construct

 

Isis Innovation Limited

28-

Mar- 06

28-

Mar

-07

28-

Oct- 14

 

US8871487

 

Compositions, methods and uses for inducing viral growth

 

Takeda Vaccines, Inc.

5-

Dec- 08

4-

Dec

-09

28-

Oct- 14

 

US8871442

 

Enhanced deposition of chromogens

 

Ventana Medical Systems, Inc.

30-

Dec- 10

28-

Dec

-11

28-

Oct- 14

 

US8865865

N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic

 

Philipps-Universitat Marburg

29-

Oct- 08

29-

Oct

-09

21-

Oct- 14

 

US8865166

 

Antibodies to IL-17A and uses thereof

 

MedImmune Limited

23-

Jun- 06

22-

Jun

-07

21-

Oct- 14

 

US8859568

 

Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy

 

Astrazeneca AB

6-

Dec- 04

3-

Nov

-10

14-

Oct- 14

 

US8859251

 

Oligoadenylate synthetase (OAS)

 

Kineta Two, LLC

23-

Nov- 05

1-

Jul- 13

14-

Oct- 14

 

US8858958

 

Adjuvant comprising aluminum, oligonucleotide and polycation

 

Novartis AG

27-

Aug- 09

27-

Aug

-10

14-

Oct- 14

 

US8858957

 

GAS57 mutant antigens and GAS57 antibodies

 

Novartis AG

12-

Sep- 07

14-

Mar

-13

14-

Oct- 14

 

US8854617

 

Compounds and markers for surface-enhanced Raman scattering

 

Julius-Maximilians-Universitat Wurzburg

24-

Sep- 07

24-

Sep

-08

7-

Oct- 14

 

US8853382

 

Expression of antibody or a fragment thereof in lactobacillus

 

Hera Pharmaceuticals, Inc.

5-

Aug- 10

4-

Aug

-11

7-

Oct- 14

 

US8846710

 

Method of preferentially inducing the biosynthesis of interferon

 

3M Innovative Properties Company

23-

Feb- 05

22-

Feb

-06

30-

Sep

-14

 

US8846697

 

Purine analogs

 

The Regents of the University of California

31-

May- 06

23-

Apr

-07

30-

Sep

-14

 

US8846643

 

Phosphonates with reduced toxicity for treatment of viral infections

 

The Regents of the University of California

14-

Apr- 10

11-

Oct

-12

30-

Sep

-14

 

US8846051

Modulation of replicative fitness by deoptimization of synonymous codons

The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention

8-

Oct- 04

7-

Oct

-05

30-

Sep

-14

 

US8841100

 

Use of methylsulfonylmethane (MSM) to modulate microbial activity

 

Biogenic Innovations, LLC

30-

Oct- 09

16-

Feb

-11

23-

Sep

-14

 

US8840899

 

Use of mTOR inhibitors to enhance T cell immune responses

 

Emory University

5-

Aug- 08

5-

Aug

-09

23-

Sep

-14

 

US8840890

Rapid expression cloning of human monoclonal antibodies from memory B cells

 

University of Maryland, Baltimore

12-

Nov- 08

12-

Nov

-09

23-

Sep

-14

 

US8840873

Method of treating second and third degree burns using oxidative reductive potential water solution

 

Oculus Innovative Sciences, Inc.

23-

Mar- 05

23-

Mar

-06

23-

Sep

-14

 

US8840774

Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode

 

Board of Regents of the University of Texas System

3-

Jun- 05

28-

Oct

-13

23-

Sep

-14

 

US8835107

Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics

 

Amsterdam Institute of Viral Genomics B.V.

18-

Aug- 03

26-

Jul- 10

16-

Sep

-14

 

US8834445

Methods of treating or preventing peritonitis with oxidative reductive potential water solution

 

Oculus Innovative Sciences, Inc.

20-

Jan- 06

30-

Mar

-12

16-

Sep

-14

 

US8828962

SiRNA compositions and methods for potently inhibiting viral infection

 

Xiangxue Group (Hong Kong) Company Limited

11-

Dec- 08

12-

Dec

-11

9-

Sep

-14

 

US8828956

 

Carbohydrate conjugates as delivery agents for oligonucleotides

 

Alnylam Pharmaceuticals, Inc.

4-

Dec- 07

4-

Dec

-12

9-

Sep

-14

 

US8828940

Method of treating an ischemia-reperfusion injury-related disorder by administering GPCR ligands

 

Compugen Ltd.

18-

Sep- 06

14-

Dec

-10

9-

Sep

-14

 

US8828929

Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof

Japan as Represented by Director-General of National Institute of Infectious Diseases

28-

Nov- 08

27-

Nov

-09

9-

Sep

-14

 

US8828673

Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses

 

Diagnostic Hybrids Inc

24-

Apr- 98

1-

Mar

-12

9-

Sep

-14

 

US8828659

 

Method for producing nucleic acid probes

 

Ventana Medical Systems, Inc.

1-

Sep- 06

11-

Mar

-13

9-

Sep

-14

 

US8828407

 

Chimaeric protein

 

The Pirbright Institute

7-Jul- 09

5-

Jul- 10

9-

Sep

-14

 

US8828406

 

Influenza viruses and uses thereof

 

Icahn School of Medicine at Mount Sinai

30-

Jul-09

29-

Jul- 10

9-

Sep

-14

 

US8822512

 

Crystalline tripeptide epoxy ketone protease inhibitors

 

Onyx Therapeutics, Inc.

20-

Mar- 09

20-

Sep

-11

2-

Sep

-14

 

US8822409

Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith

 

Phylogica Limited

20-

Jun- 07

20-

Jun

-08

2-

Sep

-14

 

US8821897

 

Viral adjuvants

 

The University of North Carolina at Chapel Hill

9-Jul- 04

24-

Nov

-10

2-

Sep

-14

 

US8816089

Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity

 

Masatoshi Hagiwara

26-

Dec- 03

19-

Nov

-12

26-

Aug

-14

 

US8816053

Methods for treating viral infection using IL-28 and IL-29 cysteine mutants

 

ZymoGenetics, Inc.

2-

Apr- 04

7-

Sep

-12

26-

Aug

-14

 

US8815837

 

Respiratory disease treatment

 

Pulmagen Therapeutics (Inflammation) Limited

7-

Aug- 08

29-

Jun

-12

26-

Aug

-14

 

US8815831

 

Treatment of Acinetobacter with alginate oligomers and antibiotics

 

Algipharma AS

3-

Jun- 09

3-

Jun

-10

26-

Aug

-14

 

US8815611

 

Surface for label independent detection and method thereof

 

Corning Incorporated

10-

Apr- 08

3-

Apr

-09

26-

Aug

-14

 

US8815249

 

Ii-key/antigenic epitope hybrid peptide vaccines

 

Antigen Express, Inc.

4-

Sep- 99

26-

Jul- 10

26-

Aug

-14

 

US8815244

 

Method for production of antibody using ostrich

 

Japan Science and Technology Agency

29-

Aug- 05

16-

Aug

-11

26-

Aug

-14

 

US8809377

 

Deubiquitinase inhibitors and methods for use of the same

 

The Regents of the University of Michigan

24-

Sep- 10

23-

Sep

-11

19-

Aug

-14

 

US8808703

Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc

 

Not Available

23-

Mar- 10

23-

Mar

-11

19-

Aug

-14

 

US8808686

 

Adjuvant-sparing multi-dose influenza vaccination regimen

 

Novartis AG

15-

Jun- 06

19-

Sep

-11

19-

Aug

-14

 

US8802853

 

Arylalkenyl and arylalkynyl substituted imidazoquinolines

 

3M Innovative Properties Company

29-

Dec- 03

17-

Dec

-04

12-

Aug

-14

 

US8802647

Materials and methods for prevention and treatment of RNA viral diseases

 

University of South Florida

30-

Apr- 02

17-

Sep

-12

12-

Aug

-14

 

US8802106

Peptide compositions and methods for inhibiting herpesvirus infection

 

The Administrators of the Tulane Educational Fund

30-

Oct- 09

29-

Oct

-10

12-

Aug

-14

 

US8796423

Anti-TSG101 antibodies and their uses for treatment of viral infections

 

Eli Lilly and Company

15-

Nov- 06

18-

Apr

-08

5-

Aug

-14

 

US8790655

 

Conjugates of synthetic TLR agonists and uses therefor

 

The Regents of The University of California

7-

Feb- 07

8-

Jan

-13

29-

Jul- 14

 

US8785408

Compositions and methods for reducing or protecting against delayed graft function (DGF)

 

Quark Pharmaceuticals, Inc.

27-

Jun- 07

26-

Jun

-08

22-

Jul- 14

 

US8785375

 

Cyclic antimicrobial peptides for treating bacterial infections

 

Novabiotics Ltd.

22-

Dec- 05

22-

Aug

-12

22-

Jul- 14

 

US8784900

Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same

 

Oculus Innovative Sciences, Inc.

13-

Mar- 07

13-

Mar

-08

22-

Jul- 14

 

US8779132

 

Pharmaceutical compounds

 

Astex Therapeutics Limited

12-

Oct- 06

12-

Oct

-07

15-

Jul- 14

 

US8778963

Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines

 

3M Innovative Properties Company

25-

Nov- 03

24-

Nov

-04

15-

Jul- 14

 

US8778846

 

Composition, device and associated method

 

General Electric Company

4-

Dec- 06

1-

Mar

-07

15-

Jul- 14

 

US8778845

 

Composition, device and associated method

 

Genral Electric Company

15-

Dec- 05

1-

Mar

-07

15-

Jul- 14

 

US8778358

Immunogenic compositions for gram positive bacteria such as Streptococcus agalactiae

 

Novartis Vaccines and Diagnostics, Inc.

29-

Jul-04

18-

Oct

-10

15-

Jul- 14

 

US8778275

 

Methods for producing vaccine adjuvants

 

Novartis AG

3-

Dec- 09

3-

Dec

-10

15-

Jul- 14

 

US8772471

 

Targeted delivery of siRNA

 

Immune Disease Institute

26-

Jan- 07

25-

Jan

-08

8-

Jul- 14

 

US8765939

Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers

 

AstraZeneca AB

22-

Nov- 07

16-

Aug

-12

1-

Jul- 14

 

US8765704

 

Modified small interfering RNA molecules and methods of use

 

Novartis AG

28-

Feb- 08

14-

Dec

-11

1-

Jul- 14

 

US8765643

 

Composition, device and associated method

 

General Electric Company

4-

Dec- 06

1-

Mar

-07

1-

Jul- 14

 

US8765146

 

Adenoviral vector-based malaria vaccines

 

GenVec, Inc.

31-

Aug- 05

31-

Aug

-06

1-

Jul- 14

 

US8765138

 

Antiviral and antibacterial activity from medicinal mushrooms

 

Not Available

6-

Jan- 04

24-

Sep

-08

1-

Jul- 14

 

US8765133

 

Method of producing anti-CD166 antibody in ostrich

 

Japan Science and Technology Agency

29-

Aug- 05

16-

Aug

-11

1-

Jul- 14

 

US8759307

Oligonucleotide compound and method for treating nidovirus infections

 

Sarepta Therapeutics, Inc.

24-

Dec- 03

25-

Apr

-08

24-

Jun- 14

 

US8758763

 

Archaeal polar lipid aggregates for administration to animals

 

National Research Council of Canada

15-

Dec- 06

23-

Jan

-13

24-

Jun- 14

 

US8758680

 

Method and device for cleaning air

 

Not Available

29-

Sep- 10

27-

Sep

-11

24-

Jun- 14

 

US8754071

 

Compounds and compositions as c-kit kinase inhibitors

 

Not Available

1-

Sep- 11

19-

Sep

-13

17-

Jun- 14

 

US8754015

Modified phage for displaying post-translationally modified proteins and uses thereof

 

University of Rochester

21-

Nov- 06

20-

Nov

-07

17-

Jun- 14

 

US8748567

 

Method for delivery across the blood brain barrier

 

Children's Medical Center Corporation

22-

May- 06

22-

May

-07

10-

Jun- 14

 

US8748464

Use of SIRT1 activators or inhibitors to modulate an immune response

 

The J. David Gladstone Institutes

7-

Feb- 08

16-

Jul- 10

10-

Jun- 14

 

US8748405

Methods and compositions for the treatment of cancer or other diseases

 

City of Hope

26-

Jan- 07

9-

Sep

-11

10-

Jun- 14

 

US8748156

 

Animal protein-free media for cultivation of cells

 

Baxter Healthcare SA

29-

Oct- 04

16-

Apr

-13

10-

Jun- 14

 

US8741813

 

Composition, device and associated method

 

General Electric Company

15-

Dec- 05

28-

Feb

-07

3-

Jun- 14

 

US8741653

 

Single recombination system and methods of use

 

Emergent Product Development GmbH

22-

Dec- 08

16-

Dec

-09

3-

Jun- 14

 

US8741604

 

Nucleic acid molecule encoding a specific IL-1R1 antibody

 

Medimmune Limited

7-

Nov- 08

14-

Sep

-12

3-

Jun- 14

 

US8741564

Quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvements

 

HTG Molecular Diagnostics, Inc.

4-

May- 11

26-

Apr

-12

3-

Jun- 14

 

US8741311

 

Methods and compositions for immunization against virus

 

Academia Sinica

27-

Mar- 09

26-

Mar

-10

3-

Jun- 14

 

US8735567

 

Multi-targeted RNAi therapeutics for scarless wound healing of skin

 

Not Available

6-

Nov- 07

6-

Nov

-08

27-

May

-14

 

US8735559

 

Mutant protease biosensors with enhanced detection characteristics

 

Promega Corporation

11-

May- 10

11-

May

-11

27-

May

-14

 

US8735421

 

Imidazoquinolinyl sulfonamides

 

3M Innovative Properties Company

30-

Dec- 03

23-

Dec

-04

27-

May

-14

 

US8735410

 

Quinazoline derivatives as tyrosine kinase inhibitors

 

AstraZeneca AB

26-

Feb- 05

24-

Feb

-06

27-

May

-14

 

US8735348

 

Casein derived peptides and uses thereof

 

Peptera Ltd.

1-

Mar- 00

5-

Sep

-12

27-

May

-14

 

US8734823

Device including altered microorganisms, and methods and systems of use

 

The Invention Science Fund I, LLC

14-

Dec- 05

28-

May

-10

27-

May

-14

 

US8728793

 

Amphipathic alpha-helical peptide compositions as antiviral agents

The Board of Trustees of the Leland Stanford Junior University

19-

Jul-07

14-

Jul- 08

20-

May

-14

 

US8722917

 

Boron-containing small molecules

 

Anacor Pharmaceuticals, Inc.

16-

Feb- 05

23-

Jan

-12

13-

May

-14

 

US8722741

Biphenyloxyacetic acid derivatives for the treatment of respiratory disease

 

AstraZeneca AB

24-

Aug- 04

6-

Dec

-11

13-

May

-14

 

US8722725

 

Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereof

 

Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory

23-

Mar- 07

21-

Mar

-08

13-

May

-14

 

US8718948

Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector

 

Gen-Probe Incorporated

24-

Feb- 11

24-

Feb

-12

6-

May

-14

 

US8716464

 

Compositions and methods for silencing Ebola virus gene expression

 

Not Available

20-

Jul-09

20-

Jul- 10

6-

May

-14

 

US8716461

 

Human parvovirus

 

Blood Systems, Inc.

24-

May- 04

24-

May

-05

6-

May

-14

 

US8710224

 

Heterocyclic compounds as CCR2B antagonists

 

AstraZeneca AB

24-

Dec- 04

13-

Sep

-13

29-

Apr- 14

 

US8709730

 

Methods of preventing and treating viral infections by inhibiting the deISGylation activity of OTU domain-containing viral proteins

 

Icahn School of Medicine at Mount Sinai

5-

Apr- 07

7-

Apr

-08

29-

Apr- 14

 

US8709496

Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract

 

D2 Bioscience Group Ltd.

6-

Jan- 10

23-

May

-12

29-

Apr- 14

 

US8709447

Compositions and methods for activating innate and allergic immunity

 

ID Biomedical Corporation of Quebec

22-

Oct- 03

26-

Apr

-12

29-

Apr- 14

 

US8709441

 

TC-83-derived alphavirus vectors, particles and methods

 

Alphavax, Inc.

18-

May- 04

6-

Jul- 10

29-

Apr- 14

 

US8704169

 

Direct impact ionization (DII) mass spectrometry

The United States of America, as represented by the Secretary, Department of Health and Human Services

11-

Oct- 11

11-

Oct

-11

22-

Apr- 14

 

US8703748

Cleaning composition for treating tissue for transplantation derived from human/animal

 

CG BIO Co., Ltd.

11-

Feb- 09

10-

Feb

-10

22-

Apr- 14

 

US8703467

Inactivation of a pathogen in a sample by a treatment with formalin and UV light

 

Baxter Healthcare SA

27-

May- 04

26-

May

-05

22-

Apr- 14

 

US8702958

Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode

 

Board of Regents of the University of Texas System

3-

Jun- 05

31-

May

-12

22-

Apr- 14

 

US8697873

Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines

 

3M Innovative Properties Company

24-

Mar- 04

24-

Mar

-05

15-

Apr- 14

 

US8697853

 

TAL effector-mediated DNA modification

 

Iowa State University Research Foundation, Inc.

10-

Dec- 09

10-

Jan

-13

15-

Apr- 14

 

US8697659

 

Analogues of glycolipids useful as immunoadjuvants

 

Luigi Panza

12-

Oct- 07

10-

Oct

-08

15-

Apr- 14

 

US8697140

 

Virucidal disinfectant

 

B. Braun Medical AG

28-

Jan- 05

28-

May

-09

15-

Apr- 14

 

US8697088

VLPs derived from cells that do not express a viral matrix or core protein

 

Novavax, Inc.

25-

May- 07

27-

May

-08

15-

Apr- 14

 

US8697087

Influenza vaccines including combinations of particulate adjuvants and immunopotentiators

 

Novartis AG

4-

Nov- 05

6-

Nov

-06

15-

Apr- 14

 

US8691837

 

Substituted imidazo ring systems and methods

 

3M Innovative Properties Company

25-

Nov- 03

24-

Nov

-04

8-

Apr- 14

 

US8691826

 

Compounds

 

Chiesi Farmaceutici S.p.A.

14-

Sep- 11

13-

Sep

-12

8-

Apr- 14

 

US8691781

 

Compositions for treating respiratory viral infections and their use

 

Sirnaomics, Inc.

5-

Nov- 04

4-

Nov

-05

8-

Apr- 14

 

US8691777

 

Combination therapy

 

Emory University

27-

Jan- 11

25-

Jan

-12

8-

Apr- 14

 

US8686152

4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)

 

Janssen Pharmaceutica NV

10-

Mar- 10

9-

Mar

-11

1-

Apr- 14

 

US8682619

Device including altered microorganisms, and methods and systems of use

 

The Invention Science Fund I, LLC

14-

Dec- 05

28-

May

-10

25-

Mar

-14

 

US8679839

 

Cell line from rousettus as host cell for pathogen amplification

 

Probiogen AG

4-

Mar- 08

4-

Mar

-09

25-

Mar

-14

 

US8678184

 

Methods for producing vaccine adjuvants

 

Novartis AG

3-

Dec- 09

3-

Dec

-10

25-

Mar

-14

 

US8678002

 

Devices and methods for decreasing human pathogen transmission

 

Filligent Limited

26-

Jun- 07

25-

Jun

-08

25-

Mar

-14

 

US8673983

 

Melanins synthesized chemically or via enzyme catalysis

 

Loyola University Chicago

21-

Dec- 07

22-

Dec

-08

18-

Mar

-14

 

US8673932

 

Oxime substituted imidazo-containing compounds

 

3M Innovative Properties Company

12-

Aug- 03

12-

Aug

-04

18-

Mar

-14

 

 

US8673907

 

Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2- butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4- ylpropyl) amino] methyl }phenyl) acetate and their use in therapy

 

 

AstraZeneca AB

 

17-

Dec- 07

 

16-

Dec

-08

 

18-

Mar

-14

 

US8673904

 

Epoxide inhibitors of cysteine proteases

The Board of Trustees of the Leland Stanford Junior University

13-

Jun- 06

13-

Jun

-07

18-

Mar

-14

 

US8673558

 

Luciferase biosensor

 

Promega Corporation

10-

Oct- 03

24-

Apr

-12

18-

Mar

-14

 

US8673331

Composition with sterilizing activity against bacteria, fungus and viruses, application thereof and method for preparation thereof

 

GP&E

18-

Nov- 11

18-

Nov

-11

18-

Mar

-14

 

US8669263

 

Use of TAM receptor inhibitors as antimicrobials

 

Salk Institute for Biological Studies

9-

Nov- 07

8-

Mar

-13

11-

Mar

-14

 

 

US8669262

 

3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6- pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra zine-2-carboxamide

 

 

Parion Sciences, Inc.

 

27-

Jun- 11

 

26-

Jun

-12

 

11-

Mar

-14

 

US8669240

Biological specimen collection and transport system and method of use

 

Longhorn Vaccines & Diagnostics, LLC

1-

Oct- 07

19-

Mar

-13

11-

Mar

-14

 

 

US8664274

 

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses

 

 

Siga Technologies, Inc.

 

6-

Dec- 04

 

6-

Jul- 11

 

4-

Mar

-14

 

US8664218

 

Pharmaceutical compounds

 

Astex Therapeutics Ltd.

11-

Apr- 08

30-

Jan

-13

4-

Mar

-14

 

US8664188

siRNA compositions and methods for potently inhibiting viral infection

 

Xiangxue Group (Hong Kong) Company Limited

11-

Dec- 08

11-

Dec

-09

4-

Mar

-14

 

US8663922

 

Systems and methods for detecting multiple optical signals

 

Gen-Probe Incorporated

10-

Mar- 05

1-

Jun

-10

4-

Mar

-14

 

US8658767

 

Lipidated polyepitope vaccines

 

National Health Research Institutes

15-

Nov- 10

15-

Nov

-11

25-

Feb

-14

 

 

US8658697

 

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses

 

 

Siga Technologies, Inc.

 

6-

Dec- 04

 

26-

Oct

-10

 

25-

Feb

-14

 

US8658666

 

Substituted imidazoquinolines and imidazonaphthyridines

 

3M Innovative Properties Company

11-

Feb- 05

10-

Feb

-06

25-

Feb

-14

 

US8658178

 

Carbon nanotube compositions and methods of use thereof

 

Yale University

19-

Mar- 08

19-

Mar

-09

25-

Feb

-14

 

US8653252

 

Short interfering RNA (siRNA) analogues

 

Santaris Pharma A/S

21-

Mar- 03

22-

Mar

-04

18-

Feb

-14

 

US8653084

 

Hydrobenzamide derivatives as inhibitors of Hsp90

 

Astex Therapeutics Ltd.

12-

Oct- 06

12-

Oct

-07

18-

Feb

-14

 

US8653034

Compositions and methods comprising phosphatidylethanolamine- binding peptide derivatives

 

Board of Regents, The University of Texas System

15-

Jul-02

8-

May

-08

18-

Feb

-14

 

US8652836

Defective ribosomal products in blebs (DRibbles) and methods of use to stimulate an immune response

 

Providence Health System

29-

Jul-05

27-

Jul- 06

18-

Feb

-14

 

US8652782

Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids

 

Longhorn Vaccines & Diagnostics, LLC

12-

Sep- 06

26-

Apr

-11

18-

Feb

-14

 

US8652533

 

Durable biocides and disinfectants

 

Mitsui Norin Co., Ltd.

7-Jul- 04

5-

Jul- 05

18-

Feb

-14

 

US8648076

 

Cysteine protease inhibitors and their therapeutic applications

 

Hybrigenics SA

5-

Aug- 05

26-

Jul- 06

11-

Feb

-14

 

US8647676

 

Antimicrobial composition from copepods

 

Nofima Ingrediens

28-

Oct- 08

28-

Oct

-09

11-

Feb

-14

 

 

US8642596

 

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses

 

 

Siga Technologies, Inc.

 

6-

Dec- 04

 

6-

Dec

-05

 

4-

Feb

-14

 

US8642260

 

Single quantum-dot based aptameric nanosensors

 

The Research Foundation of the City University of New York

21-

Oct- 08

21-

Oct

-09

4-

Feb

-14

 

US8633322

 

Alkynyl derivatives useful as DPP-1 inhibitors

 

Janssen Pharmaceutica NV

29-

Oct- 09

28-

Oct

-10

21-

Jan- 14

 

US8633308

Compounds for preventing or treating viral infections and methods of use thereof

 

The Governors of The University of Alberta

28-

Feb- 07

27-

Feb

-08

21-

Jan- 14

 

US8632764

 

Directed evolution and in vivo panning of virus vectors

 

University of North Carolina at Chapel Hill

30-

Apr- 08

29-

Apr

-09

21-

Jan- 14

 

US8629283

Compounds that modulate negative-sense, single-stranded RNA virus replication and uses thereof

 

Icahn School of Medicine at Mount Sinai

6-

Mar- 08

6-

Mar

-09

14-

Jan- 14

 

US8629271

 

Compounds

 

AstraZeneca AB

6-

Feb- 08

2-

Apr

-12

14-

Jan- 14

 

US8629098

 

Compositions and methods for adoptive and active immunotherapy

 

Yale University

15-

Jan- 08

14-

Jan

-09

14-

Jan- 14

 

US8628786

 

Polychlorinated biphenyls and squalene-containing adjuvants

 

Novartis AG

28-

Dec- 07

2-

Dec

-11

14-

Jan- 14

 

US8624011

Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same

 

The Trustees of the University of Pennsylvania

14-

Sep- 09

14-

Sep

-10

7-

Jan- 14

 

US8623419

 

Technology for preparation of macromolecular microspheres

 

Ansun Biopharma, Inc.

24-

Jan- 06

4-

Nov

-11

7-

Jan- 14

 

US8623382

 

Immunogenic compositions for inducing an immune response to HIV

 

Wyeth LLC

17-

Jun- 04

18-

Jan

-11

7-

Jan- 14

 

US8623364

 

Antigenic GM-CSF peptides and antibodies to GM-CSF

 

Morphotek, Inc.

8-

Feb- 06

24-

Oct

-12

7-

Jan- 14

 

US8617838

 

Fluorescent proteins and related methods and compounds

 

University of Massachusetts

20-

Sep- 04

20-

Sep

-05

31-

Dec

-13

 

US8615368

 

Method for determining the amount of an analyte in a sample

 

Gen-Probe Incorporated

10-

Mar- 05

10-

Mar

-06

24-

Dec

-13

 

US8609370

Highly active glycoproteins-process conditions and an efficient method for their production

 

Glycotope GmbH

13-

Feb- 04

14-

Feb

-05

17-

Dec

-13

 

US8609101

Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies

 

Theraclone Sciences, Inc.

23-

Apr- 09

23-

Apr

-10

17-

Dec

-13

 

US8604215

 

Crystalline tripeptide epoxy ketone protease inhibitors

 

Onyx Therapeutics, Inc.

20-

Mar- 09

22-

Mar

-10

10-

Dec

-13

 

US8603469

Methods of treating cancer with human monoclonal antibodies against interleukin 8

 

Genmab A/S

16-

Dec- 02

27-

Dec

-11

10-

Dec

-13

 

US8599383

 

Optical cytometry

 

The Regents of the University of California

6-

May- 09

6-

May

-09

3-

Dec

-13

 

US8598192

 

Hydroxylamine substituted imidazoquinolines

 

3M Innovative Properties Company

14-

Nov- 03

12-

Nov

-04

3-

Dec

-13

 

US8598134

RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof

 

South Alabama Medical Science Foundation

22-

Oct- 04

23-

Jul- 10

3-

Dec

-13

 

US8598116

 

Treatment of influenza virus infection

 

Educational Fund and Autoimmune Technologies, LLC

4-

Nov- 03

29-

May

-12

3-

Dec

-13

 

US8598106

Anti-microbial composition exhibiting residual anti-microbial properties on a surface

 

Byotrol PLC

17-

Sep- 07

5-

Jul- 11

3-

Dec

-13

 

US8597650

Methods for treating rheumatoid arthritis with anti-bile salt- stimulated lipase (BSSL) antibodies

 

HERNELL OLLE

8-

Apr- 09

6-

Apr

-10

3-

Dec

-13

 

US8592567

Vaccines and immunotherapeutics using codon-optimized IL-15 and methods for using the same

 

The Trustees of the University of Pennsylvania

13-

Jan- 06

3-

May

-12

26-

Nov

-13

 

US8592391

 

Method for therapeutic, clinical and veterinary use poly-ICLC

 

SALAZAR ANDRES

1-Jul- 03

17-

Oct

-08

26-

Nov

-13

 

US8586770

 

Unsaturated steroid compounds

 

Harbor Therapeutics, Inc.

29-

Sep- 04

18-

Feb

-11

19-

Nov

-13

 

US8586364

Cells and methodology to generate non-segmented negative-strand RNA viruses

 

Institut Pasteur

22-

Dec- 06

21-

Dec

-07

19-

Nov

-13

 

US8586363

 

TAL effector-mediated DNA modification

 

Iowa State University Research Foundation, Inc.

10-

Dec- 09

10-

Dec

-10

19-

Nov

-13

 

US8581584

 

Membrane proteins, mechanisms of action and uses thereof

 

Florida State University Research Foundation

26-

May- 10

26-

May

-11

12-

Nov

-13

 

US8580927

 

Engineered antibody constant domain molecules

The United States of America, as represented by the Secretary, Department of Health and Human Services

31-

Jan- 08

30-

Jan

-09

12-

Nov

-13

 

US8580268

CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

 

Coley Pharmaceutical GmbH

27-

Sep- 06

27-

Sep

-07

12-

Nov

-13

 

US8569283

 

Compounds and compositions as c-Kit kinase inhibitors

 

LIU XIAODONG

1-

Sep- 11

29-

Aug

-12

29-

Oct- 13

 

US8562996

 

RSV-specific binding molecules and means for producing them

 

MedImmune Limited

1-

Jun- 07

30-

May

-08

22-

Oct- 13

 

US8562943

Quality control methods for oil-in-water emulsions containing squalene

 

Novartis AG

8-

Nov- 06

6-

Nov

-07

22-

Oct- 13

 

US8560339

System and method to predict the global spread of infectious agents via commercial air travel

 

Kamran Khan

2-

Apr- 07

2-

Apr

-08

15-

Oct- 13

 

US8557767

Synthetic apolipoprotein E mimicking polypeptides and methods of use

 

UAB Research Foundation

28-

Aug- 07

27-

Aug

-08

15-

Oct- 13

 

US8557248

 

Methods and compositions for treating malaria

 

Cyvax, Inc.

9-

Aug- 10

9-

Aug

-11

15-

Oct- 13

 

US8552051

 

Use of pharmaceutical compositions containing mesembrenone

 

H. L. Hall & Sons Limited

20-

Mar- 09

16-

Mar

-10

8-

Oct- 13

 

US8552032

 

Bicyclic derivatives useful as inhibitors of DPP-1

 

Janssen Pharmaceutica NV

18-

Dec- 09

16-

Dec

-10

8-

Oct- 13

 

US8551968

 

Methods for generation of antibodies

 

National Jewish Health

13-

Mar- 07

13-

Mar

-08

8-

Oct- 13

 

US8551756

 

Avian influenza chimeric VLPS

 

Novavax, Inc.

11-

Jul-03

19-

Jan

-10

8-

Oct- 13

 

US8551750

Device including bone cage and method for treatment of disease in a subject

 

The Invention Science Fund I, LLC

23-

Apr- 09

28-

Jul- 09

8-

Oct- 13

 

US8551749

Device including bone cage and method for treatment of disease in a subject

 

The Invention Science Fund I, LLC

23-

Apr- 09

23-

Apr

-09

8-

Oct- 13

 

US8551738

 

Systems and methods for rapid identification of nucleic acid variants

 

Ibis Biosciences, Inc.

21-

Jul-05

11-

Nov

-09

8-

Oct- 13

 

US8551469

Treatment of tumors and viral diseases with recombinant interferon alpha

 

Superlab Far East Limited

28-

Feb- 01

6-

Oct

-08

8-

Oct- 13

 

US8546432

 

Tetrazolones as inhibitors of fatty acid synthase

 

Infinity Pharmaceuticals, Inc.

5-

May- 10

5-

May

-11

1-

Oct- 13

 

US8546383

 

Chiral fused [1,2]imidazo[4,5-c] ring compounds

 

3M Innovative Properties Company

30-

Dec- 04

25-

May

-12

1-

Oct- 13

 

US8546082

 

Methods for identification of sepsis-causing bacteria

 

Ibis Biosciences, Inc.

11-

Sep- 03

25-

May

-07

1-

Oct- 13

 

US8541568

Compositions and methods using siRNA molecules for treatment of gliomas

 

BIGNER DARELL D

24-

May- 08

26-

May

-09

24-

Sep

-13

 

US8541457

Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors

 

Xenon Pharmaceuticals Inc.

3-

Jun- 05

5-

Jun

-06

24-

Sep

-13

 

US8541438

Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines

 

3M Innovative Properties Company

18-

Jun- 04

21-

Dec

-10

24-

Sep

-13

 

US8541221

 

Primate T-lymphotropic viruses

 

Johns Hopkins University

21-

Feb- 05

1-

Jul- 10

24-

Sep

-13

 

US8541003

Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using

 

Protein Sciences Corporation

20-

Jun- 03

21-

Jun

-04

24-

Sep

-13

 

US8529968

Decontaminating composition having simultaneously bactericidal, fungicidal and virocidal properties, methods for obtaining and using said composition

 

Hightech Bio-Activities Holding GmbH

29-

Mar- 04

29-

Mar

-05

10-

Sep

-13

 

US8524715

Phenoxyacetic acid derivatives useful for treating respiratory diseases

 

Astrazeneca AB

23-

Nov- 04

22-

Nov

-05

3-

Sep

-13

 

US8524488

Methods and devices for determining a cell characteristic, and applications employing the same

 

The Regents of the University of California

10-

Sep- 02

9-

Mar

-05

3-

Sep

-13

 

US8524241

 

Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A

 

The General Hospital Corporation

20-

Jul-07

18-

Jul- 08

3-

Sep

-13

 

US8519106

 

Monoclonal human tumor-specific antibody

 

University of Zurich

13-

Mar- 07

13-

Mar

-08

27-

Aug

-13

 

US8507545

 

Cytotoxic T cell activator comprising EP4 agonist

National University Corporation, Hamamatsu University School of Medicine

8-

May- 07

7-

May

-08

13-

Aug

-13

 

US8507544

 

Bi-aryl amide compounds as CRTh2 receptor modulators

 

Astrazeneca AB

5-Jul- 07

3-

Jul- 08

13-

Aug

-13

 

US8507455

 

Folate conjugates

 

Alnylam Pharmaceuticals, Inc.

4-

Dec- 07

4-

Dec

-08

13-

Aug

-13

 

US8506968

 

SARS vaccine compositions and methods of making and using them

 

Eli Lilly and Company

29-

Jun- 00

28-

Dec

-09

13-

Aug

-13

 

US8506966

 

Adjuvanted influenza vaccines for pediatric use

 

Novartis AG

22-

Feb- 08

20-

Feb

-09

13-

Aug

-13

 

US8501746

 

Organic compounds

 

Novartis AG

5-

Jun- 06

4-

Jun

-07

6-

Aug

-13

 

US8501699

 

Bicyclic nucleosides and nucleotides as therapeutic agents

 

Biota Scientific Management Pty Ltd

3-Jul- 08

7-

Sep

-12

6-

Aug

-13

 

US8501461

 

System for performing multi-formatted assays

 

Gen-Probe Incorporated

10-

Mar- 05

3-

Dec

-09

6-

Aug

-13

 

US8497405

 

Process for dispersing vaporous hydrogen peroxide

 

STERIS Inc.

6-

Mar- 07

28-

Feb

-13

30-

Jul- 13

 

US8497112

 

Method for producing viral vaccines

 

Baxter Healthcare SA

28-

Aug- 07

28-

Aug

-08

30-

Jul- 13

 

US8494781

Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds

 

BOGOCH ELENORE S

6-

Jun- 03

10-

Dec

-10

23-

Jul- 13

 

US8492329

 

Bioactive peptides and methods of using same

 

Compugen Ltd.

12-

Jul-07

11-

Jul- 08

23-

Jul- 13

 

US8486959

 

Dibenzo[f,h]isoquinoline derivatives

 

National Health Research Institutes

14-

Jan- 10

14-

Jan

-11

16-

Jul- 13

 

US8486678

 

Pharmaceutical compositions for the treatment of virus infection

 

Kineta Two, LLC

23-

Nov- 05

1-

Feb

-12

16-

Jul- 13

 

US8486619

Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responses

 

University of Rochester

2-

May- 08

1-

May

-09

16-

Jul- 13

 

US8486420

 

Live virus vaccines

 

Children's Hospital, Inc.

15-

Feb- 05

15-

Feb

-06

16-

Jul- 13

 

US8481547

Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1

 

Janssen Pharmaceutica NV

18-

Dec- 09

16-

Dec

-10

9-

Jul- 13

 

US8481270

Method for chromogenic detection of two or more target molecules in a single sample

 

Ventana Medical Systems, Inc.

22-

Aug- 08

21-

Aug

-09

9-

Jul- 13

 

US8481255

 

Scytovirin domain 1 related polypeptides

The United States of America, as represented by the Secretary, Department of Health and Human Services

25-

May- 05

30-

Sep

-11

9-

Jul- 13

 

 

US8476292

 

Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1- dimethylethyl}methanesulfonamide and methods

 

 

3M Innovative Properties Company

 

9-

Sep- 05

 

8-

Sep

-06

 

2-

Jul- 13

 

US8476288

 

Salts 756

 

AstraZeneca AB

21-

May- 09

20-

May

-10

2-

Jul- 13

 

US8476265

 

Compounds-801

 

AstraZeneca AB

30-

Jul-10

14-

Sep

-12

2-

Jul- 13

 

US8470771

Method and medicament for inhibiting the infection of influenza virus

 

Institute of Microbiology, Chinese Academy of Sciences

14-

Nov- 07

18-

Dec

-07

25-

Jun- 13

 

US8470769

Method of treatment of bacterial infection by administration of poly- lysine

 

Novabiotics, Ltd.

18-

Aug- 04

30-

Nov

-11

25-

Jun- 13

 

US8470346

 

Anti-viral pharmaceutical compositions

 

Mast Therapeutics, Inc.

10-

Dec- 03

19-

May

-11

25-

Jun- 13

 

US8470335

Recombinant SARS-CoV nsp12 and the use of thereof and the method for producing it

Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy

Cooperation Foundation

13-

Jun- 08

13-

Jun

-08

25-

Jun- 13

 

US8466284

Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase

 

Astra Zeneca AB

6-

Nov- 07

5-

Nov

-08

18-

Jun- 13

 

US8466167

 

Compounds and compositions as TLR activity modulators

 

IRM LLC

3-

Mar- 08

27-

Feb

-09

18-

Jun- 13

 

US8466124

RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles

 

Coley Pharmaceutical GmbH

13-

Aug- 07

12-

Jun

-12

18-

Jun- 13

 

US8465751

 

Cna—B domain antigens in vaccines against gram positive bacteria

 

Novartis AG

12-

Jan- 09

12-

Jan

-10

18-

Jun- 13

 

US8461125

 

Compositions and methods to treat asthma

 

The Children's Hospital of Philadelphia

14-

Feb- 08

13-

Aug

-10

11-

Jun- 13

 

US8460914

Decreasing potential iatrogenic risks associated with vaccines and vaccine antigens

 

Novartis AG

9-

Sep- 04

10-

Jan

-13

11-

Jun- 13

 

US8460605

 

Decontaminant dispenser suitable for use as a projectile

 

STERIS Inc.

6-

Mar- 07

20-

Feb

-08

11-

Jun- 13

 

US8455483

 

Compounds—801

 

AstraZeneca AB

31-

Jul-09

30-

Jul- 10

4-

Jun- 13

 

US8450471

 

TAL effector-mediated DNA modification

 

Iowa State University Research Foundation, Inc.

10-

Dec- 09

22-

Mar

-12

28-

May

-13

 

US8450467

 

Carbohydrate conjugates as delivery agents for oligonucleotides

 

Alnylam Pharmaceuticals, Inc.

4-

Dec- 07

14-

Dec

-11

28-

May

-13

 

US8450350

 

Triazoles as inhibitors of fatty acid synthase

 

Infinity Pharmaceuticals, Inc.

5-

May- 10

5-

May

-11

28-

May

-13

 

US8450284

Coiled-coil lipopeptide helical bundles and synthetic virus-like particles

 

Universitaet Zuerich

9-

Dec- 06

6-

Dec

-07

28-

May

-13

 

US8450055

 

Malaria antigen screening method

The United States of America as Represented by the Secretary of the Navy

31-

Aug- 05

25-

Aug

-06

28-

May

-13

 

US8445650

Mutant botulinum neurotoxin serotype A polypeptide and uses thereof

 

Thomas Jefferson University

25-

Sep- 07

25-

Sep

-08

21-

May

-13

 

US8445447

B7-DC variants immunogenic compositions and methods of use thereof

 

The Johns Hopkins University

13-

Jul-07

7-

Mar

-12

21-

May

-13

 

US8444961

RNA virus infection inhibitor, method for inhibition of infection by RNA virus, RNA virus infection-inhibiting product, and use as RNA virus infection inhibitor

 

Sekisui Chemical Co., Ltd.

16-

Jun- 09

16-

Jun

-10

21-

May

-13

 

US8440704

 

Quercetin-containing compositions

 

Quercegen Pharmaceuticals LLC

17-

Jul-06

16-

Dec

-09

14-

May

-13

 

US8440649

 

Phenanthroindolizidine analogues

 

National Health Research Institutes

24-

Feb- 09

11-

Feb

-10

14-

May

-13

 

US8440642

 

Boron-containing small molecules

 

Anacor Pharmaceuticals, Inc.

16-

Feb- 05

1-

Sep

-11

14-

May

-13

 

US8440432

 

Tal effector-mediated DNA modification

 

Iowa State University Research Foundation, Inc.

10-

Dec- 09

22-

Mar

-12

14-

May

-13

 

US8440431

 

TAL effector-mediated DNA modification

 

Iowa State University Research Foundation, Inc.

10-

Dec- 09

22-

Mar

-12

14-

May

-13

 

US8440408

 

Animal protein-free media for cultivation of cells

 

Baxter Healthcare S.A.

29-

Oct- 04

10-

Dec

-10

14-

May

-13

 

US8436178

 

Imidazoquinolines with immuno-modulating properties

 

AstraZeneca AB

8-

May- 07

6-

May

-08

7-

May

-13

 

US8436024

 

2-pyridone compounds

 

Astrazeneca AB

2-

Oct- 09

1-

Oct

-10

7-

May

-13

 

US8431160

Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions

 

Novartis AG

24-

Feb- 06

24-

Feb

-07

30-

Apr- 13

 

US8431134

Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen

The United States of America as represented by the Secretary of the Department of Health and Human

Services, Centers for Disease Control and Prevention

31-

Jul-08

31-

Jul- 09

30-

Apr- 13

 

US8426565

 

Dendritic cell marker and uses thereof

 

Walter and Eliza Hall Institute of Medical Research

30-

Aug- 07

29-

Aug

-08

23-

Apr- 13

 

US8420798

 

Method for producing nucleic acid probes

 

Ventana Medical Systems, Inc.

1-

Sep- 06

31-

Aug

-07

16-

Apr- 13

 

US8420784

 

Interleukin 10 receptor, (IL-10R) antibodies

 

Kyowa Hakko Kirin Co., Ltd.

27-

May- 08

27-

May

-09

16-

Apr- 13

 

US8420096

Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling

 

Vanderbilt University

4-

Mar- 04

4-

Mar

-05

16-

Apr- 13

 

US8420094

 

Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A

 

The General Hospital Corporation

20-

Jul-07

18-

Jul- 08

16-

Apr- 13

 

US8415394

Biphenyloxyacetic acid derivatives for the treatment of respiratory disease

 

Astrazeneca AB

6-

Oct- 05

21-

Dec

-11

9-

Apr- 13

 

US8415361

 

Use of TAM receptor inhibitors as antimicrobials

 

The Salk Institute for Biological Studies

9-

Nov- 07

7-

Nov

-08

9-

Apr- 13

 

US8415330

Biological specimen collection and transport system and method of use

 

Longhorn Vaccines & Diagnostics, LLC

1-

Oct- 07

1-

Oct

-12

9-

Apr- 13

 

US8415309

 

Bicyclic nucleosides and nucleotides as therapeutic agents

 

Biota Scientific Managment Pty Ltd

1-Jul- 09

11-

Jan

-12

9-

Apr- 13

 

US8415118

 

Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereof

 

Virginia Tech Intellectual Properties, Inc.

29-

Oct- 07

29-

Oct

-08

9-

Apr- 13

 

US8415102

Methods and computer systems for identifying target-specific sequences for use in nanoreporters

 

NanoString Technologies, Inc.

10-

Apr- 07

10-

Apr

-08

9-

Apr- 13

 

 

US8410149

 

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses

 

 

Siga Technologies Inc.

 

6-

Dec- 04

 

28-

Oct

-10

 

2-

Apr- 13

 

US8410114

2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial

 

AstraZeneca AB

8-

May- 06

6-

Jan

-12

2-

Apr- 13

 

US8409589

 

Mutant forms of streptolysin O

 

Novartis AG

21-

Dec- 07

14-

Sep

-11

2-

Apr- 13

 

US8399651

 

Nucleic acids encoding GAS57 mutant antigens

 

Novartis AG

12-

Sep- 07

10-

Sep

-12

19-

Mar

-13

 

US8398992

 

Methods and compositions for polytopic vaccination

 

Polytopos LLC

29-

Apr- 05

22-

Dec

-11

19-

Mar

-13

 

US8394986

 

Phenoxiacetic acid derivatives

 

AstraZeneca AB

21-

Aug- 03

26-

Jul- 11

12-

Mar

-13

 

US8394945

 

Compositions for use in identification of bacteria

 

Ibis Biosciences, Inc.

11-

Sep- 03

7-

Mar

-07

12-

Mar

-13

 

US8394386

Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations

 

The Trustees of the University of Pennsylvania

28-

Apr- 04

27-

Apr

-05

12-

Mar

-13

 

US7829712

 

Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase

 

Xenon Pharmaceuticals Inc.

20-

Sep- 04

20-

Sep

-05

9-

Nov

-10

 

US7829707

 

Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy

 

AstraZeneca AB

6-

Dec- 04

5-

Dec

-05

9-

Nov

-10

 

US7829302

 

Method for detecting the specificity of activated lymphocyte

 

HU JUN

8-

Dec- 03

7-

Dec

-04

9-

Nov

-10

 

US7820210

 

Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers

 

Inhalation, Inc.

3-

Apr- 00

18-

Mar

-08

26-

Oct- 10

 

US7812135

 

GITR-binding antibodies

 

TOLERRX, Inc.

25-

Mar- 05

27-

Mar

-06

12-

Oct- 10

 

US7803918

Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics

 

Amsterdam Institute of Viral Genomics B.V.

18-

Aug- 03

18-

Aug

-04

28-

Sep

-10

 

US7803796

Homopiperazine compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot structure of SARS coronavirus

Sungkyunkwan University Foundation For Corporate Collaboration

22-

Dec- 06

20-

Dec

-07

28-

Sep

-10

 

US7803765

Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom

 

Phylogica Limited

20-

Feb- 04

20-

Feb

-04

28-

Sep

-10

 

US7799800

 

Lipid-modified immune response modifiers

 

3M Innovative Properties Company

30-

Oct- 03

12-

Aug

-04

21-

Sep

-10

 

US7794998

 

Primate T-lymphotropic viruses

 

Johns Hopkins University

21-

Feb- 05

24-

Feb

-07

14-

Sep

-10

 

US7794659

 

Signal measuring system having a movable signal measuring device

 

Gen-Probe Incorporated

10-

Mar- 05

10-

Mar

-06

14-

Sep

-10

 

US7790878

RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof

 

Alnylam Pharmaceuticals, Inc.

22-

Oct- 04

25-

Jun

-09

7-

Sep

-10

 

US7790449

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor

 

The Trustees of the University of Pennsylvania

17-

Dec- 01

6-

Sep

-07

7-

Sep

-10

 

US7790159

Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Aug

-03

7-

Sep

-10

 

US7786290

Double-stranded ribonucleic acid with increased effectiveness in an organism

 

Alnylam Pharmaceuticals, Inc.

13-

Jun- 03

14-

Jun

-04

31-

Aug

-10

 

US7785775

Human virus causing severe acute respiratory syndrome (SARS) and uses thereof

 

Versitech Limited

24-

Mar- 03

8-

Jun

-07

31-

Aug

-10

 

US7785612

 

Polyamino acid for use as adjuvant

 

Masanori Baba

20-

Apr- 05

19-

Apr

-06

31-

Aug

-10

 

US7781226

 

Particle on membrane assay system

 

The Board of Regents of the University of Texas System

27-

Feb- 04

22-

Dec

-04

24-

Aug

-10

 

US7781203

Supports for assaying analytes and methods of making and using thereof

 

Corning Incorporated

29-

Dec- 05

7-

Jun

-06

24-

Aug

-10

 

US7777036

 

Heterocyclic derivatives and their use as therapeutic agents

 

Xenon Pharmaceuticals Inc.

20-

Sep- 04

20-

Sep

-05

17-

Aug

-10

 

US7777022

Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof

 

Rosetta Genomics, Ltd.

26-

Nov- 02

26-

May

-04

17-

Aug

-10

 

US7776521

 

Coronavirus isolated from humans

The United States of America as represented by the

Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention

25-

Apr- 03

14-

May

-07

17-

Aug

-10

 

US7767817

Water soluble boronic acid fluorescent reporter compounds and methods of use thereof

 

FANG HAO

5-

Sep- 03

7-

Sep

-04

3-

Aug

-10

 

US7767677

Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors

 

Xenon Pharmaceuticals Inc.

20-

Sep- 04

20-

Sep

-05

3-

Aug

-10

 

US7767658

 

Vaccine composition

 

Aventis Pasteur SA

17-

Nov- 03

9-

Jan

-08

3-

Aug

-10

 

US7767657

 

Boron-containing small molecules

 

Anacor Pharmaceuticals, Inc.

16-

Feb- 05

16-

Aug

-06

3-

Aug

-10

 

US7767210

 

RNA virus vaccines and methods

 

The Board of Regents of the University of Oklahoma

14-

Dec- 05

14-

Dec

-06

3-

Aug

-10

 

US7763618

 

Pyridyl derivatives and their use as therapeutic agents

 

Xenon Pharmaceuticals Inc.

29-

Jul-03

29-

Jul- 04

27-

Jul- 10

 

US7758868

Modified polymerases and attenuated viruses and methods of use thereof

 

The Penn State Research Foundation

22-

Dec- 06

24-

Dec

-07

20-

Jul- 10

 

US7754711

 

Pyridazine derivatives and their use as therapeutic agents

 

Xenon Pharmaceuticals Inc.

30-

Jul-03

9-

Feb

-05

13-

Jul- 10

 

US7750123

 

Antibodies against SARS-CoV and methods of use thereof

 

Dana Farber Cancer Institute, Inc.

25-

Nov- 03

24-

Nov

-04

6-

Jul- 10

 

US7749445

 

Method and apparatus for analyzing bioprocess fluids

 

BioScale, Inc.

2-

May- 05

19-

Dec

-06

6-

Jul- 10

 

US7745486

 

Quercetin-containing compositions

 

Quercegen Pharma LLC

17-

Jul-06

16-

Jul- 07

29-

Jun- 10

 

US7745442

 

Methods of reducing risk of infection from pathogens

 

Parion Sciences, Inc.

20-

Aug- 03

18-

Aug

-04

29-

Jun- 10

 

US7745147

 

Methods and uses of antibodies in the purification of interferon

 

ViraNative AB

12-

Feb- 05

13-

Feb

-06

29-

Jun- 10

 

US7745119

 

System for detecting polynucleotides

 

Investigen, Inc.

20-

May- 03

21-

Nov

-05

29-

Jun- 10

 

US7745118

 

Comparative genomic resequencing

 

Roche Nimblegen, Inc.

8-

Apr- 04

8-

Apr

-05

29-

Jun- 10

 

US7741450

 

Antibodies to GM-CSF

 

Morphotek Inc.

8-

Feb- 06

8-

Feb

-07

22-

Jun- 10

 

US7741360

 

Bi-aryl or aryl-heteroaryl substituted indoles

 

AstraZeneca AB

26-

May- 06

25-

May

-07

22-

Jun- 10

 

US7740858

 

SARS-CoV-specific B-cell epitope and applications thereof

 

National Taiwan University

21-

Sep- 04

21-

Sep

-04

22-

Jun- 10

 

US7737135

Biphenyloxyacetic acid derivatives for the treatment of respiratory disease

 

AstraZeneca AB

24-

Aug- 04

22-

Aug

-05

15-

Jun- 10

 

US7736850

 

Strain of SARS-associated coronavirus and applications thereof

 

Centre National de la Recherche Scientifique

2-

Dec- 03

2-

Dec

-04

15-

Jun- 10

 

US7732177

 

Oligoadenylate Synthetase (OAS)

 

Illumigen Biosciences, Inc.

23-

Nov- 05

17-

Nov

-06

8-

Jun- 10

 

US7731978

 

Mutant forms of streptolysin O

 

Novartis AG

21-

Dec- 07

19-

Dec

-08

8-

Jun- 10

 

US7728110

 

Antibodies to SARS coronavirus

 

Amgen, Inc.

19-

May- 06

21-

May

-07

1-

Jun- 10

 

US7725565

System and method for detecting, collecting, analyzing, and communicating event related information

 

Georgetown University

25-

Feb- 08

19-

Nov

-08

25-

May

-10

 

US7723570

 

Edible vaccines expressed in soybeans

 

SoyMeds, Inc.

12-

Oct- 04

12-

Oct

-05

25-

May

-10

 

US7723041

Assay for SARS coronavirus by amplification and detection of the replicase sequence

 

Becton, Dickinson and Company

12-

Sep- 03

3-

Feb

-09

25-

May

-10

 

US7722886

Compositions and methods for treatment of severe acute respiratory syndrome (SARS)

 

Wyeth

20-

May- 04

20-

May

-04

25-

May

-10

 

US7714109

Combinations and kits for cancer treatment using selected antibodies to aminophospholipids

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Aug

-03

11-

May

-10

 

US7713515

Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis

 

R.E.D. Laboratories N.V.

27-

May- 03

26-

May

-04

11-

May

-10

 

US7709521

Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases

 

AstraZeneca AB

18-

Aug- 03

16-

Aug

-04

4-

May

-10

 

US7709511

 

Benzothiazolone derivatives

 

AstraZeneca AB

9-

Aug- 05

3-

Aug

-06

4-

May

-10

 

US7709188

 

Multi-allelic detection of SARS-associated coronavirus

 

Birch Biomedical Research LLC

22-

Aug- 03

13-

Aug

-04

4-

May

-10

 

US7700782

 

Compounds 569

 

AstraZeneca AB

19-

Dec- 07

19-

Dec

-07

20-

Apr- 10

 

US7700728

Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors

 

Schering Corporation

24-

Mar- 05

24-

Mar

-06

20-

Apr- 10

 

US7700727

 

Compositions and kits for detecting pathogen infection

 

Biokit, S.A.

23-

Dec- 03

27-

Apr

-05

20-

Apr- 10

 

US7700273

Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptor

 

The United States of America as represented by the Department of Health and Human Services

9-

Apr- 04

11-

Apr

-05

20-

Apr- 10

 

US7700120

Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus

 

New York Blood Center

15-

Jun- 04

15-

Jun

-05

20-

Apr- 10

 

US7696406

 

Expression of a recombinant transgene

 

Board of Trustees Operating Michigan State University

3-Jul- 03

2-

Jul- 04

13-

Apr- 10

 

US7696330

 

Binding molecules against SARS-coronavirus and uses thereof

 

Crucell Holland B.V.

22-

Jul-03

20-

Jan

-06

13-

Apr- 10

 

US7691877

 

Pharmaceuticals

 

Pfizer Inc.

17-

Feb- 06

16-

Feb

-07

6-

Apr- 10

 

 

US7691646

 

Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof

 

 

Daikin Industries, Ltd.

 

28-

Mar- 03

 

21-

Nov

-08

 

6-

Apr- 10

 

US7691599

 

Mammalian genes involved in viral infection and tumor suppression

 

Zirus, Inc.

2-

May- 02

2-

May

-03

6-

Apr- 10

 

US7691390

 

Viral protein

 

CHANG MING-FU

2-

Mar- 04

19-

Sep

-07

6-

Apr- 10

 

US7687535

 

Substituted 3-sulfur indoles

 

AstraZeneca AB

27-

May- 03

25-

May

-04

30-

Mar

-10

 

US7687475

 

RNA interference in respiratory epithelial cells

 

University of Iowa Research Foundation

9-Jul- 04

16-

Oct

-07

30-

Mar

-10

 

US7682688

Microporous materials, methods, and articles for localizing and quantifying analytes

 

University of Utah Research Foundation

26-

Nov- 02

20-

Nov

-03

23-

Mar

-10

 

US7678774

 

Treating severe acute respiratory syndrome

 

Hemispherx Biopharma

16-

May- 03

26-

Jan

-07

16-

Mar

-10

 

US7678386

Liposomes coated with selected antibodies that bind to aminophospholipids

 

Board of Regents the University of Texas

15-

Jul-02

15-

Aug

-03

16-

Mar

-10

 

US7674795

Fluorene derivatives, composition containing said derivatives and the use thereof

 

Aventis Pharma SA

19-

May- 05

14-

Nov

-07

9-

Mar

-10

 

US7670807

RNA-dependent DNA polymerase from Geobacillus stearothermophilus

 

East Tennessee State Univ. Research Foundation

10-

Mar- 04

10-

Mar

-04

2-

Mar

-10

 

US7670565

 

Building decontamination with vaporous hydrogen peroxide

 

Steris Inc

31-

Jan- 03

3-

Mar

-08

2-

Mar

-10

 

US7666996

 

Casein derived peptides and uses thereof

 

Peptera Pharmaceuticals Ltd

1-

Mar- 00

1-

Mar

-04

23-

Feb

-10

 

US7666592

Methods for concurrent identification and quantification of an unknown bioagent

 

Ibis Biosciences, Inc.

18-

Feb- 04

17-

Feb

-05

23-

Feb

-10

 

US7662860

3D-structure model of SARS coronavirus 3CL protease and anti- SARS drugs

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

4-

Jun- 03

2-

Dec

-05

16-

Feb

-10

 

US7648997

 

Hydroxylamine substituted imidazoquinolines

 

Coley Pharmaceutical Group, Inc.

12-

Aug- 03

12-

Aug

-04

19-

Jan- 10

 

US7648844

Method and apparatus for detection of analyte using an acoustic device

 

BioScale, Inc.

2-

May- 05

2-

May

-06

19-

Jan- 10

 

US7645881

 

Methods for treating hepatitis C

 

PTC Therapeutics, Inc.

22-

Jul-04

14-

Jul- 05

12-

Jan- 10

 

US7642350

 

Purine derivatives

 

Pfizer Limited

4-

May- 05

3-

May

-06

5-

Jan- 10

 

US7636637

 

Variable length probe selection

 

Roche NimbleGen, Inc.

18-

Jun- 04

20-

Jun

-05

22-

Dec

-09

 

US7635557

 

Enzymatic diagnostic test for SARS and other viral diseases

 

MND Diagnostic Ltd.

23-

Jun- 03

23-

Jun

-04

22-

Dec

-09

 

US7635485

 

Method of accelerated vaccination against Ebola viruses

The United States of America as represented by the Department of Health and Human Services

1-

Aug- 03

17-

Jan

-06

22-

Dec

-09

 

US7632638

Methods and apparatus for detecting viruses using an acoustic device

 

BioScale, Inc.

2-

May- 05

2-

May

-06

15-

Dec

-09

 

US7629443

Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus

 

New York Blood Center, Inc.

2-

Jun- 04

8-

Feb

-06

8-

Dec

-09

 

US7629385

 

Sphingolipid-derived pharmaceutical compositions

 

Jado Technologies GmbH

29-

Jun- 04

29-

Jun

-05

8-

Dec

-09

 

US7629137

Methods and apparatus for detecting bacteria using an acoustic device

 

BioScale, Inc.

2-

May- 05

2-

May

-06

8-

Dec

-09

 

US7629114

Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and screening for nasopharyngeal cancer

 

World Sense Technology Limited

26-

Aug- 03

20-

Aug

-04

8-

Dec

-09

 

US7625563

Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Aug

-03

1-

Dec

-09

 

US7625492

 

Charge-based water filtration systems

 

The University of Wyoming Research Corporation

28-

Jan- 03

28-

Jan

-04

1-

Dec

-09

 

US7625428

 

Bioagent air filtration systems

 

The University of Wyoming Research Corporation

28-

Jan- 03

28-

Jan

-04

1-

Dec

-09

 

US7623997

Computer-implemented biological sequence identifier system and method

The United States of America as represented by the Secretary of the Navy

2-Jul- 04

6-

Jun

-06

24-

Nov

-09

 

US7622559

 

Human monoclonal antibodies against interleukin 8 (IL-8)

 

Genmab A/S

16-

Dec- 02

27-

Jun

-07

24-

Nov

-09

 

US7622125

 

Polycistronic HIV vector constructs

 

Novartis Vaccines and Diagnostics, Inc.

5-

May- 04

5-

May

-05

24-

Nov

-09

 

US7622118

Cancer treatment methods using selected antibodies to aminophospholipids

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Aug

-03

24-

Nov

-09

 

US7622112

 

Anti-SARS monoclonal antibodies

 

Not Available

5-

Dec- 03

6-

Dec

-04

24-

Nov

-09

 

US7619067

 

Evolved interferon-alpha polypeptides

 

Maxygen, Inc.

18-

May- 05

17-

May

-06

17-

Nov

-09

 

US7618802

Compositions of coronaviruses with a recombination-resistant genome

 

The University of North Carolina at Chapel Hill

21-

Jul-03

19-

Jan

-06

17-

Nov

-09

 

US7618788

Proteome epitope tags and methods of use thereof in protein modification analysis

 

Millipore Corporation

10-

May- 02

5-

Feb

-04

17-

Nov

-09

 

US7618635

 

Super-antigen fusion proteins and the use thereof

 

Healthbanks Biotech Co., Ltd.

21-

Jul-04

19-

Jul- 05

17-

Nov

-09

 

US7615381

Method and apparatus for detecting estradiol and metabolites thereof using an acoustic device

 

BioScale, Inc.

2-

May- 05

2-

May

-06

10-

Nov

-09

 

US7615223

 

Selected immunoconjugates for binding to aminophospholipids

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Aug

-03

10-

Nov

-09

 

US7611908

Method and apparatus for therapeutic drug monitoring using an acoustic device

 

BioScale, Inc.

2-

May- 05

2-

May

-06

3-

Nov

-09

 

US7611704

Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Aug

-03

3-

Nov

-09

 

US7605161

 

Pyridyl derivatives and their use as therapeutic agents

 

Xenon Pharmaceuticals Inc.

30-

Jul-03

29-

Jul- 04

20-

Oct- 09

 

US7605135

 

Baicalin as a treatment for SARS infection

 

The University of Hong Kong

10-

Nov- 03

8-

Nov

-04

20-

Oct- 09

 

US7604960

 

Transient protein expression methods

 

Crucell Holland B.V.

15-

Apr- 99

1-

Jun

-07

20-

Oct- 09

 

US7604801

 

Methods for detecting parvovirus infections

 

The Research Foundation of State University of New York

5-

May- 03

16-

Oct

-08

20-

Oct- 09

 

US7598382

 

Aryl substituted imidazoquinolines

 

Coley Pharmaceutical Group, Inc.

20-

Dec- 02

13-

Jan

-06

6-

Oct- 09

 

US7598094

Methods and apparatus for detecting cardiac injury markers using an acoustic device

 

BioScale, Inc.

2-

May- 05

2-

May

-06

6-

Oct- 09

 

US7598072

 

Assay to detect viral uncoating

 

Wisconsin Alumni Research Foundation

9-

Dec- 03

8-

Dec

-04

6-

Oct- 09

 

US7597936

 

Method of producing a pigmented composite microporous material

 

University of Utah Research Foundation

26-

Nov- 02

26-

May

-04

6-

Oct- 09

 

US7595381

 

Method for detecting SARS coronavirus

 

Eiken Kagaku Kabushiki Kaisha

27-

Jun- 03

10-

Jun

-08

29-

Sep

-09

 

US7595163

 

Method for detecting SARS coronavirus

 

Eiken Kagaku Kabushiki Kaisha

27-

Jun- 03

10-

Jun

-08

29-

Sep

-09

 

US7592343

Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors

 

Xenon Pharmaceuticals Inc.

20-

Sep- 04

20-

Sep

-05

22-

Sep

-09

 

US7592322

RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof

 

Alnylam Pharmaceuticals, Inc.

22-

Oct- 04

14-

Jun

-05

22-

Sep

-09

 

US7592008

 

Membrane scaffold proteins

The Board of Trustees of the University of Illinois, a body corporate and politic of the State of Illinois

20-

Nov- 00

11-

Jan

-05

22-

Sep

-09

 

US7589092

 

Prodrugs of heteroaryl compounds

 

Koronis Pharmaceuticals, Incorporated

20-

Jun- 03

27-

Dec

-06

15-

Sep

-09

 

US7585647

 

Nucleic acid encoding recombinant interferon

 

WEI GUANGWEN

28-

Aug- 03

26-

Aug

-04

8-

Sep

-09

 

US7582740

 

Methods and kits for detecting SARS-associated coronavirus

The Trustees of Columbia University In the City of New York

17-

Apr- 03

23-

Jan

-04

1-

Sep

-09

 

US7582621

 

Boron-containing small molecules

 

Anacor Pharmaceuticals, Inc.

16-

Feb- 05

16-

Feb

-06

1-

Sep

-09

 

US7579396

 

Polymer composite

 

Eastman Kodak Company

31-

Jan- 07

31-

Jan

-07

25-

Aug

-09

 

US7579359

 

1-alkoxy 1H-imidazo ring systems and methods

 

3M Innovative Properties Company

2-

Sep- 04

1-

Sep

-05

25-

Aug

-09

 

US7572621

Detection, characterization and treatment of viral infection and methods thereof

 

Canadian Blood Services

9-

Apr- 03

11-

Oct

-05

11-

Aug

-09

 

US7572448

Combined cancer treatment methods using selected antibodies to aminophospholipids

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Aug

-03

11-

Aug

-09

 

US7572442

 

Selected antibody compositions for binding to aminophospholipids

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Jul- 03

11-

Aug

-09

 

US7569536

Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity

 

Masatoshi Hagiwara

26-

Dec- 03

24-

Dec

-04

4-

Aug

-09

 

US7569384

 

Albumin fusion proteins

 

Human Genome Sciences, Inc.

9-

Feb- 04

8-

Aug

-06

4-

Aug

-09

 

US7550140

 

Antibody to the human OX40 receptor

 

Crucell Holland B.V.

13-

Jun- 02

13-

Jun

-03

23-

Jun- 09

 

US7547698

Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)

 

Xenon Pharmaceuticals Inc.

20-

Sep- 04

20-

Sep

-05

16-

Jun- 09

 

US7547516

Method for reducing the presence of amplification inhibitors in a reaction receptacle

 

Gen-Probe Incorporated

10-

Mar- 05

10-

Mar

-06

16-

Jun- 09

 

US7547512

High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)

 

The University of Hong Kong

24-

Mar- 03

24-

Mar

-04

16-

Jun- 09

 

US7544697

 

Pyrazolopyridines and analogs thereof

 

Coley Pharmaceutical Group, Inc.

3-

Oct- 03

1-

Apr

-05

9-

Jun- 09

 

US7541436

 

Interferon-alpha polypeptides and conjugates

 

Maxygen, Inc.

19-

May- 04

4-

May

-07

2-

Jun- 09

 

US7541163

 

Interferon-alpha polypeptides and conjugates

 

Maxygen, Inc.

19-

May- 04

14-

Aug

-07

2-

Jun- 09

 

US7531630

 

Interferon-alpha polypeptides and conjugates

 

Maxygen, Inc.

19-

May- 04

13-

Sep

-06

12-

May

-09

 

US7531324

 

Interferon-alpha polypeptides and conjugates

 

Maxygen, Inc.

19-

May- 04

13-

Sep

-06

12-

May

-09

 

US7521424

 

Albumin fusion proteins

 

Human Genome Sciences, Inc.

22-

Jan- 03

7-

Jul- 05

21-

Apr- 09

 

US7521185

Assay for SARS coronavirus by amplification and detection of the replicase sequence

 

Becton, Dickinson and Company

12-

Sep- 03

13-

Sep

-04

21-

Apr- 09

 

US7514436

 

Pyridazine derivatives and their use as therapeutic agents

 

Xenon Pharmaceuticals Inc.

30-

Jul-03

29-

Jul- 04

7-

Apr- 09

 

US7511124

Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Aug

-03

31-

Mar

-09

 

US7504384

 

Use of lipid conjugates in the treatment of infection

Yissum Research Development Company of the Hebrew University of Jerusalem

10-

Jan- 00

8-

Sep

-05

17-

Mar

-09

 

US7504382

Protease inhibitors for coronaviruses and SARS-CoV and the use thereof

 

Cytovia, Inc.

6-

May- 03

6-

May

-04

17-

Mar

-09

 

US7504205

Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP- dependent kinase and a target for SARS therapy

 

The Burnham Institute

17-

May- 04

17-

May

-05

17-

Mar

-09

 

US7504097

 

Interferon-alpha polypeptides and conjugates

 

Maxygen, Inc.

18-

Nov- 02

30-

Oct

-06

17-

Mar

-09

 

US7498409

 

Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists

 

Schering Corporation

24-

Mar- 05

23-

Mar

-06

3-

Mar

-09

 

US7498152

 

Interferon-alpha polypeptides and conjugates

 

Maxygen, Inc.

18-

Nov- 02

30-

Oct

-06

3-

Mar

-09

 

US7495011

 

Anti-coronavirus drug

 

aRigen Pharmaceuticals, Inc.

15-

Jul-03

14-

Jul- 04

24-

Feb

-09

 

US7491793

 

Influenza virus inhibiting peptides

 

The Administrators of the Tulane Educational Fund

4-

Nov- 03

3-

Nov

-04

17-

Feb

-09

 

US7491706

Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof

 

Changchun Huapu Biotechnology Co., Ltd.

25-

Jul-03

26-

Jul- 04

17-

Feb

-09

 

US7491508

Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses

 

The Trustees of the University of Pennsylvania

20-

Jun- 03

15-

Jun

-04

17-

Feb

-09

 

US7491489

Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof

 

The University of Hong Knog

22-

Nov- 04

28-

Oct

-05

17-

Feb

-09

 

US7491397

 

Receptor binding polypeptides

 

National Health Research Institutes

9-

Jan- 04

10-

Jan

-05

17-

Feb

-09

 

US7488801

 

Interferon-alpha polypeptides and conjugates

 

Maxygen, Inc.

18-

Nov- 02

30-

Oct

-06

10-

Feb

-09

 

US7488589

 

Interferon-alpha polypeptides and conjugates

 

Maxygen, Inc.

18-

Nov- 02

30-

Oct

-06

10-

Feb

-09

 

US7488473

 

Interferon-alpha polypeptides and conjugates

 

Maxygen, Inc.

18-

Nov- 02

30-

Oct

-06

10-

Feb

-09

 

US7485432

 

Selective modulation of TLR-mediated biological activity

 

3M Innovative Properties Company

27-

Feb- 03

27-

Feb

-04

3-

Feb

-09

 

US7482334

 

Therapeutic treatment methods

 

Hollis-Eden Pharmaceuticals, Inc.

28-

Aug- 02

12-

Feb

-07

27-

Jan- 09

 

US7482149

Inhibition of SARS coronavirus infection with clinically approved antiviral drugs

 

Genome Institute of Singapore

9-

Jun- 03

9-

Jun

-04

27-

Jan- 09

 

US7479484

Peptides and peptidomimetics having immune-modulating, anti- inflammatory, and anti-viral activity

 

Takeda Pharmaceutical Company Limited

25-

Jun- 03

25-

Jun

-04

20-

Jan- 09

 

US7470666

Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome

 

Guangdong Techpool Biochem. Pharma. Co., Ltd.

26-

May- 03

25-

May

-04

30-

Dec

-08

 

 

US7470548

 

Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof

 

 

Daikin Industries, Ltd.

 

28-

Mar- 03

 

26-

Mar

-04

 

30-

Dec

-08

 

US7468418

 

Compositions for enhancing transport of molecules into cells

 

AVI BioPharma., Inc.

29-

Apr- 03

29-

Apr

-04

23-

Dec

-08

 

US7465836

Hydrolytically-resistant boron-containing therapeutics and methods of use

 

Anacor Pharmaceuticals, Inc.

16-

Jun- 03

15-

Jun

-04

16-

Dec

-08

 

US7462615

Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications

 

Hybrigenics SA

8-

Dec- 05

8-

Dec

-05

9-

Dec

-08

 

US7460960

Proteome epitope tags and methods of use thereof in protein modification analysis

 

Epitome Biosystems, Inc.

10-

May- 02

13-

Nov

-03

2-

Dec

-08

 

US7456180

 

Piperazine derivatives and their use as therapeutic agents

 

Xenon Pharmaceuticals Inc.

30-

Jul-03

29-

Jul- 04

25-

Nov

-08

 

US7455833

Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Aug

-03

25-

Nov

-08

 

US7452542

 

Live attenuated coronavirus vaccines

 

Vanderbilt University

21-

May- 04

23-

May

-05

18-

Nov

-08

 

US7445889

 

Methods for detecting parvovirus infections

 

The Research Foundation of State University of New York

5-

May- 03

5-

May

-04

4-

Nov

-08

 

US7442761

 

Replikin peptides and uses thereof

 

BOGOCH ELENORE S

6-

Jun- 03

4-

Jun

-04

28-

Oct- 08

 

US7442508

 

Methods for detection and production of influenza viruses

 

Diagnostic Hybrids, Inc.

24-

Apr- 98

28-

Apr

-06

28-

Oct- 08

 

US7439349

Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof

 

Not Available

 

3-Jul- 02

1-

Jul- 03

21-

Oct- 08

 

US7439052

 

Method of making modified immunodeficiency virus particles

 

Lipid Sciences

29-

Jun- 00

10-

Apr

-06

21-

Oct- 08

 

US7435588

Systems for detection and production of respiratory, herpes and enteric viruses

 

Diagnostic Hybrids, Inc.

20-

Sep- 05

28-

Apr

-06

14-

Oct- 08

 

US7435538

High throughput screening method of drug for physiologically active protein

 

CellFree Sciences Co., Ltd.

8-

Sep- 03

8-

Sep

-04

14-

Oct- 08

 

US7432045

 

Method of inhibiting influenza infection with antiviral peptides

 

Wisconsin Alumni Research Foundation

1-

Dec- 03

1-

Dec

-04

7-

Oct- 08

 

US7429656

Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference

 

The University of Hong Kong

19-

May- 03

14-

Jun

-06

30-

Sep

-08

 

US7427479

Methods and kits for identifying target nucleotides in mixed populations

 

Applera Corporation

30-

Apr- 04

29-

Apr

-05

23-

Sep

-08

 

US7424370

Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential

 

Council of Scientific and Industrial Research

20-

Jul-04

7-

Feb

-05

9-

Sep

-08

 

US7407663

 

Modified immunodeficiency virus particles

 

Lipid Sciences, Inc.

29-

Jun- 00

20-

Jun

-03

5-

Aug

-08

 

US7407662

Modified viral particles with immunogenic properties and reduced lipid content

 

Lipid Sciences, Inc.

29-

Jun- 00

21-

Jun

-04

5-

Aug

-08

 

 

US7405207

 

Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof

 

 

Epigenesis Pharmaceuticals, Inc.

 

17-

Jun- 02

 

17-

Jun

-03

 

29-

Jul- 08

 

US7405046

 

Compositions and methods for treatment of rhinovirus

 

The Quigley Corporation

6-

Aug- 01

27-

Oct

-06

29-

Jul- 08

 

US7399588

 

Method for detecting SARS coronavirus

 

Eiken Kagaku Kabushiki Kaisha

27-

Jun- 03

15-

Jun

-04

15-

Jul- 08

 

US7396914

 

SARS nucleic acids, proteins, antibodies, and uses thereof

 

University of Massachusetts

4-

Aug- 03

4-

Aug

-04

8-

Jul- 08

 

US7393856

 

Anti-viral uses of borinic acid complexes

 

Anacor Pharmaceuticals, Inc.

14-

Jun- 04

14-

Jun

-05

1-

Jul- 08

 

US7393638

 

Assay system and methods for detecting SARS-CV

 

AsiaGEN Corporation

1-Jul- 03

1-

Jul- 03

1-

Jul- 08

 

US7387271

 

Immunostimulatory combinations

 

3M Innovative Properties Company

30-

Dec- 02

30-

Dec

-03

17-

Jun- 08

 

US7384909

Anti-viral treatment methods using phosphatidylethanolamine- binding peptides linked to anti-viral agents

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Aug

-03

10-

Jun- 08

 

US7378386

Anti-viral treatment methods using phosphatidylethanolamine- binding peptide derivatives

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Aug

-03

27-

May

-08

 

US7375210

PCR primer set for detecting severe acute respiratory syndrome (SARS)-Coronavirus, method and kit for detecting SARS- Coronavirus using the same

 

Samsung Electronics Co., Ltd.

12-

Dec- 03

24-

Nov

-04

20-

May

-08

 

US7375202

Human virus causing severe acute respiratory syndrome (SARS) and uses thereof

 

The University of Hong Kong

24-

Mar- 03

24-

Mar

-04

20-

May

-08

 

US7375180

Methods and compositions related to IRM compounds and Toll-like receptor 8

 

3M Innovative Properties Company

13-

Feb- 03

12-

Feb

-04

20-

May

-08

 

US7374883

Method and kit for the detection of a novel coronoavirus associated with the severe acute respiratory syndrome (SARS)

 

QIAGEN Diagnostics GmbH

30-

Apr- 03

30-

Apr

-04

20-

May

-08

 

US7371850

 

Method and composition for reducing expression of ROCK-II

 

Myriad Genetics, Inc.

20-

Aug- 03

20-

Aug

-04

13-

May

-08

 

US7371837

 

Human virus causing respiratory tract infection and uses thereof

 

The University of Hong Kong

21-

Jul-04

16-

May

-05

13-

May

-08

 

US7371525

Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS)

 

The Chinese University of Hong Kong

29-

Jul-03

28-

Jul- 04

13-

May

-08

 

US7361747

Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus

 

The University of Hong Kong

22-

May- 03

24-

May

-04

22-

Apr- 08

 

US7361304

 

Building decontamination with vaporous hydrogen peroxide

 

Steris Inc.

31-

Jan- 03

29-

Jan

-04

22-

Apr- 08

 

US7358068

 

Antiviral oligonucleotides

 

Replicor, Inc.

13-

Sep- 02

12-

Sep

-03

15-

Apr- 08

 

US7354908

Materials and methods for prevention and treatment of RNA viral diseases

 

University of South Florida

30-

Apr- 02

30-

Apr

-03

8-

Apr- 08

 

US7354551

 

Room decontamination with hydrogen peroxide vapor

 

Steris Inc

8-Jul- 04

8-

Jul- 04

8-

Apr- 08

 

US7344740

 

Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers

 

Inhalation, Inc.

3-

Apr- 00

27-

Nov

-04

18-

Mar

-08

 

US7344720

 

Vaccine composition

 

Sanofi Pasteur SA

17-

Nov- 03

15-

Nov

-04

18-

Mar

-08

 

US7339051

Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)

 

Isis Pharmaceuticals, Inc.

28-

Apr- 03

26-

Apr

-04

4-

Mar

-08

 

US7335658

 

Pyridazine derivatives and their use as therapeutic agents

 

Xenon Pharmaceuticals Inc.

30-

Jul-03

29-

Jul- 04

26-

Feb

-08

 

US7332475

 

Preventive or therapeutic composition for viral infectious disease

 

Kyowa Hakko Kogyo Co., Ltd.

22-

Jul-03

22-

Jul- 04

19-

Feb

-08

 

US7332294

 

CXCL10-based diagnosis and treatment of respiratory illnesses

 

University Health Network

17-

Aug- 04

17-

Aug

-04

19-

Feb

-08

 

US7320857

Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof

 

Chinese National Human Genome Center at Shanghai

9-Jul- 04

9-

Jul- 04

22-

Jan- 08

 

US7318918

 

Interferon-alpha polypeptides and conjugates

 

Maxygen, Inc.

19-

May- 04

18-

May

-05

15-

Jan- 08

 

US7314613

 

Interferon-alpha polypeptides and conjugates

 

Maxygen, Inc.

18-

Nov- 02

19-

May

-04

1-

Jan- 08

 

US7312036

Compositions for use in identification of viral hemorrhagic fever viruses

 

ISIS Pharmaceuticals, Inc.

22-

Mar- 04

21-

Mar

-05

25-

Dec

-07

 

US7297786

 

RNA interference in respiratory epitheial cells

 

University of Iowa Research Foundation

9-Jul- 04

11-

Jul- 05

20-

Nov

-07

 

US7291498

Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses

 

The Trustees of the University of Pennsylvania

20-

Jun- 03

20-

Jun

-03

6-

Nov

-07

 

US7282568

 

Human monoclonal antibodies against interleukin 8 (IL-8)

 

Genmab A/S

16-

Dec- 02

16-

Dec

-03

16-

Oct- 07

 

US7282199

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

 

The Trustees of the University of Pennsylvania

17-

Dec- 01

25-

Apr

-03

16-

Oct- 07

 

US7267942

Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)

 

The University of Hong Kong

24-

Mar- 03

24-

Mar

-04

11-

Sep

-07

 

US7261867

Production of silver sulfate grains using organo-sulfate or organo- sulfonate additives

 

Eastman Kodak Company

7-

Apr- 06

7-

Apr

-06

28-

Aug

-07

 

US7247303

 

Selected antibody CDRs for binding to aminophospholipids

 

Board of Regents, The University of Texas System

15-

Jul-02

15-

Aug

-03

24-

Jul- 07

 

US7244732

 

Prodrugs of heteroaryl compounds

 

Koronis Pharmaceuticals, Incorporated

20-

Jun- 03

31-

Mar

-04

17-

Jul- 07

 

US7223787

Prenylation inhibitors reduce host cell permissiveness to viral replication

 

Board of Regents, The University of Texas System

21-

Oct- 03

21-

Oct

-03

29-

May

-07

 

US7220852

 

Coronavirus isolated from humans

The United States of America as represented by the

Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention

25-

Apr- 03

12-

Apr

-04

22-

May

-07

 

US7183300

Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof

 

AGARWAL ATUL

11-

Nov- 04

10-

Nov

-05

27-

Feb

-07

 

US7166435

Compositions and methods for reducing the transmissivity of illnesses

 

The Quigley Corporation

6-

Aug- 01

14-

Dec

-04

23-

Jan- 07

 

US7163947

 

1-Amino 1H-imidazoquinolines

 

3M Innovative Properties Company

7-

Mar- 03

3-

Sep

-04

16-

Jan- 07

 

US7151163

Antiviral agents for the treatment, control and prevention of infections by coronaviruses

 

Sequoia Pharmaceuticals, Inc.

28-

Apr- 03

28-

Apr

-04

19-

Dec

-06

 

US7151091

 

Compositions and methods for preventing infection

 

La Jolla Biosciences LLC

20-

Sep- 02

22-

Sep

-03

19-

Dec

-06

 

US7148248

Method of treating or inhibiting the development of brain inflammation and sepsis

 

NOZAKI MASAKO

29-

Nov- 02

26-

Nov

-03

12-

Dec

-06

 

US7129223

Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference

 

The University of HongKong

19-

May- 03

19-

May

-04

31-

Oct- 06

 

US7129042

Compositions and methods for detecting severe acute respiratory syndrome coronavirus

 

Diagnostic Hybrids, Inc.

3-

Nov- 03

3-

Nov

-03

31-

Oct- 06

 

US7115563

 

Composition and its therapeutic use

 

Insignion Holding Limited

29-

May- 02

29-

May

-03

3-

Oct- 06

 

US7091214

 

Aryl substituted Imidazoquinolines

 

3M Innovative Properties Co.

20-

Dec- 02

18-

Dec

-03

15-

Aug

-06

 

US7048953

Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)

 

Inhalation, Inc.

3-

Apr- 00

2-

May

-03

23-

May

-06

 

US7023593

 

Apparatus for forming nano-grating device

 

Industrial Technology Research Institute

28-

Nov- 03

17-

Mar

-04

4-

Apr- 06

 

US6946291

 

Mixed cell diagnostic systems

 

Diagnostic Hybrids, Inc.

24-

Apr- 98

30-

Mar

-04

20-

Sep

-05

US20200176 079

METHODS AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME DETERMINATION OF DISEASE STATES

 

Not Available

19-

Jul-17

18-

Jul- 18

4-

Jun- 20

 

US20200173 925

MICROSCOPIC BODY ENCLOSING METHOD, MICROSCOPIC BODY DETECTION METHOD, AND MICROSCOPIC BODY DETECTION DEVICE

 

JAPAN SCIENCE AND TECHNOLOGY AGENCY

29-

Mar- 17

28-

Mar

-18

4-

Jun- 20

US20200172 883

COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS

 

Not Available

19-

Nov- 09

13-

Sep

-19

4-

Jun- 20

US20200172 879

 

DHFR TUNABLE PROTEIN REGULATION

 

Not Available

3-

Mar- 17

2-

Sep

-19

4-

Jun- 20

US20200172 600

 

RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME

 

GLAXOSMITHKLINE BIOLOGICALS, SA

15-

Jul-09

16-

Aug

-17

4-

Jun- 20

US20200172 513

 

DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS

 

Hoffmann-La Roche Inc.

12-

Jun- 16

5-

Feb

-20

4-

Jun- 20

US20200172 480

CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS

 

HANGZHOU DAC BIOTECH CO., LTD.

12-

Jul-12

5-

Feb

-20

4-

Jun- 20

US20200171 085

 

Method of Treating Respiratory Tract Infection

 

Not Available

19-

May- 17

18-

May

-18

4-

Jun- 20

US20200171 060

FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST FILOVIRUSES AND FLAVIVIRUSES

 

Not Available

31-

Jul-17

26-

Jan

-18

4-

Jun- 20

 

US20200166 505

METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS

 

The U.S.A., as represented by the Secretary, Department of Health and Human Services

1-

Sep- 15

30-

Jan

-20

28-

May

-20

US20200165 632

ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION

 

Spark Therapeutics, Inc.

7-

Jun- 17

6-

Jun

-18

28-

May

-20

US20200165 630

 

COMPOSITIONS FOR THE TREATMENT OF DISEASE

 

Not Available

29-

Apr- 16

28-

Apr

-17

28-

May

-20

US20200165 613

 

VIRUS LIKE PARTICLE

 

The University of Leeds

1-

Jun- 17

31-

May

-18

28-

May

-20

US20200165 594

 

CRISPR SYSTEM BASED ANTIVIRAL THERAPY

 

MASSACHUSETTS INSTITUTE OF TECHNOLOGY

7-Jul- 17

6-

Jul- 18

28-

May

-20

US20200165 585

 

NEW CHIMERIC ENZYMES AND THEIR APPLICATIONS

 

Not Available

27-

Jul-17

27-

Jul- 18

28-

May

-20

US20200165 357

CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF

 

Not Available

2-

Dec- 05

21-

Oct

-19

28-

May

-20

US20200164 334

 

MICROSPOTTING DEVICE

 

Not Available

18-

Apr- 12

11-

Oct

-19

28-

May

-20

US20200164 067

 

Methods and Compositions for Inhibiting Akt3

 

Not Available

15-

Jan- 16

5-

Feb

-20

28-

May

-20

 

US20200164 058

 

TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS

 

King Abdulaziz University

27-

Nov- 18

27-

Nov

-18

28-

May

-20

US20200164 020

 

PUM 1 PROTEIN AS TARGET FOR VIRUS INHIBITION

 

Not Available

12-

Apr- 17

12-

Apr

-17

28-

May

-20

US20200163 878

 

LIPID NANOPARTICLE MRNA VACCINES

 

Not Available

26-

Oct- 16

26-

Oct

-17

28-

May

-20

US20200157 600

METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION

 

Not Available

19-

Nov- 18

19-

Nov

-18

21-

May

-20

US20200157 222

 

ANTI-PD-L1 ANTIBODIES AND USES THEREOF

 

Not Available

29-

Mar- 18

29-

Mar

-19

21-

May

-20

US20200157 221

 

ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES

 

Not Available

30-

Jun- 16

28-

Jan

-20

21-

May

-20

 

US20200155 704

 

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR

 

Not Available

30-

Sep- 03

30-

Jan

-20

21-

May

-20

US20200155 699

 

MODIFIED VIRUS-LIKE PARTICLES OF CMV

 

Not Available

22-

Oct- 14

26-

Nov

-19

21-

May

-20

US20200155 667

 

VACCINE COMPOSITIONS

 

Not Available

27-

Jul-17

24-

Jan

-20

21-

May

-20

US20200155 664

 

INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE

 

Not Available

10-

Feb- 09

26-

Jun

-19

21-

May

-20

US20200155 662

COMBINATION IMMUNOTHERAPIES COMPRISING IL-15 SUPERAGONISTS

 

Not Available

26-

May- 17

25-

May

-18

21-

May

-20

US20200155 660

COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY

 

Not Available

23-

Sep- 15

22-

Nov

-19

21-

May

-20

US20200155 646

EV576 For Use in the Treatment of Viral Infections of the Respiratory Tract

 

Volution Immuno Pharmaceuticals SA

8-

Jan- 10

7-

Jun

-19

21-

May

-20

US20200149 062

 

ENGINEERED TSC2

 

Not Available

14-

Jul-17

13-

Jul- 18

14-

May

-20

US20200149 048

 

Transbiotic Regulation of Bacterial Gene Expression

 

Not Available

22-

May- 17

22-

May

-18

14-

May

-20

US20200148 749

 

ANTIBODIES AND PROCESSES FOR PREPARING THE SAME

 

Not Available

16-

May- 08

10-

Oct

-19

14-

May

-20

US20200147 203

 

VACCINATION OF IMMUNOCOMPROMISED SUBJECTS

 

Not Available

26-

Sep- 14

10-

Jan

-20

14-

May

-20

 

US20200147 193

 

COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY INVOLVING HER ANTIGENS

 

Not Available

2-

Jun- 17

2-

Jun

-18

14-

May

-20

 

US20200147 171

COMPOSITIONS OF CRACC FUSIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE AGAINST CANCERS, INFECTIONS DISEASES AND DISORDERS

 

Not Available

18-

Sep- 18

18-

Sep

-19

14-

May

-20

US20200140 547

MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE

 

Not Available

26-

May- 17

25-

May

-18

7-

May

-20

US20200140 493

 

Engineering Virus-like Nanocarriers for Biomolecule Delivery

 

Not Available

26-

Oct- 18

25-

Oct

-19

7-

May

-20

US20200140 398

 

HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS

 

AZIENDA OSPEDALIERA UNIVERSITARIA SENESE

13-

Feb- 15

6-

Jan

-20

7-

May

-20

US20200138 937

 

Genetically Attenuated Nucleic Acid Vaccine

 

Not Available

2-

Jun- 17

1-

Jun

-18

7-

May

-20

US20200138 936

 

Phenotypically Wild-Type and Genetically Attenuated Viruses

 

Not Available

2-

Jun- 17

1-

Jun

-18

7-

May

-20

US20200138 818

METHODS OF TREATING PAIN AND/OR INFLAMMATORY DISORDERS USING LAPATINIB

 

Not Available

7-

Nov- 18

6-

Nov

-19

7-

May

-20

 

US20200138 780

METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

 

 

Not Available

 

14-

Mar- 13

 

19-

Dec

-19

 

7-

May

-20

US20200131 518

CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE

 

Not Available

14-

Mar- 17

14-

Mar

-18

30-

Apr- 20

US20200129 487

 

CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND

 

TAIHO PHARMACEUTICAL CO., LTD.

30-

Jun- 17

29-

Jun

-18

30-

Apr- 20

US20200127 954

 

RNA TARGETING METHODS AND COMPOSITIONS

 

Salk Institute for Biological Studies

22-

Aug- 17

31-

Dec

-18

23-

Apr- 20

 

US20200124 599

ACCURATE, RAPID AND CONVENIENT SINGLE-STEP DISEASE DIAGNOSTIC METHOD USING SELF-AMPLIFICATION PRINCIPLE OF DETECTION SIGNAL

 

CELLEMEDY CO., LTD

13-

Apr- 17

13-

Apr

-18

23-

Apr- 20

 

US20200123 233

 

AMINO ACID SEQUENCES  DIRECTED AGAINST  ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES

 

 

Ablynx N.V.

 

5-

Jun- 08

 

1-

Aug

-19

 

23-

Apr- 20

US20200123 205

 

Inhibition Of TCR Signaling With Peptide Variants

 

Not Available

22-

Oct- 18

18-

Dec

-19

23-

Apr- 20

US20200123 203

 

COMPOSITIONS COMPRISING CURONS AND USES THEREOF

 

FLAGSHIP PIONEERING INNOVATIONS V, INC.

13-

Jun- 17

13-

Jun

-18

23-

Apr- 20

 

US20200115 448

 

CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF

 

Not Available

26-

Apr- 17

22-

Oct

-19

16-

Apr- 20

US20200115 434

ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF

 

Not Available

23-

Oct- 15

29-

Oct

-19

16-

Apr- 20

US20200113 996

CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES

 

Not Available

23-

Jun- 17

21-

Jun

-18

16-

Apr- 20

US20200113 967

 

PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS

 

Not Available

26-

May- 17

26-

May

-17

16-

Apr- 20

US20200113 831

LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES

 

GLAXOSMITHKLINE BIOLOGICALS SA

6-Jul- 11

16-

Dec

-19

16-

Apr- 20

US20200113 830

PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA

 

GLAXOSMITHKLINE BIOLOGICALS S.A.

31-

Aug- 11

16-

Dec

-19

16-

Apr- 20

US20200109 403

 

IN VIVO DELIVERY OF OLIGONUCLEOTIDES

 

Not Available

12-

Dec- 11

18-

Dec

-19

9-

Apr- 20

US20200108 136

 

METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES

 

Not Available

6-

Apr- 07

22-

Nov

-19

9-

Apr- 20

US20200102 558

TRANSKINGDOM PLATFORM FOR THERAPEUTIC NUCLEIC ACID DELIVERY

 

Not Available

3-

Apr- 17

3-

Oct

-19

2-

Apr- 20

US20200102 550

 

TAL EFFECTOR-MEDIATED DNA MODIFICATION

 

Not Available

10-

Dec- 09

28-

Aug

-19

2-

Apr- 20

 

US20200102 544

 

POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND METHODS OF MAKING AND USING THE SAME

 

 

Not Available

 

30-

Dec- 13

 

11-

Sep

-19

 

2-

Apr- 20

US20200102 362

TUMOR NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN COMPLEX WITH IMPROVED BINDING AND BIOACTIVITY

 

Not Available

6-

Apr- 17

5-

Apr

-18

2-

Apr- 20

US20200102 292

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF

 

Not Available

3-Jul- 13

10-

Jul- 19

2-

Apr- 20

US20200101 158

ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF

 

Not Available

1-

Oct- 15

22-

Oct

-19

2-

Apr- 20

US20200101 153

 

MVA-BN AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMEN

 

Not Available

6-

Apr- 17

6-

Apr

-18

2-

Apr- 20

US20200101 142

 

PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY

 

Not Available

12-

Jun- 17

12-

Jun

-18

2-

Apr- 20

US20200101 119

 

METHODS OF TREATMENT OF INFECTIONS USING BACTERIA

 

Not Available

27-

Sep- 18

26-

Sep

-19

2-

Apr- 20

US20200101 087

 

PHARMACEUTICAL COMPOSITIONS AND METHODS

 

Not Available

3-

Aug- 15

21-

Nov

-19

2-

Apr- 20

US20200100 480

 

TRAIT SELECTION IN AVIANS

 

Not Available

31-

May- 17

31-

May

-18

2-

Apr- 20

US20200095 324

ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF

 

Not Available

30-

Mar- 17

30-

Mar

-18

26-

Mar

-20

US20200093 919

 

MODIFIED PEDV SPIKE PROTEIN

 

Not Available

20-

Sep- 18

18-

Sep

-19

26-

Mar

-20

 

US20200093 909

 

PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO

 

Not Available

19-

Apr- 17

19-

Apr

-18

26-

Mar

-20

US20200093 855

ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE

 

Not Available

11-

Sep- 17

3-

Jun

-19

26-

Mar

-20

US20200093 841

 

Broad Spectrum Antiviral and Methods of Use

 

Not Available

17-

Apr- 06

30-

Apr

-19

26-

Mar

-20

US20200087 655

PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES

 

Not Available

14-

Jul-15

22-

Nov

-19

19-

Mar

-20

US20200087 646

OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION CASSETTES AND THEIR USE

 

Not Available

31-

May- 17

31-

May

-18

19-

Mar

-20

US20200087 630

 

INFLUENZA VIRUS AND TYPE 1 DIABETES

 

Istituto Zooprofilattico Sperimentale delle Venezie

10-

Oct- 12

25-

Jul- 19

19-

Mar

-20

US20200087 359

 

GRIFFITHSIN MUTANTS

The United States of America,as represented by the Secretary,Department of Health and Human Services

10-

Feb- 15

27-

Nov

-19

19-

Mar

-20

US20200087 313

 

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

 

Not Available

29-

Jul-11

25-

Apr

-19

19-

Mar

-20

US20200087 298

Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups

 

Not Available

1-

Mar- 17

27-

Feb

-18

19-

Mar

-20

US20200087 280

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS

 

Not Available

5-

Feb- 15

25-

Nov

-19

19-

Mar

-20

US20200086 324

 

DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION

 

Not Available

30-

Jun- 16

27-

Dec

-18

19-

Mar

-20

US20200085 984

APPARATUS, METHOD AND SYSTEM FOR SELECTIVELY AFFECTING AND/OR KILLING A VIRUS

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

7-

Mar- 11

25-

Nov

-19

19-

Mar

-20

US20200085 947

 

VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER

 

Not Available

7-

Sep- 12

14-

May

-19

19-

Mar

-20

 

US20200085 943

PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN

 

CureVac AG

31-

Jan- 12

29-

Aug

-19

19-

Mar

-20

US20200085 872

 

IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS

 

Not Available

19-

Apr- 17

19-

Apr

-18

19-

Mar

-20

US20200085 852

 

EPIDERMAL MRNA VACCINE

 

Not Available

5-

Aug- 15

5-

Aug

-16

19-

Mar

-20

US20200085 756

NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE THEREOF

 

Not Available

14-

Sep- 18

12-

Jul- 19

19-

Mar

-20

US20200080 141

METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS

 

Not Available

11-

Dec- 13

19-

Nov

-19

12-

Mar

-20

US20200080 111

Methods for Autocatalytic Genome Editing and Neutralizing Autocatalytic Genome Editing and Compositions Thereof

 

Not Available

18-

Sep- 15

19-

Sep

-16

12-

Mar

-20

US20200079 820

DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE

 

Hangzhou DAC Biotech Co., Ltd.

20-

Apr- 16

20-

Apr

-16

12-

Mar

-20

 

US20200079 781

Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases

 

Not Available

5-

Sep- 18

1-

Aug

-19

12-

Mar

-20

US20200078 335

 

COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS

 

Not Available

1-

May- 17

1-

May

-18

12-

Mar

-20

US20200072 836

MEDIA ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES (MENSA) AND USES THEREOF

 

Not Available

5-

May- 14

2-

Apr

-19

5-

Mar

-20

US20200071 723

 

RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL

 

Not Available

30-

Aug- 18

29-

Aug

-19

5-

Mar

-20

US20200071 421

 

BISPECIFIC ANTIBODY

 

Not Available

20-

Nov- 13

8-

Apr

-19

5-

Mar

-20

US20200069 814

 

CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE

 

Hangzhou DAC Biotech Co., Ltd.

6-

Apr- 17

6-

Apr

-17

5-

Mar

-20

US20200062 764

ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING AND USING SAME

 

Not Available

17-

Nov- 16

17-

Nov

-17

27-

Feb

-20

US20200061 187

 

METHODS FOR PREPARING SQUALENE

 

Not Available

12-

May- 10

4-

Nov

-19

27-

Feb

-20

US20200061 185

 

PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE

 

The Scripps Research Institute

25-

Oct- 16

25-

Oct

-17

27-

Feb

-20

US20200060 981

CATIONIC NANOPARTICLES FOR ENHANCING INFECTIOUS CAPACITY OF LIVE VIRUSES

 

Not Available

9-

Dec- 16

11-

Dec

-17

27-

Feb

-20

US20200056 221

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA

 

Not Available

8-

Nov- 13

25-

Oct

-19

20-

Feb

-20

US20200056 159

NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR

 

Not Available

28-

Feb- 17

27-

Feb

-18

20-

Feb

-20

US20200055 927

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION

 

Not Available

8-

Sep- 16

25-

Oct

-19

20-

Feb

-20

US20200055 926

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION

 

Not Available

8-

Sep- 16

25-

Oct

-19

20-

Feb

-20

US20200054 731

IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF

 

Not Available

7-

Jan- 14

15-

Jul- 19

20-

Feb

-20

US20200054 660

 

DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY

 

St. Jude Children's Research Hospital

9-

Dec- 16

7-

Dec

-17

20-

Feb

-20

US20200054 259

 

HIGH DENSITY ANALOG MULTIPEXING

 

EnLiSense, LLC

17-

Aug- 18

16-

Aug

-19

20-

Feb

-20

 

US20200048 722

METHODS FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION AND IDENTIFICATION OF BACTERIAL, VIRAL, AND PROTOZOAN NUCLEIC ACIDS

 

Not Available

8-

May- 15

24-

Aug

-19

13-

Feb

-20

US20200048 649

 

VIRUS-LIKE PARTICLES AND USES THEREOF

 

Not Available

13-

Mar- 17

13-

Mar

-18

13-

Feb

-20

US20200048 636

 

IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA

 

GLAXOSMITHKLINE BIOLOGICALS SA

6-Jul- 10

18-

Oct

-19

13-

Feb

-20

US20200046 865

DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION

 

Not Available

29-

Dec- 17

22-

Aug

-19

13-

Feb

-20

US20200046 826

METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS

 

Academia Sinica

27-

Mar- 09

4-

Jun

-19

13-

Feb

-20

US20200046 692

 

SPECIFIC AKT3 INHIBITOR AND USES THEREOF

 

Not Available

15-

Jan- 16

2-

Oct

-19

13-

Feb

-20

US20200040 408

HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION

 

Not Available

8-

Feb- 16

6-

May

-19

6-

Feb

-20

US20200040 042

 

CHIMERIC MOLECULES AND USES THEREOF

 

Not Available

30-

Mar- 17

29-

Mar

-18

6-

Feb

-20

 

 

US20200038 871

 

DEVICES, PROCESSES, AND SYSTEMS FOR DETERMINATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, COPY NUMBER, OR METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE, POLYMERASE, AND SEQUENCING REACTIONS

 

 

Not Available

 

 

29-

Mar- 17

 

 

29-

Mar

-18

 

 

6-

Feb

-20

US20200038 373

 

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

 

Not Available

9-

May- 12

16-

May

-19

6-

Feb

-20

US20200033 343

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES

 

Not Available

6-

Oct- 08

14-

Oct

-19

30-

Jan- 20

US20200032 255

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES

 

Not Available

26-

Jan- 07

6-

Mar

-19

30-

Jan- 20

US20200031 871

 

NOVEL DEPSIPEPTIDES AND USES THEREOF

 

Not Available

4-

Apr- 17

30-

Mar

-18

30-

Jan- 20

US20200031 819

 

COMPOSITIONS AND METHODS FOR INHIBITING KINASES

 

Not Available

23-

Apr- 15

26-

Jun

-19

30-

Jan- 20

US20200030 441

Lipidated Immune Response Modifier Compound Compositions, Formulations, and Methods

 

Not Available

17-

Aug- 10

8-

Jul- 19

30-

Jan- 20

US20200030 432

 

ZOONOTIC DISEASE RNA VACCINES

 

ModernaTX, Inc.

17-

Mar- 17

16-

Mar

-18

30-

Jan- 20

US20200030 422

 

COMBINATION OF VACCINATION AND OX40 AGONISTS

 

CureVac AG

9-

Sep- 16

15-

Apr

-19

30-

Jan- 20

 

US20200024 616

 

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN PANCREATIC TROPISM

 

Not Available

30-

Mar- 18

29-

Mar

-19

23-

Jan- 20

US20200024 310

 

NOVEL DEPSIPEPTIDE AND USES THEREOF

 

Not Available

3-

Dec- 12

1-

Aug

-19

23-

Jan- 20

 

US20200020 420

 

Method for Establishing Machine Learning Model for Predicting Toxicity of siRNA to Certain Type of Cells and Application Thereof

 

Not Available

8-

Dec- 16

7-

Dec

-17

16-

Jan- 20

US20200017 926

CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOF

 

Not Available

7-

Nov- 13

28-

Aug

-19

16-

Jan- 20

 

US20200017 832

COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC CELLS OR ANTIGEN PRESENTING CELLS, METHODS AND USES THEREOF

 

Not Available

5-

Apr- 17

5-

Apr

-18

16-

Jan- 20

US20200017 588

 

MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORM

 

Not Available

14-

Oct- 16

16-

Oct

-17

16-

Jan- 20

US20200017 554

SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN SIX- HELIX BUNDLE PROTEINS

 

Not Available

23-

Mar- 17

22-

Mar

-18

16-

Jan- 20

US20200017 514

ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION

 

Not Available

12-

Jul-18

12-

Jul- 18

16-

Jan- 20

 

US20200017 455

CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS

 

Not Available

24-

Jan- 14

19-

Mar

-19

16-

Jan- 20

US20200016 589

 

LOADING VIALS

 

Not Available

10-

Nov- 11

24-

Sep

-19

16-

Jan- 20

US20200016 286

Production of Immune-Response-Stimulating Aerosols By Non- Thermal Plasma Treatment Of Airborne Pathogens

 

Not Available

13-

Jul-18

12-

Jul- 19

16-

Jan- 20

US20200016 280

 

Compositions For Enhancing Transport Of Molecules Into Cells

 

Not Available

29-

Apr- 03

9-

Apr

-19

16-

Jan- 20

US20200016 161

 

METHODS FOR TREATING VIRAL DISORDERS

 

TRUSTEES OF BOSTON UNIVERSITY

24-

Sep- 09

22-

Jul- 19

16-

Jan- 20

US20200010 883

METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS

 

Not Available

9-

Oct- 15

7-

Jun

-19

9-

Jan- 20

US20200010 519

NUCLEASE FUSIONS FOR ENHANCING GENOME EDITING BY HOMOLOGY-DIRECTED TRANSGENE INTEGRATION

 

Not Available

10-

Mar- 17

9-

Mar

-18

9-

Jan- 20

US20200009 244

NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL COMPONENTS

 

Not Available

13-

Jun- 18

13-

Jun

-19

9-

Jan- 20

US20200002 674

 

ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE

 

Not Available

18-

Nov- 13

16-

Sep

-19

2-

Jan- 20

US20200000 931

SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS

 

Not Available

15-

Jul-16

10-

Apr

-19

2-

Jan- 20

US20190391 150

 

COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES

 

Not Available

1-

May- 15

10-

Sep

-19

26-

Dec

-19

US20190390 249

 

BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM

 

Longhorn Vaccines and Diagnostics, LLC

1-

Oct- 07

19-

Jun

-17

26-

Dec

-19

US20190390 229

 

GENE EDITING REAGENTS WITH REDUCED TOXICITY

 

Not Available

21-

Apr- 16

20-

Apr

-17

26-

Dec

-19

US20190390 179

 

SYNTHETIC REVERSE TRANSCRIPTASES AND USES THEREOF

 

Not Available

12-

Apr- 16

12-

Apr

-17

26-

Dec

-19

 

US20190390 176

 

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN SKELETAL MUSCLE TROPISM

 

Not Available

2-

Dec- 15

3-

Jul- 19

26-

Dec

-19

US20190389 816

 

ANTIVIRAL COMPOUNDS AND METHODS

 

Biotron Limited

26-

Jun- 03

29-

Aug

-19

26-

Dec

-19

US20190388 473

 

METHODS AND COMPOSITIONS FOR IMMUNOMODULATION

 

Not Available

1-

Apr- 14

30-

Aug

-19

26-

Dec

-19

US20190382 799

 

VIRAL METHODS OF MAKING GENETICALLY MODIFIED CELLS

 

Not Available

27-

Oct- 16

19-

Apr

-19

19-

Dec

-19

US20190382 433

GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY

 

THE UNIVERSITY OF NOTTINGHAM

4-

Apr- 14

25-

Jul- 19

19-

Dec

-19

US20190381 180

 

HYBRID CARRIERS FOR NUCLEIC ACID CARGO

 

Not Available

9-

Jun- 16

9-

Jun

-17

19-

Dec

-19

US20190381 162

PAN FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF MAKING

 

Not Available

28-

Mar- 16

27-

Mar

-17

19-

Dec

-19

US20190381 155

COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY

 

CureVac AG

22-

Feb- 13

29-

Aug

-19

19-

Dec

-19

US20190380 995

 

PREVENTION AND TREATMENT OF VIRAL INFECTIONS

 

Not Available

2-

Jun- 16

3-

Jul- 19

19-

Dec

-19

US20190380 891

 

MOBILE CLINICS

 

Baylor College of Medicine

12-

Nov- 14

28-

Aug

-19

19-

Dec

-19

 

US20190376 151

 

MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING NUCLEIC ACIDS